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FUNCTIONAL HETEROGENEITY AND METABOLIC ADAPTATION OF
FIBROBLASTS IN CANCER

Lisa Maria Becker, MS
Advisory Professor: Raghu Kalluri, MD., Ph.D.

The tumor microenvironment is comprised of a multitude of cell types producing a milieu
of cytokines, growth factors an extracellular matrix. Together, this intricate network of cells plays
highly critical roles in determining a tumor’s potential to progress and metastasize. As the
predominant cell types in the tumor microenvironment, cancer-associated fibroblasts (CAFs) are
a key component in the regulation of tumor development and progression, but their exact
functions in tumorigenesis remain poorly understood. This is partly due to the considerable
heterogeneity amongst these cells, which confounds the characterization of their roles within the
tumor microenvironment. Nevertheless, recent studies have provided fresh insights in CAFs
biology and how these cells contribute to tumorigenesis at different stages, suggesting that CAFs
can reshape the tumor immune response via interactions with immune cells, as well as induce
tumor angiogenesis and support cancer cell proliferation through modifying tumor metabolism.
These reports provided excellent groundwork to further unravel the complex and heterotypic
functions of this cell type.
In this work, we identified phenotypically and functionally distinct CAF subtypes critical in
mammary carcinoma progression using multiplex staining techniques and genetically engineered
mouse models that enables the specific targeting of CAF subtypes. Specifically, the distinct
functional roles played by aSMA+, FAP+ and PDGFRb+ CAFs were characterized. While targeting
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FAP+ CAFs did not cause any dramatic changes in primary tumor growth or metastasis, depletion
of PDGFRb+ CAFs moderately reduced tumor growth and metastasis. On the other hand, aSMA+
CAFs-depleted tumors grew significantly slower and showed decreased angiogenesis.
Compellingly, despite primary tumor growth stagnation and notably smaller tumors, metastasis to
the lungs continued unabated or even slightly increased in mice with tumors lacking aSMA+ CAFs.
Intriguingly, we observed a down-regulation of tumor metabolites in tumors depleted of aSMA+
CAFs. We further examined the metabolic relationship between CAFs and cancer cells to arrive
at a mechanistic understanding of the observed metabolic phenotypes in CAFs. Our work
demonstrates that CAFs’ metabolic reprogramming can be triggered by hypoxia-induced
epigenetic modification of HIF-1a and rate-limiting glycolytic enzymes.
As an extension to this work, we further explored fibroblasts’ contributions to cancer
initiation. Here, we leveraged a previously reported mouse model in which Tgfb signaling in
fibroblasts has shown to modulate epithelial growth, resulting in squamous carcinoma of the
forestomach. In our studies, we uncovered a complex feed forward loop, in which the loss of Tgfb
receptor 2 in FSP1+ fibroblasts leads to a Smad4-dependent up-regulation of HGF production to
induce increased proliferation in neighboring epithelial cells. The proliferating epithelial cells
release BMP7 which, in turn, promotes fibroblast proliferation. Interestingly, we demonstrated that
this signaling cross-talk is specific to FSP1+ fibroblasts, highlighting the importance of fibroblast
heterogeneity not only in cancer progression, but also in normal tissue homeostasis.

The work presented in this thesis offers novel insights into fibroblast biology at different
stages of cancer development and progression. Our studies shed new light on how fibroblast
subsets can phenotypically and functionally be defined. We also showed in two settings how
fibroblast - epithelial cell interactions are critical for tumor initiation or progression. In one context,
we demonstrated the metabolic liaison between CAFs and cancer cells can drive tumorigenesis.
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In the second context, we showed an intricate signaling cross-talk between fibroblasts and
epithelial cells is required to provoke epithelial carcinogenesis.
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CHAPTER 1

BACKGROUND AND SIGNIFICANCE

1

Tumor microenvironment
After more than 40 years of cancer research, significant progress has been made towards
our understanding of the underlying mechanisms of tumorigenesis. Our initial view of tumor
formation was based on the simplistic model in which endogenous mutations in specific tumor
suppressor genes or oncogenes transform healthy cells into cancerous cells, which then gradually
expand into a large tumor mass. This view has evolved over the past three decades into what can
be described as a tumor-organ model. In contrast to a mass of cancerous cells, a tumor is now
regarded as an organ-like construction encompassing specific cell types and extracellular matrix
to provide structure and tissue homeostasis. Although specific gene mutations and chromosomal
anomalies can indeed transform healthy cells and eventually lead to their accumulation due to
uncontrolled proliferation and enhanced survival, once a tumor reaches a certain mass, oxygen
and nutrient availability come into play as a limiting factor for cancer cells at the center of the
mass. At this point, cancer cells employ several mechanisms that allow them to receive sufficient
support from normal, non-cancerous cells in the host organ. For instance, cancer cells release
several angiogenic factors, such as vascular endothelial growth factor (VEGF), fibroblast growth
factor (FGF),1 etc., in order to activate and attract endothelial cells to induce angiogenesis
resulting in increased oxygen and nutrients access to the tumor tissue. In order to evade immune
surveillance, cancer cells secrete immunosuppressive factors such as transforming growth factor
beta (TGFb)2,3, or recruit immunosuppressive cells (e.g., T regulatory cells) by prostaglandin E2
(PGE2) production4. Such immunosuppressive cells inhibit T-cell’s anti-tumor activities.
Additionally, fibroblasts can be activated through platelet-derived growth factor (PDGF), FGF and
TGFb secreted by cancer cells5,6. In their activated state fibroblasts facilitate tumor growth and,
in later stages, promote metastasis5 through various mechanisms. These specialized cell types
surrounding the cancer cells, together with factors such as pH, oxygen tension, and interstitial
fluid pressure, are referred to as the tumor stroma, or tumor microenvironment (Figure 1A). The
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tumor microenvironment in which the cancer cells are embedded into plays a critical role in tumor
progression and represents a key factor to consider and overcome in developing efficacious anticancer therapeutics.
The

tumor

microenvironment is
a complex interplay
of endothelial and
perivascular
immune
various

cells,

cells

of

types,
fibroblasts,

Figure 1 The tumor microenvironment
A. Illustration of the tumor microenvironment B. Signaling crosstalk between different cell
types in the tumor microenvironment

extracellular matrix
(ECM)

proteins,

cytokines, and growth factors secreted by all participating cells. Mirroring how cancer cells attract
and activate stromal cells, stromal cells in turn affect cancer cells through paracrine signaling.
Epidermal growth factor (EGF), FGF, TGFb, tumor necrosis factor alpha (TNFa) and interleukins
secreted by immune cells stimulate cancer cell growth7. Fibroblasts can induce epithelial to
mesenchymal transition (EMT) in cancer cells via TGFb and support cancer growth through
release of hepatocyte growth factor (HGF), EGF family members, insulin-like growth factor-1
(IGF-1), stromal cell-derived factor-1 (SDF-1 or CXCL12), and a variety of fibroblast growth
factors (FGFs)8–13. In addition to their essential functions in angiogenesis, endothelial cells secrete
hypoxia-inducible factor 1 alpha (Hif1a), which facilitates cancer cell metastasis14.
In addition to active signaling and crosstalk between stromal and cancer cells, different
stromal cell types also interact with one another, arbitrating their respective functions and the
relative abundance of different subtypes of stromal cells to achieve and maintain homeostasis in
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the tumor microenvironment. Fibroblast-derived TGFb not only induces EMT in cancer cells, but
also inhibits cytotoxic T-cell functions as well as NK cells15. Through MMP secretion, immune
cells, together with fibroblasts, actively remodel ECM and thereby provide growth support and
structure to the tumor organ5,16. ECM degradation and remodeling releases many growth factors
and cytokines that are sequestered in these frameworks and can further influence all cells in the
tumor microenvironment17,18. Fibroblasts and endothelial cells can influence the functions of
immune cells at all stages of tumor progression, thereby actively regulating the immune response
to the tumor. In turn, immune cells, specifically myeloid cells release cytokines (VEGF, TNFa,
TGFb and others), chemokines (such as IL6 and CXCL12), MMPs and several other soluble
factors regulating angiogenesis and tumor vascularization7. Fibroblasts within the tumor stroma
secrete similar cytokines and growth factors and therefore are also critical regulators of
angiogenesis11. As it becomes apparent, the tumor microenvironment is a highly complex
signaling network within which a tumor grows (Figure 1B).
Over the past two decades, ample evidence confirmed the notion that tumor
microenvironment is essential for tumor formation and progression. In the 1980s, studies by Mina
Bissell showed that wounding can trigger tumor development in animals infected with tumor
initiating viruses and transgenic mice overexpressing oncogenes19–21. Today we know that
conditions of excessive wound healing, such as fibrosis elevate the risk for cancer development
enormously. For instance, patients with idiopathic pulmonary fibrosis have a significantly higher
risk to develop lung cancer than healthy individuals22,23. An additional example are patients with
liver cirrhosis that are at higher risk to develop hepatocellular carcinoma24. Together, these
studies suggest that tissue remodeling and activation in immune and endothelial cells, as well as
fibroblasts are required for a tumor growth. In support of this, clinical studies have correlated
increased stromal content with poor prognosis25–27, and functional studies showed that altering
components of the tumor microenvironment affects tumorigenesis11,28,29.
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How exactly the tumor microenvironment is developed is not fully understood, but several
different theories have been postulated. As mentioned above, one possibility is that the cancer
cells themselves create their own stroma by attracting stromal cells and hijacking their functions
through targeted signaling. An alternative school of thought is that an inflammatory
microenvironment provides the necessary niche for tumor formation to develop in the first place.
This idea was first forwarded in 1862 by Rudolf Virchow, who observed that tumors develop at
sites of previous injury at an increased rate30. This was later supported by the above-mentioned
studies using Rous sarcoma virus to induce cancer formation, which was only possible in the
presence of tissue injury where active tissue remodeling is taking place19,20. Further supporting
this is the fact that conditions of chronic inflammation such as fibrosis are known cancer risk
factors22–24. Moreover, irradiation of stroma and subsequent ECM remodeling has been shown to
induce tumorigenesis in non-irradiated epithelial tissue31,32. In line with these observations,
several studies have suggested that genetic alterations in tumor associated stroma, which were
not found in the epithelial carcinoma cells, might also contribute to tumor formation33–35. A few
studies have provided direct evidence that mutations in stromal cells, such as fibroblasts can
indeed induce epithelial tumorigenesis36,37. Lastly, a line of research attributes the presence of
stromal cells within a tumor to failed anti-tumor host responses. This theory supposes that, in
early cancer development, the host tissue mounts an anti-tumor immune response in order to
clear out damaged cells or to contain the cancerous cells, if the tumor cannot be overcome.
Support for this idea comes mainly from post mortem studies, which identified many cancerous
lesions in patients who died of cancer-unrelated causes38. In these studies, the presence of
cancerous lesions in thyroid glands is so frequent, that it is considered a normal finding39. Such
observations suggest that stroma can prevent the growth of tumors from pre-cancerous lesions.
Another example is the condition of ductal carcinoma in situ (DCIS) of the breast. It is considered
a non-invasive breast cancer that remains indolent. Although DCIS lesions often harbor many
cancer driver mutations, they develop into invasive carcinomas only in minority of patients

5

presenting with such lesions40. These observations highlight that interplay between stroma and
mutated epithelial cells plays a critical role in determining tumor progression. Based on the fact
that indolent cancerous lesions are more frequently found in people than the occurrence of
cancer, we may conclude that in many cases the stroma is able to contain tumor growth and can
indeed also exhibit anti-cancer functions. However, the determinants in tumor microenvironment
that are permissive or restrictive to tumor growth remain largely unknown.
In summary, research in the past two decades has firmly established the concept of the
tumor microenvironment into which cancer cells are embedded and the plethora of interactions
within the tumor microenvironment continues to be unraveled. It is not certain how the tumor
microenvironment forms in the first place, but most likely all described scenarios can happen
depending on the disease and tissue context.

Cancer-associated fibroblasts
Fibroblasts are the most abundant cell type amongst the different components of the
stroma. Paradoxically they are also the least understood. In their normal physiological roles,
fibroblasts mediate key processes in the wound healing response. During tissue injury, growth
factors and cytokines such as TGFβ, PDGF, and EGF are released by the damaged tissue, which
activate fibroblasts and induce their differentiation into so-called myofibroblasts10,41,42.
Myofibroblasts received their name because of their features that are similar to smooth muscle
cells with contractile properties essential for wound closure. These cells are generally identifiable
via their expression of alpha smooth muscle actin (aSMA). In their activated state, fibroblasts
secrete extracellular matrix proteins, such as collagens, which become part of the granulation
tissue and later scars41,42. The wound healing process involves paracrine signaling among
fibroblasts, endothelial cells and immune cells, all critical for wound closure. This process is
reminiscent of the aforementioned cell-cell interactions in the tumor microenvironment during
tumor progression. The parallelism between cancer and the wound healing process had been
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recognized as early as 1986, when Harold Dvorak famously referred to tumors as “wounds, that
do not heal”, and cancer initiation as “wound healing gone awry”43. It is not surprising that the
identification and characterization of the roles fibroblasts play in the tumor microenvironment had
been largely drawn from their known functions in the wound healing process. In the context of a
tumor, fibroblasts are referred to as cancer-associated fibroblasts or CAFs. CAFs can stem from
several different sources, such as resident tissue fibroblasts44,45, bone-marrow derived cells46, or
normal tissue epithelial cells, in addition to tumor cells themselves by undergoing epithelial to
mesenchymal transition (EMT) and transdifferentiation18. CAFs are defined as activated
fibroblasts in the tumor microenvironment that can actively promote tumor growth through their
secretion of growth factors, cytokines and ECM proteins. Expression of certain markers, such as
aSMA47, platelet derived growth factor receptor alpha/beta (PDGFRa/β)9 and fibroblast activation
protein (FAP)48 have been identified as the hallmark to the activated state for these fibroblasts.
Numerous other fibroblast-associated proteins such as intermediate filament associated proteins
(e.g. Vimentin, Desmin, fibroblast specific protein 1 (FSP1 or S100A4))49–52, transmembrane
proteins and receptors (e.g. Neural glial antigen 2 (NG2), discoidin domain-containing receptor 2
(DDR2)48,51,52,53,54 , and
Table 1 Most commonly used CAF markers
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summarizes the most important and most commonly used CAF markers. Notably, none of the
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listed markers universal to the entire CAF population, and different teams have used one or a few
of these markers in combination to identify CAFs in their studies.
Historically, CAFs were thought to facilitate tumorigenesis in virtually all solid tumors. The
first in vivo studies showed CAFs co-implanted with cancer cells into animals (co-called admix
experiments) resulted in increased tumor growth compared to cancer cells injected alone or with
normal fibroblasts. Further studies demonstrated CAFs secrete various factors such as HGF,
EGF, IGF-1, and SDF1, which promote cancer cell proliferation and metastasis5,58,59. Targeting
CAFs has been shown to reduce tumor growth and metastasis in breast, colon, lung and
pancreatic carcinoma animal models60,61, supporting a growth promoting function for CAFs.
However, research in the past few years had changed this view. In colon and pancreatic cancer
xenograft models, CAFs have been shown to promote tumor growth via paracrine Hedgehog (Hh)
signaling62. When Hh signaling was inhibited in the fibroblasts however, pancreatic tumor growth,
as well as the survival of mice with stroma-depleted tumors, was reduced in a subsequent study63.
When aSMA-expressing CAFs were directly targeted for depletion in a mouse model of pancreatic
ductal carcinoma, the tumors exhibited increased invasive abilities, and the survival of the animals
was diminished64. These studies stand in contrast to the presumption of CAF’s tumor growth
promoting roles and suggest these cells can also suppress tumor growth in certain contexts. As
we continue to unravel CAF functions in tumorigenesis, it becomes increasingly obvious, that the
roles they play in the tumor microenvironment are highly diverse and context-dependent.

CAF heterogeneity
The concept of CAF heterogeneity had risen to prominence alongside the new insights in CAFs
biology and functions. The multitude of functions and the plethora of distinct signaling pathways
involved to elicit such functions led to the concept that, instead of presenting as one cell type with
a specific role in tumorigenesis, CAFs are actually comprised of multiple subpopulations, each
with distinct functions. The variety of markers used to identify CAFs, as well as the different
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reported sources of these cells further support this hypothesis. By categorizing specific CAFs
functions into broad areas, different CAF subtypes have been postulated65 (Figure 2).
Primarily, tumor restraining and
tumor

promoting

CAFs

could

be

regarded as two main CAF subsets. A
third

subset

was

proposed

in

association with a secretory phenotype,
releasing
Figure 2 CAF subsets with different functions. Adapted from
65
with permission.

increased

amounts

of

signaling molecules that impact immune
cells, tumor vasculature and cancer cell

proliferation. CAFs that are predominantly responsible for extracellular matrix remodeling were
proposed as a fourth subtype65. It is likely that each of these subtypes can be further subdivided
into distinct subpopulations. For instance, another subpopulation of tumor-promoting CAFs may
be CAFs with specific metabolic features supplying tumors with metabolites to meet their
energetic needs. Secretory CAFs might be further defined to describe specialized CAFs
responsible for recruiting immune-suppressive cells via the secretion of IL6, IL4 and IL8 or CAFs
directly modifying cancer cell proliferation and invasiveness via specific signaling mediators such
as TGFβ58 (Figure 2). While these fine-grained functional subsets of CAFs have been proposed,
how these subsets can be uniquely identified by means of molecular markers remains largely
undetermined. Some functional studies attributed expression of a specific marker, or the lack
thereof, to a specific function. For instance, the lack of Caveolin in fibroblasts has been associated
with increased lactate production that can feed into cancer cells’ metabolism66. On the other hand,
Caveolin-expressing CAFs are associated with ECM remodeling and the enhancement of tumor
invasiveness56. In addition, analyses of patient tumor tissues have attributed expression of
specific CAF markers to different clinical outcomes. For instance, Collagen and FAP have been
identified as predictors of poor outcome in patients with pancreatic cancer, whereas aSMA was
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correlated with favorable outcome67. While these studies suggest that specific mesenchymal
markers can be used for CAF subtype identification, whether single markers can sufficiently define
a CAF subtype, or whether markers can provide meaningful subtype identity only in the context
of co-expressing additional CAF markers remain open questions. Studies aiming to discover
distinct CAF subtypes should also take into consideration that CAFs likely can change their
phenotypes dynamically in a context-dependent manner, such as the stage of tumorigenesis.
Moreover, it is unknown whether different origins or locations of CAFs correspond with different
CAF markers and/or functions. There is an increased urgency to answer these questions as more
studies utilizing mesenchymal markers are emerging in the CAF field.

Glucose metabolism in CAFs
A specific example of a tumor promoting pathway involves CAFs functioning as metabolic support
cells for proliferating cancer cells. Highly proliferative cells, such as cancer cells, present with
enhanced glycolytic rates. In physiological conditions, cells metabolize glucose into pyruvate
(glycolysis), which gets shuttled through the tricarboxylic acid cycle (TCA or Krebs cycle) in the
mitochondria68. This process creates NADH, which feeds into the electron transport chain (ETC).
The ETC consists of several complexes (complex I-V), through which electrons pass. This
process, which absolutely requires oxygen, produces large amounts of ATP (34 mol ATP per mol
of glucose)68.
When oxygen in tissues is sparse, the pyruvate produced by the glycolytic pathway is converted
into lactate, resulting in only 2 mol of ATP per mol of glucose. Although energetically less efficient,
the conversion of pyruvate to lactate releases NAD+, which fuels continuous glycolysis and a cell
can repurpose the intermediates of glycolysis for nucleotide biosynthesis via the pentose
phosphate pathway68.
In the 1920s Otto Warburg observed that cancer cells present with enhanced glycolytic
rates, metabolizing glucose to lactate regardless of oxygen availability. This phenomenon is
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referred to as the Warburg effect, and was initially thought to result from dysfunctional
mitochondria in cancer cells. Subsequent research disproved this hypothesis and it is now
believed that the enhanced demand for biosynthetic products necessary for cancer cell growth
and divisions causes these cells to change their metabolism preference to this less efficient, but
much faster way for energy production69.
Similar to cancer cells’ altered metabolism, CAFs have been proposed to undergo
metabolic reprogramming toward aerobic glycolysis and have been suggested to participate in a
tumor-promoting lactate shuttle with cancer cells (“Reverse Warburg Effect”)70–73. Here, the
glycolytic CAFs are suggested to secrete lactate, which is taken up by cancer cells to fuel their
own energetic needs. A few possible mechanisms of how this metabolic relationship develops
had been proposed, but the precise details of how such metabolic programming of CAFs emerges
and how it is sustained are not well understood. Of note, crosstalk between cancer cells and CAFs
involving additional metabolites, such as glutamine, have been proposed as cancer growth
supporting mechanisms74.

Dissertation goals and major findings
CAFs are a heterogenous cell population that exhibits a plethora of functions critical for
tumor development and progression. In this work, we aimed to further unravel novel functions of
CAFs in the context of CAF heterogeneity. The majority of our studies focuses on mammary
carcinoma, which consists up to 80% of stroma, suggestive of the tremendous relevance of CAFs
in this cancer type. In order to address CAF heterogeneity, we employed multiplex staining
techniques to identify distinct CAF subsets in mammary tumors based on the expression patterns
of several CAF markers and their overlaps. This method enabled us to identify phenotypically
distinct subsets, whose functions were subsequently assessed in transgenic animal models of
mammary carcinoma that allowed for specific targeting of CAFs. These functional studies
confirmed that phenotypically distinct CAF subtypes also differed in their functions in the tumor
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microenvironment. A particularly intriguing observation from CAF targeting studies was these
cells’ impact on tumor metabolism. Here, we sought to further investigate the metabolic
relationships between CAFs and breast cancer cells, thus uncover the underlying mechanisms of
this metabolic reprogramming in CAFs. Our studies suggest the glycolytic, CAF-like phenotype
can be induced in normal fibroblasts by exposing them to chronic hypoxic conditions.
Having observed that normal fibroblasts can gain CAF-like functions via altered
metabolism, we further aimed to investigate how other changes in fibroblasts might influence
epithelial cells. Here, we were interested not in how cancer growth is sustained, but rather if
indeed changes in fibroblasts in healthy tissues can initiate tumorigenesis in the neighboring
epithelium. We used a well-established model that showed disrupted TGFβ signaling in fibroblasts
can lead to development of carcinogenesis of the forestomach. Deciphering the underlying
signaling mechanisms revealed an intricate feed forward signaling loop between fibroblasts and
cancer cells that plays a critical role in cancer initiation.
In summary, in this thesis different aspects of CAF biology were investigated. We
uncovered distinct CAF subtypes with differing roles in mammary carcinoma progression and
further specifically explored CAFs’ roles in providing metabolic support for cancer cells. Here, the
hypoxia dependent reprogramming of fibroblasts was identified as a mechanism driving the
glycolytic phenotype of CAFs. Lastly, the complex signaling between epithelial cells and
fibroblasts that can lead to cancer initiation was elucidated. In this context, we not only further
elucidated the intricate interactions between fibroblasts and epithelial cells, but showed that
already in this state distinct fibroblast subtypes can be identified.
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CHAPTER 2
MATERIALS AND METHODS

Parts of the methods section are taken verbatim from previously published work:
Eikesdal, H. P.*, Becker, L. M.*, Teng, Y.*, Kizu, A., Carstens, J. L., Kanasaki, K., Sugimoto, H,
LeBleu, V. S., Kalluri, R. (2018). BMP7 Signaling in TGFBR2-Deficient Stromal Cells
Provokes Epithelial Carcinogenesis. Molecular Cancer Research, 16(10), 1568-1578.
https://doi.org/10.1158/1541-7786.mcr-18-0120
Vo, A. P. Glucose Metabolism in Cancer-Associated Fibroblasts. Harvard Univ. (2013).
doi:10.1029/91JD03139
Becker, L. M.*, O’Connell, J. T.*, Vo, A. P., Cain, M. P., Tampe, D., Bizarro, L., Sugimoto, H.,
McGow, A. K., Asara, J. M., Lovisa, S., McAndrews, K. M., Zielinski, R., Lorenzi, P. L., Zeisberg,
M., Raza, S., LeBleu, V. S., and Kalluri, R. Epigenetic Reprogramming of Cancer Associated
Fibroblasts Deregulates Glucose Metabolism and Facilitates Progression of Breast
Cancer. Cell Reports, 31(9), 107701. https://doi.org/10.1016/j.celrep.2020.107701
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Murine cell lines
4T1 Balb/c mammary tumor epithelial cells (ATCC) were grown in Dulbecco’s Modified Eagle’s
Medium supplemented with 10% fetal calf serum and penicillin/streptomycin (each 100U/ml). In
same experiments, 4T1 were modified to express GFP and luciferase (GFP luc). 4T1 cells were
validated by STR analysis and confirmed negative for mycoplasma. Mouse normal mammary
fibroblasts and cancer-associated fibroblasts were grown from tissues obtained from MMTVPyMT mice75,76. Tissues were minced into 1 mm3 pieces and digested overnight in 300U Type I
collagenase per ml of RPMI-1640 media containing 20% fetal bovine serum (FBS) with 100U/ml
penicillin/streptomycin and 250ng/ml amphotericin (PSA) (complete media). Fibroblasts were
subsequently allowed to grow out of the tissue pieces maintained in complete media.

To isolate fibroblasts from forestomaches, the forestomaches of wild-type (wt),
TGFBR2cKO, and TGFBR2/SMAD4cKO mice were collected, minced into small pieces, and
digested with 400 units/ml of collagenase IV (Worthington) in Dulbecco Minimal Essential Medium
(DMEM, Cellgro) at 37C for 24 hours in a cell incubator. Next day, the medium was replaced with
DMEM, supplemented with 20% fetal bovine serum (FBS), 100 units/mL of penicillin and 100
mg/mL of streptomycin (Cellgro). The cells were grown at 37C in a humidified chamber and 5%
CO2 under sterile tissue culture conditions and passaged when they reached 80% confluency.
The resulting fibroblast cell cultures at passages 4 to 6 were used for all the experiments. The
fibroblast cultures were confirmed for the presence of FSP1 protein by immunostaining.

Patient-derived cell lines
Human benign mammary fibroblasts and cancer-associated fibroblasts were grown from breast
biopsy tissue samples obtained as part of an institutionally approved clinical study at Boston’s
Brigham and Women’s Hospital. The breast biopsies were either ultrasound-guided (Ultrasound
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core needle biopsy = US-CNB) or stereotactically-guided (Stereo-CNB) core needle biopsies. In
Stereo-CNB, the biopsy target was always microcalcifications, but the core samples provided for
this study did not contain calcifications, as determined by x-ray. All patients (n=499) were female
and between 18 and 88 years of age (median age of 51 years). The tissues were mounted into
O.C.T mounting media and frozen for subsequent immunolabeling studies or processed for
fibroblast propagation. For the latter, after an ethanol and subsequent phosphate-buffered saline
(PBS) wash, 1 mm3 pieces were digested overnight in 300 U Type I collagenase per ml of RPMI1640 media containing 20% fetal bovine serum (FBS) with 100 U/ml penicillin/streptomycin and
250 ng/ml amphotericin (PSA) (complete media). Fibroblasts were subsequently allowed to grow
out of the tissue pieces and maintained in complete media. These patient-derived fibroblasts were
isolated by previous lab members at Harvard Medical School.

Mice
aSMA-vTK, and PDGFRb-vTK have been previously described77,78. FAP-vTK mice have been
created by Dr. Toru Miyake in the Kalluri lab. Tg(S100a4-cre)1EgnYunkJ (FSP1-Cre) and FSP1GFP mice were a kind gift from E. G. Neilson (Northwestern)36. Tgfbr2tm1.2Hlm (Tgfbr2floxE2) mice
were a kind gift from H. L. Moses (Vanderbilt)79 Smad4tm1.1Rdp (Smad4floxE8/9) mice80 were kindly
provided by R. A. DePinho (MDACC). R26R-LSL-EYFP (R26R-EYFP) reporter mice81 were kindly
provided by B. G. Neel (Harvard). The aSMA-Cre and aSMA-RFP mice were previously described
77,82

. Mice strains employed in these studies include control (wt) mice which include both Cre-

negative littermates of TGFBR2cKO and TGFBR2/SMAD4cKO strains or Cre-positive littermates
with heterozygous loss of TGFBR2. Control mice for experiments with aSMA-vTK, PDGFRb-vTK
and FAP-vTK mice were littermates vTK– mice. The FSP1-GFP and aSMA-RFP strains were bred
to generate the double transgenic strain. Both male and female young and adult mice were
studied in the studies involving TGFBR2cKO and TGFBR2/SMAD4cKO mice; whereas only female
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adult mice were used for experiments involving mammary carcinoma. The genetic backgrounds
were C57Bl/6, Balb/c, sv129 or a mixture of these backgrounds. Animal studies were carried out
at the Beth Israel Deaconess Medical Center and at the MD Anderson Cancer Center and
approved by the Institutional Animal Care and Use Committee of each institution.

4T1 orthotopic mammary cancer models
Adult virgin female mice (~8 weeks of age) were used for orthotopic implantation of 1x106 4T1
mammary epithelial cancer cells, as previously described. When the average combined tumor
volume reached ~500 mm3 (14 days post cancer cell implantation), aSMA-vTK and WT control
mice received daily intraperitoneal (i.p.) injections with 50 mg/kg of ganciclovir (GCV). Tumors
were measured every 2 to 3 days using Vernier callipers. Mice were euthanized when the average
tumor volume reached 1500 to 2000 mm3 in the control group (24 days post cancer cell
implantation). When probing for glycolytic fibroblasts in different tumor stages, mice were
sacrificed when tumors reached ~50-80 mm3, ~150-250 mm3, ~400-500 mm3, ~700-900 mm3,
1200-1500 mm3, respectively. For each stage, tumors from 4-6 mice were obtained. At time of
sacrifice, mice were injected with hypoxyprobe to probe for pimonidazole adduct formation in
tumor tissues. To ascertain metastatic burden in lungs of mice with a tumor volume of 500 mm3,
1x106 4T1 cells were injected in the right mammary fat pad and volume was monitored until
sacrifice when tumor volume reached 500 mm3. To measure aSMA expression in animal tissues,

aSMA-RFP mice77 were crossed to S100A4-GFP mice83 and subsequently implanted with 4T1
carcinoma cells as described above. 5µm sections from formalin fixed paraffin-embedded lung
tissues were stained with hematoxylin and eosin. Slides were scanned using Aperio Digital
Scanner (Department of Veterinary Medicine and Surgery at MDACC). Metastases were identified
by histopathological analysis and metastatic area was quantified with Aperio eSlide Manager and
Aperio Image Scope v12.3.2.8013 as a percentage of the total area of the lung. While performing
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tumor measurements and lung metastasis analysis, the operator was blinded to the experimental
groups the mice were stratified into or to their genotypes.

4T1 intravenous injections in aSMA-vTK mice
0.5x106 4T1 mammary carcinoma cells were injected intravenously (retroorbital route) in aSMAvTK and WT control mice. GCV treatment was started 2 days prior cancer cell injection and
continued until the endpoint of the experiment (10 days after cancer cell injection). Lung
metastases were quantified as described above.

MMTV-PyMT mammary cancer mouse models
MMTV-PyMT transgenic mice spontaneously develop tumors at 8-12 weeks of age in their
mammary fat pads76. For studies on tumor progression, mice were sacrificed when tumors
reached a combined volume of approximately 800 mm3. The single tumors were measured,
harvested and paraffin embedded. In total, 24 tumors from 11 distinct mice were used for
analyses. For depletion studies, MMTV-PyMT mice were crossed to aSMA-vTK mice to obtain
MMTV-PyMT; aSMA-vTK transgenic mice. In these animals, GCV treatment was started when
the combined tumor volume reached ~500 mm3 and continued until endpoint of the experiment
(20 days post GCV treatment start). For the transplantation experiments, MMTV-PyMT mice were
sacrificed when combined tumor volume reached ~1000 mm3. Individual tumors were collected
and tumors of ~0.8 g were chosen for transplantation. These were cut into small pieces of ~1 mm3
and implanted into the right mammary fat pads of recipient aSMA-vTK, FAP-vTK or PDGFRbvTK78 mice (one piece/fat pad). Each donor tumor was distributed to five recipient mice. GCV
treatment was started once the tumors reached ~ 400 mm3 in recipient mice and continued until
the endpoint of the experiment (20 days post GCV treatment start). In all experiments, tumors
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were measured every other day with Vernier calipers. Lung metastases in MMTV-PyMT; aSMAvTK mice, as well as in the transplantation model were quantified as described above.

Immunofluorescence on human tissues
For human tissues, 5 µm cryosections were fixed in acetone at 4°C for 5 minutes (min). After
incubating with blocking solution (1% BSA in PBS) for 20 min at room temperature (RT), primary
antibodies against extracellular matrix proteins or other stromal markers were applied followed by
FITC-conjugated secondary antibodies. Subsequently, sections were incubated with a CK8
antibody, which was visualized by Cy3-anti-rat IgG secondary antibody. Sections were incubated
with individual antibodies for 1hour (h) at RT. For staining with aSMA and CAIX, primary aSMA
antibody was followed by Cy3-conjugated secondary antibody incubation. For the subsequent
incubation with CAIX antibody, a FITC-conjugated secondary antibody was used. The following
primary antibodies were used: CK8 (Throma-1; the University of Iowa, 1:50), Collagen I
(SouthernBiotech 1310-01; 1:200), Collagen III (SouthernBiotech 1330-01; 1:200), Laminin 1
(Sigma L9393; 1:200), Tenascin C (Abcam ab108930; 1:200), aSMA (Sigma F3777; 1:200),
FSP1 (a gift from Dr. Eric Neilson, Vanderbilt Univ.; 1:500), CD31 (DAKO, JC70A; 1:50), CAIX
(Novus Biologicals 1:100) and NG2 (Millipore AB5320; 1:200). FITC anti-goat IgG (Jackson
ImmunoResearch 705-095-147; 1:200), FITC anti-rabbit IgG (Jackson ImmunoResearch 711095-152; 1:200), Rhodamine anti-rabbit IgG (Jackson ImmunoResearch 711-295-152; 1:200),
FITC anti-rat IgG (Jackson ImmunoResearch 712-095-153; 1:200), and Rhodamine anti-rat IgG
(Jackson ImmunoResearch 712-295-153; 1:200) secondary antibodies were utilized. The slides
were washed with PBS three times for 10 min and mounted with Vectashield plus DAPI. Staining
was visualized on a Zeiss AxioSkop 2 fluorescent microscope and the images were taken with
Axiovision Rel 4.8 software. FITC staining and stromal area were quantified in 3 to 5 visual fields
per sample using the NIH Image J Analysis Software, where the same threshold was used for all
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compared conditions. Collagen I, III and tenascin C staining was determined as a ratio of FITC
staining signal/ stromal area for each visual field. Laminin1 staining was assessed as a ratio of
FITC signal/perimeter length around tumor or epithelial structures. CD31, NG2, aSMA and FSP1
positive cells only within the stroma were quantified as a ratio of individual marker positive cell
number/ stromal area per visual field. In case of NG2-covered microvessels (CD31+), the numbers
were calculated as a percentage out of all microvessels per visual field.

Immunolabeling of mouse tissues
Immunohistochemistry and immunofluorescence on murine mammary carcinoma tissues
Immunohistochemistry on paraffin-embedded mouse tissues for aSMA and Hypoxyprobe
was performed using the Vector M.O.M. kit (Vector Laboratories, BMK-2202). Slides were
deparaffinized, rehydrated and microwaved for 15 min at 98°C in citrate buffer (pH 6), before
incubated with Hydrogen-peroxide (Fisher H325-100; 15 min at RT). Tissues were blocked with
M.O.M. blocking reagent (prepared according to manufacturer’s recommendations) for 30 min at
RT, before incubated with primary antibody (aSMA DAKO M0851; 1:100, or Hypoxyprobe HPI
Inc., 1:50) over night at 4°C. After washing 3x3 min with TBS, secondary antibody (part of M.O.M.
kit) incubation followed for 30 min at RT. Subsequently, slides were washed (TBS, 3x 3 min) and
incubated with ABC reagent (Vector Laboratories, VECTASTAIN® Elite® ABC HRP Kit, PK-6100;
prepared as recommended by manufacturer) for 30 min at RT. After another wash, incubation
with DAB (Life Technologies, 750118) for 4 min at RT followed, before tissues were counter
stained with Hematoxylin (30 s incubation, Sigma-Aldrich GHS316-500ML). Slides were
dehydrated before coverslipping. Immunofluorescence stainings on paraffin-embedded mouse
tissues were performed using Tyramide Signal Amplification (TSA) technology (Perkin Elmer) as
previously described84. In short, tissues were deparaffinized, rehydrated and microwaved for 15
min at 98°C in citrate buffer (pH 6) for antigen retrieval (AR; number of 15 min-long ARs varied
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by antibody; described below). After blocking with 1% BSA in TBST for 10 min at RT, sections
were incubated with primary antibody for 1 h at RT. A secondary antibody incubation followed
using a horseradish peroxidase (HRP)-conjugated polymer (Biocare) for 10 min, before incubation
with TSA reagent (Opal reagent, 1:50, Perkin Elmer; 10min at RT). In between steps, slides were
washed with TBST 3x3 min. An additional antigen retrieval followed the immunolabeling to wash
off antibodies. In case of co-immunolabeling with additional antibodies, the same procedure was
repeated for each antibody. The following antibodies were used: CK8 (Throma-1; the University
of Iowa, 1:50, 3 ARs), aSMA (DAKO M0851; 1:2000; 4 ARs), FBP1 (Abcam ab109020; 1:50; 2
ARs), PKM2 (Cell Signaling, CS #4053; 1:800, 2 ARs), HK2 (CS #2867; 1:200; 2 ARs), Lyve1
(Angio Bio Co 11-034; 1:100, 1 AR), GLUT1 (Abcam ab115730, 1:200, 4 ARs) CAIX (Novus
Biologicals NB100-417; 1:1000; 2 ARs with Tris-EDTA buffer, pH 9.0, 0.05% Tween (TE buffer)).
Co-immunolabeling of tissues for CD31, PDGRFb and aSMA was performed in a similar
procedure, without usage of TSA technology. Tissue sections were subjected to a 30 min AR
using TE buffer before blocking with 4% Aurion Cold Water Fish Skin Gelatine (Electron
Miscroscopy Sciences, 25560) for 1h at RT. Incubation with primary antibodies: CD31 (Dianova,
DIA 310; 1:400), aSMA (DAKO M0851; 1:400), PDGFRb (Thermo Fisher, MA5-15143; 1:100) (1h
at RT) was followed by 30 min incubation with secondary antibodies: goat anti-rabbit Alexa Fluor
(Invitrogen, A11034, 1:250), donkey anti-mouse Alexa Fluor (Invitrogen, A3157, 1:250), goat antirat Alexa Fluor (Invitrogen, A11007, 1:250). All immunofluorescence labeling experiments were
followed by a 5-minute incubation with DAPI (Life Tech) before mounted using Fluoroshield
mounting media (Sigma Aldrich, F618). OCT-embedded tissues from aSMA-RFP; S100A4-GFP
mice were fixed with acetone at 4°C for 5 min, before slides were mounted with Vectashield +
DAPI. Immunofluorescence images were acquired either with Vectra Multispectral Imaging
System version 2 (Perkin Elmer), or Zeiss AxioSkop 2. Immunoreactive scores (IRS) were
obtained from the sum of distribution and intensity scores for each section. Sections were
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evaluated for staining intensity throughout the entire tissue section and ranked on a scale of 1 to
4 (or adapted to 1-5, depending on the respective experiment) with the section with the lowest
staining intensity being scored 1; and the section with the highest staining intensity being scored
4/5. Distribution scores were determined similarly determining the staining distribution in the entire
tissue section. The distribution score and intensity score were added together to make up the final
score. IRS scores were quantified while blinded to genotype or experimental group the tissues
belonged to. All quantifications were performed on pictures taken with identical exposure settings.
For representative pictures shown in the figure, in some cases picture contrast and brightness
were enhanced.

Immunohistochemistry and immunofluorescence on murine forestomach tissues
Tissues were fixed in formalin, paraffin embedded, and 4 mm sections were prepared. Briefly,
sections were deparaffinized and rehydrated, before antigen retrieval at 98C for 1 hour in 0.01
mol/L citrate buffer (pH 6.0). After blocking with diluted serum from the secondary antibody host
for 30 minutes, the slides were incubated overnight (4C) with the primary antibody. After blocking
endogenous peroxidase activity for 20 minutes with 3% hydrogen peroxide (Sigma), a biotinylated
anti-goat or anti- rabbit secondary antibody was applied for 30 minutes (Vector Laboratories). The
antigen–antibody complex was revealed by incubating with avidin–biotin–peroxidase (ABC) for
30 minutes according to the manufacturer's instructions (Vector Laboratories, VECTASTAIN®
Elite® ABC HRP Kit, PK-6100). Staining was visualized by incubation with diamino-benzidine
tetrahydrochloride (Vector Laboratories) for 2 to 10 minutes, as appropriate. The sections were
then counter- stained with hematoxylin (Fisher) where appropriate, dehydrated and mounted with
Entellan (Electron Microscopy Services). Parallel sections were run for all the experiments without
primary antibody, to ensure the specificity of the immunoreactions. The above protocol was also
used for ALK6 and FSP1 and CD45 and FSP1 double staining, with the following modifications:
Blocking was performed with diluted donkey serum. The goat anti-ALK6 or rat anti-CD45 antibody
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was added as the first antibody and incubated overnight at 4C, followed by a biotinylated donkey
anti-goat or anti-rat secondary antibody (Jackson Immuno- Research) and ABC reagent. Staining
was visualized by incubating for 20 minutes with 3-amino-9-ethylcarbazole (AEC, Vector
Laboratories), before washing thoroughly and adding an avidin– biotin blocking solution (Vector).
Thereafter, the tissue sections were blocked again with diluted donkey serum, before adding a
rabbit anti-FSP1 polyclonal antibody for 60 minutes, followed by a biotinylated goat anti-rabbit
antibody. The antigen–antibody complex was revealed by incubation with avidin–biotin–alkaline
phosphatase for 30 minutes according to the manufacturer's instructions (Vectastain ABC-AP Kit,
Vector Laboratories). Staining was visualized by incubating for 30 minutes with Vector Blue
(Vector Laboratories). The sections were then dehydrated and mounted with Vectamount AQ
(Vector Laboratories).
Co-immunofluorescence staining was performed using the TSA-based staining technique
as described above. After tissue were prepared as described above, an additional fixation step
was added using formaldehyde:methanol (1:10) prior to antigen retrieval.
For immunolabeling for CK5, mouse tissues were fixed overnight at 4˚C in 4%
paraformaldehyde (PFA); then transferred into 30% sucrose/phosphate buffered saline (PBS,
Cellgro) for at least 24 hours. After rinsing with PBS, the tissues were embedded in OCT
compound (Sakura) and frozen in liquid nitrogen. Cryosections (10 μm) were prepared, blocked
with 1% bovine serum albumin (BSA, Sigma), before incubating with a rabbit anti-CK5 antibody
for 60 minutes. Thereafter a TRITC-conjugated donkey anti-rabbit secondary antibody (Jackson)
was applied for 60 minutes to detect the CK5 positive cells. The sections were then mounted with
Vectashield with DAPI and analyzed by fluorescence microscopy. EYFP positive cells were
visualized directly, without the need for antibody staining.
The following antibodies were used: For immunohistochemistry: Goat anti-BMP7 (Santa
Cruz Biotechnology, sc-6899, dilution: 1:25), goat anti-ALK2 (R&D, AF637, 1:50), rabbit anti-ALK3
(Santa Cruz Biotechnology, sc-20736, 1:150), goat anti-ALK6 (Santa Cruz Biotechnology, sc-
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5679, 1:150), rat anti-CD45 (R&D, MAB114, 1:50), rabbit anti-CK5 (Abcam, ab24647, 1:1200),
rabbit anti-CK20 (Abcam, ab53120, 1:200), rabbit anti-Met (phosphorylated Tyr1001, Abcam,
ab61024, 1:50), rabbit anti-S100A4/FSP1 (gift from E.G. Neilson, 1:450), rabbit anti-HGF (Santa
Cruz Biotechnology, sc-7949, 1:50), rabbit anti-Ki67 (Abcam, ab15580, 1:500), and rabbit antip63 (phosphorylated Ser160/162, Cell Signaling Technology, #4981, 1:100). Anti-CD45 is a
monoclonal antibody; all other antibodies are polyclonal. For immunofluorescence: anti-CK5
(Abcam, ab24647, 1:300), anti-S100A4/FSP1 (DAKO, A5114; Opal 690 1:50, 2ARs), anti-Ki67
(Thermo Scientific, RM-9106-S, 1:500, Opal 520, 1:200, 3 ARs). Anti-Ki67 is rabbit monoclonal;
all other antibodies are rabbit polyclonal.
Immunofluorescence pictures (400x) were taken of representative forestomach epithelium
and stroma by one observer (Hikaru Sugimoto.), and the pictures were given random numbers.
The number of Ki67 positive cells in the forestomach were counted by another observer (Hans
Petter Eikesdal), blinded to the mouse genotype. Ki67 positive cells in the epithelium (FSP1
negative), and in the stroma (FSP1 positive) were summarized for the whole tissue section framed
within the picture, and from at least three separate mice per genotype. After unblinding by the first
observer (Hikaru Sugimoto.), the number of Ki67 positive cells in the epithelium (FSP1 negative)
and the stroma (FSP1 positive) were compared between the three genotypes.

TSA-based multiplex staining on murine mammary carcinoma tissues
TSA-based multiplex immunolabeling was performed as described above (Immunohistochemistry
and immunofluorescence on murine mammary carcinoma tissues). The panels used are listed in
below, which includes the number of 15 min antigen retrievals was used for each antibody, as
well as concentration for primary antibodies and the Opal fluorescent reagent. It also informs
about which Opal fluorescent reagent was used in conjunction with which antibody. Data analysis
was performed using Inform Software. For each marker, detection thresholds determined
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positivity. An R script created by Ehsan Ehsanipour in the Kalluri lab then summarized for each
cell which expression thresholds were met and therefore was positive for which markers.
Antibodies used:
Antigen

Company
and Lot #
Abcam
ab53066
Dako

Number of AR
(15 min each)
1

AR
Buffer
TE

Concentration

2

Citrate

1:8000

3

Citrate

1:50

aSMA

Throma-1;
the University
of Iowa
Dako M0851

4

Citrate

1:2000

Vimentin

CS5741

5

Citrate

1:200

CD31

Dianova Dia310
Thermo

6

Citrate

1:50*

7

Citrate

1:500

FAP
FSP1
CK8

Ki-67

1:100*

Secondary
reagent
Biocare
Rabbit
Biocare
Rabbit
Rat Polymer

Opal

Biocare
Mouse
on
mouse
polymer
Biocare
Rabbit
Rat Polymer

Biocare
Rabbit
*primary antibody was used with Aurion 4% Cold water fish gel instead of 1% BSA

Opal 570

Opal
concentration
1:100

Opal 650

1:100

Opal 620

1:400

Opal 690

1:100

Opal 520

1:100

Coumarin

1:50

Opal 540

1:400

Imaging of FSP1-GFP and aSMA-RFP signal
Tissues from FSP1-GFP;aSMA-RFP double transgenic and wt mice were fixed in 4% PFA
overnight at 4˚C; then transferred into 30% sucrose/PBS for at least 24 hours. After rinsing with
PBS, the tissues were embedded in OCT compound and frozen in liquid nitrogen. Cryosections
(7.5 μm) were prepared, hydrated with a brief wash in PBS, mounted with Vectashield with DAPI
and analyzed by fluorescence microscopy. Both the GFP and RFP transgene could be visualized
directly by fluorescence microscopy.

Immunofluorescence analyses of cultured cells
Primary forestomach fibroblasts were grown to sub-confluency on eight-well BD Falcon culture
slides and fixed in ice-cold methanol (–20°C). After blocking with 1% donkey serum, the cells
were incubated with the primary antibody overnight at 4˚C. Subsequently, the immunoreactions
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were detected by rhodamine-conjugated secondary antibodies (Jackson Immunoresearch),
mounted with Vectashield with DAPI (Vectorlabs) and analyzed by fluorescence microscopy.
Parallel wells were run for all the experiments without primary antibody, to assure the specificity
of the immunoreactions. The following antibodies were used: Anti-ALK6 (Santa Cruz, sc-25455,
1:50), anti-Met (phosphorylated Tyr1001, Abcam, ab61024, 1:50), anti-FSP1 (gift from E.G.
Neilson, 1:150), anti-HGFa (Santa Cruz, sc-7949, 1:50), anti-Tgfbr2 (Santa Cruz, sc-220, 1:100).
All antibodies are polyclonal.

Chromogenic in situ hybridization (CISH)
Sense and anti-sense oligonucleotide probes (Operon) for HGF and BMP7 RNA were designed
and labeled with digoxigenin using the DIG oligonucleotide 3´-End Labeling Kit (Roche). Glass
slides were coated with a 2% solution of 3-aminopropyl-triethoxy-silane (Sigma) and washed with
acetone and DEPC-water before use. Cryosections (14 µm) were applied to the coated slides,
fixed immediately with 4% PFA, permeabilized with 0.2M HCl and proteinase K, fixed again in 4%
PFA, and then incubated 3 hours in hybridization buffer (50% formamide, 2x SSC, 50mM
phosphate buffer, 1x Denhard´s solution, 5% sodium dextran). Thereafter, the sections were
incubated in hybridization buffer with either the sense or anti-sense DIG-labeled probes, overnight
at 37°C. The next day the sections were washed in washing buffer (100 mM Tris HCl, pH 7.5, 150
mM NaCl), and incubated 30 minutes with blocking buffer (Roche DIG High Prime DNA Labeling
and Detection Starter kit I), before adding an alkaline phosphatase-conjugated anti-DIG antibody
(Roche) for 60 minutes at 37°C. After repeated washes, the sections were equilibrated in
detection buffer (100 mM Tris HCl, pH 9.5, 100 mM NaCl) and the immunoreaction was visualized
by incubating with NBT/BCTP color substrate (Roche) for three hours. The color reaction was
stopped using TE-buffer and the sections were mounted using Vectashield. Parallel sections were
run with sense and anti-sense oligonucleotide probes, with or without DIG antibody, and with or
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without NBT/BCTP color substrate, to assure the specificity of the in situ RNA hybridization and
of the immunoreaction.
Sequences of the CISH oligonucleotide primers:
HGF sense: CAGTGTTCAGAAGTTGAATGCATGACCTGC
HGF anti-sense: GCAGGTCATGCATTCAACTTCTGAACACTG
BMP7 sense: AGCGATTTGACAACGAGACCTTCCAGATCACAGTCTATCAGGTGC TCCAG
BMP7 anti-sense: CTGGAGCACCTGATAGACTGTGATCTGGAAGGTCTCGTTGTCAAA
TCGCT

Analysis of immune cell populations in CAF-depleted tumors
Tumors were collected and transferred into cold RPMI/10% FBS and kept on ice. Subsequently,
tumors were cut into small pieces and placed in C-tubes (gentle MACS, Miltenyi Biotech) in
digestion buffer 0.1 mg/ml Liberase and 0.2 mg/ml DNaseI in RPMI. The pre-installed program:
m_imp Tumor_02 was run on GentleMACS octo dissociator. Homogenized samples were
incubated in C-tubes at 37C for 30 min at 150 rpm before the second program m_impTumor_03
was run twice on the dissociate. Samples were strained through 100 µm mesh into 50-ml conical
tube and 5 ml and RPMI (10mM M EDTA, 10% FBS (pH8.0) was added. FACS buffer (1% FBS
in PBS) was added to wash before pelleting the cells by spinning 5 min at 600g. The wash step
was repeated before sample was layered on Histopaque (Sigma Aldrich) and spun at 700g for 20
min. The white interphase was collected, pelleted and resuspended in FACS buffer. Samples
were stained in 96 well plates. Plate was spun 2 minutes at 800g at 4C, before cell pellets were
resuspended in 100 µl staining mix (FACS buffer + 1/5 of final volume BV Buffer + 50 µg/ml
CD16/32 block + surface antibodies + viability dye). Primary antibody incubation lasted 30 min on
ice before spinning the plate again and washing twice with 200 μl FACS buffer. Cells were
permeabilized and fixed with FoxP3 Fix-perm (Biolegend) for 1-12 h at 4C before washing with
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FoxP3 Fix Perm wash (Biolegend) and incubation with intracellular antibodies. After 2 additional
washes with FoxP3 Fix Perm wash, pellets were resuspended in 200 μl of BD Cytofix, incubated
on ice for 30 min (covered with foil) and washed with FACS buffer before flow cytometry analysis
on Fortessa X-20. Samples were run at 7,000 – 10,000 events/sec (do not exceed 20,000
events/sec) and up to 2,500,000 events were recorded per sample. Analysis was performed with
FlowJo software.
Antibody panels:
T-cell panel
Marker
PD1 (CD 279)
GranzB

Color
PerCP-Cy5.5
APC

1/100
1/100

CD8

Dilution

Cat # (Clone)
BioLeg 135208 (29F.1A12)
Invitrogen GRB05 (GB11)

1/200

BioLeg 100742 (53-6.7)

CD45
Live/dead
CD11b

BV650 (Qdot
655)
Pac Blue
780 (APC-Cy)
BV711

1/100
1/1000
1/400

Bio Legend 103126 (30-F11)
eBio 65-0865-14
BD 563168 (M1/70)

Ki67
CD49b

A488
PE

1/100 (i)
1/100

BD 558616 (B56)
eBio 12-5971-81

CD4

BV605

1/200

BioLeg 100548 (RM4-5)

Foxp3

A700

1/50 (i)

eBio 56-5773-82 (FJK-16s)

CD3

PE-Cy

1/200 (i)

eBio 25-0031-82 (145-2c11)

Marker
CD11b
Ly6C

Color
BV711
APC

Dilution
1/400
1/200

Cat # (Clone)
BD 563168 (M1/70)
BD 560595 (AL-21)

Ly6G

PE-Cy7

1/200

BD 560601 (1A8)

CD45
PDL1 (B7-H1)

Pac Blue
PE (=CD274)

1/100
1/100

Bio Legend 103126 (30-F11)
eBio 12-5982-83 (MIH5)

CD19

1/100

BioLeg 115541 (6D5)

Live/Dead
CD3

BV650 (Qdot
655)
780 (APC-Cy7)
A700

1/1000
1/50 (i)

eBio 65-0865-14
eBio 56-0032-82 (17A2)

PD1

PerCP-Cy5.5

1/100

BioLeg 135208 (29F.1A12)

Macrophage panel:
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CD11c

PE-CF594

1/50

BD 562454 (HL3)

Ki67

A488

1/100 (i)

BD 558616 (B56)

(i) means this is an intracellular antibody used in the second round of staining after
permeabilization.

Quantitative real time PCR
Human and mouse mammary fibroblasts
Primers were used with SYBR Green PCR Master Mix in a 7300 Sequence Detector System
(Applied Biosystems) and measurements were standardized to expression of the housekeeping
genes, either acidic ribosomal phosphoprotein PO (ARP/ 36B4), 18s, or β-actin. Fold-change in
gene expression was determined using the ddCt method. Technical triplicates were used, and
statistical analyses computed on the dCt that compared biological replicates (cell lines from
distinct mice or biopsies). Primer sequences are below:

Gene

Species

SLC2A1 (GLUT1)

H. Sapiens

Hk2

M. Musculus

HK2

H. Sapiens

LDHA

H. Sapiens

Pkm

M. Musculus

PKM

H. Sapiens

PFKL

H. Sapiens

Slc16a3 (Mct4)

M. Musculus

Primer sequences
F 5' AAGGTGATCGAGGAGTTCTACA 3'
R 5' ATGCCCCCAACAGAAAAGATG 3'
F 5’ GGAACCGCCTAGAAATCTCC 3’
R 5’ GGAGCTCAACCAAAACCAAG 3’
F 5' TTTGACCACATTGCCGAATGC 3'
R 5' GGTCCATGAGACCAGGAAACT 3'
F 5' CAGCCCGAACTGCAAGTTG 3'
R 5' CCCCCATCAGGTAACGGAATC 3'
F 5’ GCCGCCTGGACATTGACTC 3’
R 5’ CCATGAGAGAAATTCAGCCGAG 3’
F 5’ ATGTCGAAGCCCGATAGTGAA 3’
R 5’ TGGGTGGTGAATCAATGTCCA 3’
F 5’ GCTGGGCGGCACTATCATT 3’
R 5’ TCAGGTGCGAGTAGGTCCG 3’
F 5' GGGGCCTACTGCTCAACTG 3'
R 5' CGGTCTCGGAAGACACTCAG 3'
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SLC16A3 (MCT4)

H. Sapiens

HIF1A

H. Sapiens

Arp/36b4

M. Musculus

ACTB (β-Actin)

H. Sapiens

18s

M. Musculus

F 5' TGACTGGACAGGTATCCTTGAG 3'
R 5' AGTAGTGGAAATGTGGTGGCTA 3'
F 5' CTGCCACCACTGATGAATTA 3'
R 5' GTATGTGGGTAGGAGATGGA 3'
F 5’ GGAGCCAGCGAGGCCACACTGCTG 3’
R 5’ CTGGCCACGTTGCGGACACCCTCC 3’
F 5' CATGTACGTTGCTATCCAGGC 3'
R 5' CTCCTTAATGTCACGCACGAT 3'
F 5’-GTAACCCGTTGAACCCCATT-3’
R 5’-CCATCCAATCGGTAGTAGCG-3’

Murine forestomach fibroblasts
Primary forestomach fibroblasts were plated on 6-well plates (Falcon), at 150,000 cells per well,
and starved 24 hours in DMEM with 0.1% FBS. Thereafter the media was changed to DMEM
with 0.1% FBS with or without Activin A (50 ng.ml-1) or 100 ng.ml-1 BMP7 (R&D), and the cells
were treated for 24 hours. Then the cells were washed with warm (37°C) PBS, and RNA was
isolated with Trizol, as described in the Invitrogen product manual, followed by DNAse
(Invitrogen) treatment. RNA concentration was measured using an Eppendorf BioPhotometer.
Reverse transcription of 0.5 μg of RNA from each sample was performed with Superscript IITM
reverse transcriptase (Invitrogen) or MultiscribeTM reverse transcriptase (Applied Biosystems),
followed by RNAse treatment, before running PCR (35 cycles) with the below primers.
Primer sequences:

Gene

Sequence

Activin A forward

5’ TGGAGCAGACCTCGGAGATCATC 3’

Activin A reverse

5’ AAGCACTAGACTGGCACCACTC 3’

Activin B forward

5’ TCCGAGATCATCAGCTTTGCAG 3’

BMP2 forward

5’ ATCTGTACCGCAGGCACTCAGG 3’

BMP2 reverse

5’ TGTGTGGTCCACCGCATCACAG 3’
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BMP4 forward

5’ AGCCATGCTAGTTTGATACCTG 3’

BMP4 reverse

5’ AAGCAGAGCTCTCACTGGTCC 3’

BMP6 forward

5’ TGCTGGATCTCTACAACGCCCTG 3’

BMP6 reverse

5’ ACAGTCCTTGTAGACGCGGAACTC 3’

BMP7 forward

5’ TGGACAACGAGGTGCACTCCAG 3’

BMP7 reverse

5’ TGGTTGCTGGTGGCTGTGATATC 3’

HGF forward

5’ ACCAAACTTCTGCCGGTCCTGTTG 3’

HGF reverse

5’ ATCATGGAATTCCAAGGCTGGC 3’

b-actin forward

5’ TGGCATTGTTACCAACTGGG 3’

b-actin reverse

5’ AGTTTCATGGATGCCACAGG 3’

CCL5 forward:

5’ TCACCATCATCCTCACTGCAGC 3’

CCL5 reverse

5’ TCTCTGGGTTGGCACACACTTG 3’

CTGF forward

5’ ATGTCAGTGCGCAGCCGAAGCAG 3’

CTGF reverse

5’ AGTCTGCAGAAGGTATTGTCATTG 3’

EGF forward

5’ AAGCAAGGCGATTTGGATAGCC 3’

EGF reverse

5’ TTCGCAGTACTTCCGGTCTCGG 3’

FGF2 forward

5’ ACTACAACTCCAAGCAGAAGAGAG 3’

FGF2 reverse

5’ TCAGCTCTTAGCAGACATTGGAAG 3’

FGF10 forward

ATGTGGAAATGGATACTGACAC 3’

FGF10 reverse

5’ TCATGGCTAAGTAATAGTTGCTG 3’

GM-CSF forward

5’ ATTGTGGTCTACAGCCTCTCAGC 3’

GM-CSF reverse

5’ AGGTGGTAACTTGTGTTTCACAGTC 3’

HB-EGF forward

5’ ACTGGATCCACAAACCAGCTGC 3’

HB-EGF reverse

5’ TGAGAAGTCCCACGATGACAAG 3’
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IGF1 forward

5’ AGATACACATCATGTCGTCTTCAC 3’

IGF1 reverse

5’ TTCTGAGTCTTGGGCATGTCAG 3’

IGF2 forward

5’ AAGTCGATGTTGGTGCTTCTC 3’

IGF2 reverse

5’ TCACTGATGGTTGCTAGACATC 3’

IL-6 forward

5’ ACTGATGCTGGTGACAACCACG 3’

IL-6 reverse

5’ AGCTTATCTGTTAGGAGAGC 3’

KGF forward

5’ ATACTGACACGGATCCTGCCAAC 3’

KGF reverse

5’ TGCATAGAGTTTCCCTTCCTTG 3’

NGF forward

5’ TGGATGGCATGCTGGACCCAAGC 3’

NGF reverse

5’ ATGAACCTCCAGGCAGCCTGC 3’

SDF1a forward

5’ AGTCAGCCTGAGCTACCGATG 3’

SDF1a reverse

5’ TAAAGCTTTCTCCAGGTACTC 3’

SFRP1 forward

5’ AGCGAGTACGACTACGTGAGC 3’

SFRP1 reverse

5’ ACCGTTCTTCAGGAACAGCACAA 3’

TNC forward

5’ TGTCCCCTCCCAAAGACCTTATTG 3’

TNC reverse

5’ TCGGGTGTTGTTTTTCACAATGTGC 3’

TGFa forward

5’ ACAGCTCGCTCTGCTAGCGCTG 3’

TGFa reverse

5’ TTCTCATGTCTGCAGACGAGG 3’

TGFb1 forward

5’ ACTCTCCACCTGCAAGACCATCGAC 3’

TGFb1 reverse

5’ TGGTAGAGTTCCACATGTTGCTCC 3’

Wnt1 forward

5’ TCTACTACGTTGCTACTGGCAC 3’

Wnt1 reverse

5’ TTGCACTCTTGGCGCATCTCAGAG 3’

Wnt3 forward

5’ TCCTCGCTGGCTACCCAATTTG 3’

Wnt3 reverse

5’ GTGCTTGTTCATAGCTG 3’
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Immunoblotting
Human mammary fibroblasts
Cells were lysed with RIPA buffer using standard protocol. Protein concentrations were
determined by BCA Protein Assay (Thermo Scientific) with a microplate reader at 562 nm. Wes
system (Protein Simple) was utilized and assay was performed according to manufacturer’s
recommendations with the following antibodies: HIF1a antibody (Novus Biologicals, AF1935,
1:10), b-Actin (Sigma Aldrich, A3854, 1:100). Band intensities were quantified using the Compass
Software (Protein Simple).

Isolated forestomach fibroblasts and tissues
Cells and tissues were homogenized and lysed with protein lysis buffer (50 mM Tris HCl, pH 7.5,
150 mM NaCl, 0.1% SDS, 1% deoxycholate, 1% Triton X-100) containing a protease inhibitor
cocktail (Roche). Protein concentrations were measured by a bicinchoninic acid (BCA) assay
(Pierce), and 30 µg of protein was loaded per lane for the whole tissue immunoblots and 15µg of
protein was loaded per lane for the cell culture immunoblots. For the BMP7 stimulation
experiment, primary forestomach fibroblasts were plated on 6-well plates (Falcon), at 150 000
cells per well, and starved 24 hours in DMEM with 0.1% FBS. Thereafter, the cells were either
harvested directly or the media was changed to DMEM with 0.1% FBS with 100 ng/ml-1 of BMP7,
and the cells were treated for 24 or 48 hours before harvesting protein. The protein lysates were
fractionated using SDS-PAGE gel electrophoresis, transblotted to PVDF membranes by semi-dry
technique, before performing coomassie staining to assure equal protein loading. Thereafter, the
membranes were blocked with 5% fat-free dry milk for 60 minutes, before immunoblotting
overnight with the primary antibody. The immobilized antibody was detected using the appropriate
horseradish peroxidase-conjugated secondary antibody (Sigma) and ECL (Pierce). The
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immunoreaction was visualized using Hyblot autoradiography films (Denville). Immunoblots for
actin were performed for all samples to assure equal protein loading. The intensity of the bands
from uncropped blots were quantified using ImageJ software. The areas under each peak for the
proteins of interest were normalized to those of actin in each blot. The following antibodies were
used: Rabbit anti-Actin (Sigma, A2066, 1:2500), rabbit anti-Akt (phosphorylated Ser473, Cell
Signaling, #4060, 1:1000), mouse anti-BMP7 (Sigma, B2555, 1:2000), rabbit anti-ERK1/2
(phosphorylated Thr202/Tyr204, Cell Signaling, #9101, 1:500), mouse anti-HGF (Assay Designs,
#905-165, 1:5000), rabbit anti-PTEN (Cell Signaling, #9559, 1:1000), rabbit anti-Smad1/5
(phosphorylated Ser463/465, Cell Signaling, #9516, 1:1000), rabbit anti-Smad2 (phosphorylated
Ser465/467, Cell Signaling, #3101S, 1:1000). BMP7, HGF, phosphorylated-Akt, phosphorylatedSmad1/5, and PTEN are monoclonal antibodies; all other antibodies are polyclonal.

5-Azacytidine treatments of hBFs
hBFs were seeded in 10 cm plates (100,000 cells/plate). 3 days after seeding media was
replaced with media containing 3 µM 5-Azacytidine. Media was replaced with fresh 5Azacytidine containing media after 24 h. After 48 h, cells were harvested. hBF # 33 and # 38
were used in 3 independent experiments (biological replicates) and hBF #120 was used in 2
independent experiments (biological replicates). These experiments were performed by Joyce
Tse O’Connell.

E10 epithelial cell proliferation assays
Primary forestomach fibroblasts were grown to sub-confluency in DMEM with 20% FBS.
Thereafter, the media were changed to DMEM with 0.1% FBS, and the cells were incubated for
48 hours. Then, the conditioned media were sterile filtered (0.22 µm, Fisherbrand) and stored at
-80°C until further use. E10 epithelial cell lines were used to determine the influence of
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conditioned fibroblast media on epithelial cell function. The E10 lung epithelial cell line was a
kind gift from A. Malkinson (UCHSC). The E10 cells were grown in CMRL-1066 Medium
(Gibco), supplemented with L-glutamine (0.15 g.L-1, Cellgro), 10% FBS, 100 units.ml-1 of
penicillin and 100 µg.ml-1 of streptomycin. The cells were seeded at 1,800 cells per well in 96well plates (Falcon) and allowed to attach overnight in CMRL-1066 with 10% FBS. Next, the
E10 cells were serum starved in DMEM with 0.1% FBS for 24 hours, before culturing for 48
hours with the conditioned fibroblast media, with or without the Met inhibitor SU11274 (10µM,
kind gift from Pfizer). The surviving cell number was assessed by methylene blue assay, as
described previously85. Multiple rows of eight wells were subsequently analyzed. Cells were
regularly tested and negative for mycoplasma.

BMP7 stimulation of forestomach fibroblast proliferation
Primary forestomach fibroblasts were seeded at 2,000 cells per well in 96-well plates and
allowed to attach overnight in DMEM with 20% FBS. Thereafter, the cells were serum starved in
DMEM with 0.1% FBS for 24 hours, before treating for 48 hours with 0, 1, 10 or 100 ng.ml-1
recombinant human BMP7 (BMP7, R&D) in DMEM with 0.1% FBS. The surviving cell number
was assessed by methylene blue assay, as previously described.

13

C glucose labeling experiments

hCAFs were incubated in media (10% FBS (dialyzed, Thermo Scientific), 2 mM L-glutamine
(Gibco), 2.5 mM

13

C6 glucose in glucose-free DMEM) containing uniformly

13

C labeled glucose

([U-13C] glucose, Cambridge Isotope Laboratories) for 48 h to allow labeling of all glucose-derived
metabolites in the cells. The cells were washed four times with PBS and processed for mass
spectrometry as described above, or, after incubation in media containing [U-13C] glucose,
washed three times with PBS to remove any residual [U-13C] glucose before incubation with media
containing unlabeled glucose (10% FBS, 2 mM L-glutamine, 2.5 mM glucose in DMEM) to collect

34

conditioned media (CM), which contained labeled secreted metabolites. The CM metabolites were
extracted and measured (as described above) or fed to MDA-MB-231 cells for 24 h. MDA-MB231 cells were then washed four times with PBS and processed for mass spectrometry as
described above. Unlabeled MDA-MB-231 cells, as well as unlabeled hCAFs served as controls.
If false positive rate in controls exceeded 5% (for metabolites secreted by hCAFs) or 10% (for
metabolites in hCAFs and MDA-MB-231 cells), metabolites were excluded. These experiments
were performed by Margo Cain and data analysis was done by myself.

Seahorse Glycolysis Stress Test
Glycolysis stress tests were performed using a Seahorse XF96 analyzer (Agilent). The assays
were performed according manufacturer’s instructions. Specifically, microplates (part of Agilent
product pack 102416-100) were coated with 10 µg/ml rat tail Collagen I (Corning 354249) before
mouse fibroblasts (10,000 cells/well) and human fibroblasts (8000cells/well) were seeded. Assays
were performed 2 days after seeding to allow cells to attach to the plate. 24 h before the assay,
cartridge (part of Agilent product pack 102416-100) was filled with H2O and placed in a non-CO2
incubator. After overnight incubation, H2O was replaced with Calibrant (part of Agilent product
pack 102416-100), and placed back in a non-CO2 incubator. Seahorse XF prep station was used
to replace cell culture media with Base Media (Agilent, 102353-100) supplemented with 2 mM
Glutamine (Gibco; pH of media adjusted to 7) 45 min prior to the assay. After media change, cells
were placed in non-CO2 incubator. 10 min before start of the assay, medium was replaced once
again using Seahorse XF prep station, to ensure correct baseline readings. Assay was performed
with a standard protocol: for each stage, 3 measurements were taken; for each measurement,
media was mixed for 3 min and the measurement lasted 4 min. After baseline measurements,
glucose (10 mM final concentration, Agilent 103020-100) was injected from port A. After 3
measurements, Oligomycin (3 µM final concentration, Agilent 103020-100) was injected from port
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B and measurements were repeated. Lastly, 2 deoxy-glucose (100 mM final concentration,
Agilent 103020-100) was injected from port C and 3 measurements followed before assay ended.
Data was analyzed with Seahorse Wave software. After the assay, cells were fixed to the plates
with 4% paraformaldehyde (Electron Microscopy Sciences 15710-S) and stained with DAPI (Life
Tech). Subsequently, pictures were taken of each well (5 pictures in 20x magnification) and %
DAPI positive area was quantified with ImageJ software to determine cell density, which was used
to normalize ECAR values. Glycolysis, glycolytic capacity and glycolytic reserve were determined
as recommended in the Seahorse XF User Manual: Glycolysis: last rate measurement before
glucose injection is subtracted from the max rate measurement before oligomycin injection.
Glycolytic capacity: last rate measurement before glucose injection is subtracted from the max
rate after oligomycin injection. Glycolytic reserve: glycolysis is subtracted from glycolytic capacity.

Statistical analysis
For comparison between two groups, a one-tailed or two-tailed unpaired t-test (with Welch’s
correction when appropriate) or Mann-Whitney test was performed, as listed in the figure legend.
For comparison between three groups, an ordinary one-way ANOVA test was used. A P value <
0.05 was used to define statistical significance.
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CHAPTER 3

CHARACTERIZATION OF FIBROBLAST HETEROGENEITY IN MURINE MODELS OF
MAMMARY CARCINOMA

This work has been done with the help and in collaboration with Drs. Ehsan Ehsanipour, Pedro
Correa de Sampaio, Julie Carstens, Hikaru Sugimoto and Patricia Philips. Some of the data
shown in this chapter was generated by Joyce Tse O’Connell and Hikaru Sugimoto (indicated in
figure legends) and is shown with their permission.

Parts of the work in this chapter has been published previously and is taken verbatim from the
publication:
Becker, L. M.*, O’Connell, J. T.*, Vo, A. P., Cain, M. P., Tampe, D., Bizarro, L., Sugimoto, H.,
McGow, A. K., Asara, J. M., Lovisa, S., McAndrews, K. M., Zielinski, R., Lorenzi, P. L., Zeisberg,
M., Raza, S., LeBleu, V. S., and Kalluri, R. Epigenetic Reprogramming of Cancer Associated
Fibroblasts Deregulates Glucose Metabolism and Facilitates Progression of Breast
Cancer. Cell Reports, 31(9), 107701. https://doi.org/10.1016/j.celrep.2020.107701
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Summary
CAFs are now widely recognized as a heterogenous cell population, comprised of multiple
functionally distinct subsets. Several recent studies have identified breast cancer CAF subtypes
based on the expression patterns of different mesenchymal markers. However, the majority of
CAF populations remains to be identified. More importantly, phenotypically-defined CAF
populations need to be further attributed to specific functions to provide new insight into their
specific roles in tumorigenesis. This chapter describes a project in which we leveraged multiplex
immunofluorescent staining technology to catalogue overlapping expression patterns of different
mesenchymal markers in two mammary carcinoma rodent models. Based on differential marker
expression, we defined several distinct CAF populations and constructed a comprehensive map
of the evolution of CAF marker composition in the TME during tumor initiation and progression.
Surprisingly, the majority of CAFs was identified by expression of single markers, with little overlap
in the expression patterns of the four different markers tested. Phenotypically defining these CAF
subtypes served as the basis for several follow-up studies to further characterize their functions
which are presented in Chapter 4.

Introduction
Several studies aiming to unravel CAF heterogeneity in breast cancer had been published
in recent years. Sugimoto et al. investigated the expression pattern of six major CAF makers in
4T1 mouse mammary tumors by measuring co-expression of marker pairs. NG2, aSMA and
PDGFRβ showed significant overlap (80-90%) in their expression patterns, whereas FSP1
displayed expression restricted to a single, distinct CAF population. In contrast, Vimentin and
Collagen1 (Col1) were shown to be ubiquitous mesenchymal markers86. RNA sequencing
analyses were used to identify three distinct CAF subpopulations in the MMTV-PyMT transgenic
model of mammary carcinoma. Vascular CAFs (vCAFs), developmental CAFs (dCAFs), and
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matrix CAFs (mCAFs) were each associated with a distinct gene expression signature, and
immunolabeling evidence suggested unique origins for these subpopulations. Commonly used
CAF markers such as aSMA, FAP and FSP1 were found in all discovered CAF subsets, and
therefore not useful in further resolving CAF subsets on the level of gene expression. Instead,
protein expression of more restricted CAF markers such as PDGFRa, Nidogen2, and scrapieresponsive protein 1 (SCRG1) could each define a unique CAF subset (mCAFs, vCAFs, dCAFs,
respectively). Although no functional characterization experiments were performed in this study,
the abundance of vCAFs and mCAFs in patient-derived samples were observed to be correlated
with increased risk of developing metastatic disease87. A follow-up study compared the described
subsets in mammary fat pads as well as in early and late stage MMTV-PyMT tumors and
demonstrated dynamic changes in CAF populations through tumorigenesis using multiplex
immunolabeling. In addition, gene expression signatures were determined for early and late stage
CAFs. Early stage CAF signatures were correlated with more positive patient outcome, while late
stage CAFs signatures were associated with disease features such as increased NFkB signaling
which is itself linked to increased risk for developing metastases88.
Clinical studies have suggested increased stromal content as a predictor of improved
outcome in ER+ breast cancer, whereas in triple negative breast cancer it is a predictor of poor
outcome25–27,89. Recently, a paper described “reactive stroma”, a stroma subtype characterized
by high level of protein expression of Caveolin-1, Collagen VI, and aSMA, as well as a higher cell
density in the stromal compartment independent of molecular subtypes. This subtype predicted
favorable clinical outcome in estrogen receptor (ER)+/ human epidermal growth factor receptor 2
(HER2)- breast cancers, but had no prognostic value in triple-negative cases90. A very thorough
flow cytometry-based study using patient-derived fibroblasts was successful in identifying four
CAF subsets based on the differential expression patterns of CD29, FAP, aSMA, PDGFRb, FSP1,
and CAV1. Subsequent in vitro experiments demonstrated two of the identified subsets interacting
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with

different

immune

cell

populations,

thereby

promoting

an

immunosuppressive

microenvironment 91.
As it becomes obvious, several breast CAF subsets have been identified using RNA
sequencing, multiplex immunolabeling or flow cytometry in transgenic animal models and patient
tissues. The variety of marker sets used in these studies and the inconsistency in observed
differential expression pattern highlights the difficulty of CAF subset identification and highlights
a need for more standardized determination of CAF populations. In an effort to further unravel the
complexity of heterogenous CAF marker expression, we used Tyramide Signal Amplification
(TSA)-based multiplex immunolabeling to probe for different mesenchymal markers in tissue
sections from two distinct animal models of mammary carcinoma. Specifically, expression
overlaps of ⍺SMA, Vimentin, FSP1, FAP were investigated. ⍺SMA is the most commonly used
marker to identify CAFs and FSP1 had already been shown to uniquely label a distinct CAF
population in mammary carcinoma92. While the prominent CAF marker FAP is thought to
specifically label activated fibroblasts, Vimentin presents a more ubiquitous fibroblast marker. We
hypothesized that we would be able to identify distinct CAF populations by the differential
expression patterns of these 4 markers.

CAF heterogeneity in the 4T1 murine mammary carcinoma model
To confirm the distinct, minimally overlapping expression pattern of aSMA and FSP1 in
CAFs, we utilized aSMA-RFP;S100A4-GFP transgenic mice, which express RFP and GFP that
are respectively driven by aSMA and FSP1 (S100A4) promoters. RFP and GFP expression was
assayed in healthy tissues of aSMA-RFP;S100A4-GFP mice, or in tumors and metastatic lungs
of aSMA-RFP;S100A4-GFP mice bearing 4T1 tumors. aSMA+ stromal cells comprised the
majority of stromal cells in the mammary fat pads (~80%) and in the lungs (~62%) of healthy mice,
as well as in tumors (~94%) and metastatic lungs (~66%) of 4T1 tumors bearing mice when
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compared to FSP1+ stromal cells (~17% in the mammary fat pad, ~22% in the lungs, ~2% in 4T1
tumors, and ~28% in metastatic lungs) (Figure 3A). Stromal cells or CAFs (in tumors and
metastatic lungs) double positive for aSMA and FSP1 were rare, consistent with our previous
report using immunohistochemistry86 and direct visualization of GFP (FSP1) and RFP (aSMA) in
tissue

sections

(Figure

Following

the

3B).

identification

of

distinct

aSMA+ and FSP1+ CAF
subsets,

expression

of

additional CAF markers
was tested in the same
populations.

To

detect

CAF subsets that can be
identified by expression of
either

a

single

mesenchymal marker or a
combination
Figure 3. aSMA and FSP1 expression in healthy and mammary tumor
bearing mice
A. aSMA-RFP;S100A4-GFP transgenic mice were implanted with 4T1
mammary carcinoma cells. Expression of RFP and GFP was analyzed in
tumors and metastatic lungs of the mice, as well as in mammary fat pads
and lungs of healthy control animals. FACS blots with quantification are
shown. B. Representative tissue sections. Scale bar: 16 µm. C. Gating
strategy used in (A). n = 3 healthy and 4 tumor bearing mice. Experiment
performed by Joyce Tse O’Connell and panels are reproduced with
permission. A similar experiment using aSMA-RFP mice is shown in
doctoral dissertation of Joyce Tse O’Connell96.
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and CD31 on a single tissue section of excised 4T1 mammary tumors. CAFs were defined as
non-epithelial (CK8–), non-endothelial (CD31–) cells that expressed at least one of the
mesenchymal markers tested. A CD45 antibody for detection of mesenchymal marker expression
by immune cells was not included, due to the limitation of 8 fluorescence filters used to unmix the
channels. However, immune cells were excluded based on their shape and size in the analysis
using the Inform program. In end-stage (~2000mm3) 4T1 tumors, the majority of CAFs were
single-positive for one of the four mesenchymal markers probed (Figure 4). FSP1 was observed
to label a very minor CAF subset in these tumors (<0.05%) in comparison to aSMA which was
more widely expressed (~20%). Vimentin was ubiquitously expressed in end-stage tumor CAFs
(~95%), with Vimentin single-positive (s+, Vims+) CAFs being the most abundant CAF subset
(~80%), followed by aSMA+Vim+ (~14%) and aSMAs+ CAFs (3%). 10-20% of each population
were co-expressing Ki67 (data not shown).
The minimal expression overlap between FSP1 and aSMA observed in the transgenic animals
(aSMA-RFP; S100A4-GFP) was confirmed with multiplex immunolabeling. Note however, that a
direct comparison of CAF abundance assayed using different approaches can present with
difficulties, as discussed later
in this chapter.
4T1

mammary

carcinomas are thought to
mimic
Figure 4. Overlaps in CAF marker expression in 4T1 tumors
4T1 mammary tumors were stained for FSP1, Vimentin, aSMA, FAP, CK8,
CD31, Ki67 and DAPI. Representative picture of the staining and Venn
diagram of expression overlaps of aSMA, FSP1, Vimentin and FAP is
shown. Numbers represent the number of cells in any 10,000 CAFs (CK8–
CD31–) in the tumor. The analysis is the average of 9 individual tumors.
Scale bar: 20µm.
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stroma often compare TNBC
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breast cancers, we further expanded our experiments to include the MMTV-PyMT transgenic
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mammary carcinoma mouse model (referred to as PyMT) representing the ER+, luminal B
subtype.

CAF heterogeneity in the MMTV-PyMT murine mammary carcinoma model
4T1 and PyMT-derived mammary tumors differ not only in their molecular subtype, but also in
their histological features. 4T1 tumors present with large necrotic areas and less differentiated
tissue compared to PyMT tumors. Hypoxia is also increased in 4T1 tumors (Figure 5).

Figure 5 4T1 and MMTV-PyMT tumor histological features
A. H&E stained 4T1 and MMTV-PyMT (PyMT) tumors with representative pictures of edge and center, as
well as necrotic and intact tissue. B. Assessment of hypoxia with CAIX staining in 4T1 and PyMT tumors
with representative pictures and quantification. Scale bars = 50µm.
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In PyMT tumors, expression of CAF markers by non-fibroblast cells was determined by
two (2) multiplex immunolabeling panels: In both panels, CK8 and CD31 served as control
markers for epithelial and endothelial cells, and Ki67 was used to measure proliferation. Panel1
includes aSMA and FAP; whereas Panel2 includes Vimentin and FSP1 (Figure 6). All CAF
markers were expressed by cancer cells (15% - 40%), but the majority of CAF marker expression
(>50% for all markers except Vim (45%)) were in the CAFs. Proliferative index differed depending
on the markers tested, but was similar to the 4T1 model ~10-25% depending on the marker (data
not shown).

Figure 6 Expression of CAF markers by different cell types in PyMT tumors
Two TSA-based multiplex panels were used to determine expression of FSP1, Vimentin, ⍺SMA and FAP by epithelial (CK8)
and endothelial (CD31) cells. Mesenchymal marker expression by immune cells were excluded based on size (see
methods). Scale bar: 20µm.

We subsequently measured the expression overlaps of ⍺SMA, Vimentin, FSP1, and FAP
in PyMT tumors using TSA-based multiplex staining. Surprisingly, only a small fraction (<10%) of
CAFs co-expressed multiple markers simultaneously and the majority of the cells expressed a
single CAF marker (single-positive; s+). The most abundant CAFs in PyMT tumors expressed only
⍺SMA (⍺SMA single positive: ⍺SMAs+) (49% of all CAFs), followed by Vims+ CAFs (23%). FSP1
and FAP were expressed only in a minority of CAFs (Figure 7A).
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Figure 7 Expression overlaps of CAF markers in PyMT tumors
A. Representative picture of TSA-based multiplex staining of FSP1, FAP, Vimentin, ⍺SMA, Ki67
and DAPI in PyMT tumors. Scale bar: 20µm. B. Quantification of stromal area via Mason Trichrome
staining (MTS) at different stages of tumorigenesis. Scale bar: 50µm. Arrows indicate stromal
areas.

Tumors from PyMT transgenic mice represent an excellent system to model multi-stage
progression of human disease delineated by histological features. To describe and resolve the
population dynamics of distinct CAF subsets in disease progression, we staged the tumors into
four groups based on tumor volume. Stromal content (as assessed by Mason Trichrome Straining
(MTS)) remained unchanged as tumors progressed (Figure 7B). We next measured the
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abundance of the major CAF populations we had identified specifically in these groups, using
healthy mammary fat pads as a baseline (Figure 8B-C).

Figure 8 CAF marker expression changes during tumorigenensis in PyMT tumors.
A. Expression of the largest identified CAF subsets based on expression of ⍺SMA, FAP, FSP1 and Vimentin
in tumors of different stages. Representative H&E pictures of tumors at different stages are shown. Scale
bar: 50µm B. Quantification of A. Note, that stages in A. refer to tumors of different volumes in B.

In healthy tissues, ⍺SMAs+, Vims+ and ⍺SMA+Vim+ stromal cells represented the largest
fibroblast populations. Changes in the distribution of different populations were readily observable
in early stage tumors (Figure 8A-B). Notably, healthy mammary fat pads contain 5% fibroblasts
(by cell number), whereas in tumors, up to 20% of cells were CAFs irrespective of their staging
(data not shown). In early-stage tumors, Vimentins+ CAFs were the most abundant, with their
abundance decreasing in larger, later-stage tumors. In contrast, ⍺SMAs+ CAFs were less
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abundant in early stage tumors but the population expanded as the tumors progressed. The
percentage of cells co-expressing multiple CAF markers, including aSMA+Vim+ also decreased
with tumor growth. In tumors £ Stage 2, ⍺SMAs+, Vims+ and aSMA+Vim+ CAF populations were
similar in size. As the tumors progressed beyond Stage 2, ⍺SMAs+ CAFs outpaced all other
populations (Figure 8A-B).
In summary, our approach successfully identified distinct CAF subsets by expression of
single mesenchymal markers or combination of multiple co-expressed markers. Most CAFs were
found to express only one of the four markers tested. Next, we sought to validate our findings in
human breast cancer tissues.

Mesenchymal marker expression in human samples
In collaboration with Sughra Raza from the Brigham and Women’s hospital in Boston, MA,
we established a collection of patient samples from a large patient cohort (Figure 9A). Tissue
biopsies were isolated from patients with benign pathologies (~65%), such as fibroadenomas or
calcifications, and breast cancer (~35%, Figure 9A) with varying mammographic breast densities
(Figure 9A). A total of 499 biopsies were collected from patients between 18 and 88 years of age
(Median age: 51 years). All cancer cases were 82% White, 10% Hispanic/Latino, 3%
Black/African American, 2% Asian and 3% not indicated. Amongst the patients with benign
pathologies, 77% were White, 10% Hispanic/Latino, 9% Black/African American, 2% Asian, 0.3%
American Indian/Alaska Native and 2% not indicated.
As TSA-based multiplex staining was unsuccessfully applied to preserved human
samples, we opted to investigate the expression of stromal markers individually. CK8 staining
was used as an epithelial cell marker to exclude non-stromal mesenchymal marker expression
from our results. ECM proteins Collagen I, Collagen III and tenascin expression was increased in
cancer tissues when compared to benign tissues. Laminin expression, in contrast, was decreased
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in breast cancer samples. FSP1 and aSMA expression was upregulated in cancer samples. In
agreement with previous studies probing for tumor angiogenesis, CD31 expression was also
increased; whereas pericyte coverage of CD31 vessel was decreased (Figure 9).

Figure 9 CAF marker expression in patient tissues of different pathologies
A. Pathology and mammographic density of patient samples collected. B.
Immunolabeling of patient tissues with mesenchymal markers. This experiment was
performed and analyzed by Hikaru Sugimoto. Scale bar: 20µm
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Interpretation of findings
We were able to identify phenotypically distinct CAF subtypes with our multiplex
immunolabeling approach in two distinct mouse models of mammary carcinoma. Unlike previous
studies in which CAF subsets were identified by co-expression of several mesenchymal
markers91, we found that the majority of CAFs expressed only a single marker (out of the four
tested). However, we can only conclude single positivity for the markers we investigated. Any of
the identified single-positive populations may co-express additional, untested mesenchymal
markers. Nonetheless, the markers used in these experiments are very commonly used CAF
markers. Their restrictive expression pattern suggests that none are suitable to be used as a
universal CAF identifier capturing the entire CAF population. It remains to be determined whether
the addition of untested markers can, in conjunction, identify the entire CAF population in a given
tumor. The distinct CAF populations may play unique roles in tumorigenesis. This would explain
why previous functional studies concluded varying, and sometimes contradictory roles for CAFs:
Since each study used a different measure to identify CAFs, comparison among such studies
may not be as meaningful.
CAF identification by flow cytometry and multiplex immunolabeling showed ⍺SMA and
FSP1 label distinct CAFs. While this observation was consistent from one method to another,
absolute CAF abundance differed between the two experiments. This is not surprising due to
many factors: flow cytometry analyses and immunolabeling reveal different amounts of protein
expression, likely due to loss of cells during enzymatic tissue digestion. Moreover, our flow
cytometry analysis solely measured GFP and RFP expression in digested tumor tissue without
controlling for expression of these markers by non-fibroblast cells. When probing CAF marker
expression using multiplex immunolabeling, control markers CD31 and CK8 were used to exclude
CAF marker expression attributed to endothelial and epithelial cells.
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In PyMT tumors, CAF marker overlaps were not tested in conjunction with additional
control markers such as CD31 and CK8 because the expression of each tested markers by
epithelial or endothelial cells was measured in separate experiments. Here, only two of the four
CAF markers were labeled simultaneously with control markers. The experiments shown in this
chapter do not allow conclusions about CAF-specific expression overlaps of all four mesenchymal
markers. However, follow-up studies on these tumors (discussed in Chapter 4) included more
comprehensive multiplex immunolabeling, permitting the interpretation of CAF-specific
expression of the four mesenchymal markers. As discussed in Chapter 4, expression patterns
remained consistent between the experiments.
4T1 and PyMT tumors represent different breast cancer subtypes, therefore, it is not
surprising that CAF marker expression patterns differ between these two animal models.
However, in both models, ⍺SMA and Vimentin were the most highly expressed markers by CAFs,
both individually, or together as a pair. The accumulation of ⍺SMA CAFs in growing PyMT tumors
is in agreement with a recent study87,88 and supports Dvorak’s notion of a cancer wound.

Potential pitfalls and alternate approaches
The major limitation in this method is the limited number of markers that can be measured
simultaneously. Flow cytometry allows detection of up to 18 markers simultaneously and would
provide a more complex picture of overlap in expression of different markers as an alternative
approach. However, tissue digestion might bias the analysis towards more viable populations that
survive harsh enzymatic digestion processes93. Yet, another potential future approach might be
imaging mass cytometry, which allows for detection of a multitude of different markers without
losing cell populations or any spatial information. In future studies we aim to analyze spatial
distribution of CAF marker expression as previously shown with TSA-based multiplex
immunolabeling84 to further take advantage of this immunolabeling approach. Moreover,
mammary fat pads might not present the best control tissues and future analysis will be
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investigating the glandular and surrounding stromal regions of tumors of smaller volumes as
additional controls for comparison.
ECM proteins are secreted proteins that are also often used as markers for CAFs and
should be included in our analyses. However, staining for these would fail to identify the cells
secreting the respective protein. Combining TSA with in situ hybridization may circumvent this
limitation. We have tested a Collagen I in situ probe on tumor tissues from both PyMT mice as
well as orthotopic 4T1 tumors with success (data not shown). Integration of in situ hybridization
in TSA panels is a potential possibility94, which would allow the detection of ECM mRNA levels
together with the protein expression of additional markers.
Future directions
Now that we have identified different CAF subsets with multiplex staining, we want to
investigate their spatial distribution within the tumor and in relation to each other and the other
cells in the tumor microenvironment. Moreover, we are interested in probing each identified CAF
population for additional markers. ⍺SMA is a very ubiquitous CAF marker and previous studies
had found ⍺SMA expression in nearly all CAF subsets identified in the respective study87,88,91.
While we detected CAFs co-expressing ⍺SMA together with other markers, the majority of ⍺SMA+
CAFs were single positive in the PyMT model, and ~20% of all ⍺SMA+ CAFs were single positive
in the 4T1 model, suggesting a predominantly single-positive population. Future studies are
needed to test how previously reported CAF subtypes fall into the ⍺SMA+ populations we have
discovered. Newly developed cytof or cytof imaging technologies can be used to test whether the
identified CAF subsets co-express other previously reported mesenchymal markers. Moreover,
human samples can be probed using single-cell RNAseq or cytof imaging in order to draw
parallels between fibroblasts in human tissues and animal models.
Lastly, while it is critical to phenotypically distinguish different CAF types, it is even more
important to test the functions of the identified CAF types during tumor progression. Correlative

51

studies, or in vitro co-culture studies as shown previously may be insufficient to decipher the
biological relevance of the identified CAF types.
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CHAPTER 4

DISTINCT FIBROBLAST SUBTYPES EXHIBIT DIFFERENT FUNCTIONS IN MAMMARY
CARCINOMA

This work has been done with the help and collaboration of Drs. Hikaru Sugimoto, Valerie
LeBleu, Sara Lovisa, Elena Rodriges Blanko, Ehsan Ehsanipour, Pedro Correa de Sampaio,
Julienne Carstens and Joyce Tse O’Connell. Some of the data shown in this chapter was
generated by using tissues from previously described experiments by Joyce Tse O’Connell95
and Sara Lovisa and is shown with their permission. Such instances are indicated in figure
legends.

Parts of the work in this chapter has been published previously and is taken verbatim from the
publication:
Becker, L. M.*, O’Connell, J. T.*, Vo, A. P., Cain, M. P., Tampe, D., Bizarro, L., Sugimoto, H.,
McGow, A. K., Asara, J. M., Lovisa, S., McAndrews, K. M., Zielinski, R., Lorenzi, P. L., Zeisberg,
M., Raza, S., LeBleu, V. S., and Kalluri, R. Epigenetic Reprogramming of Cancer Associated
Fibroblasts Deregulates Glucose Metabolism and Facilitates Progression of Breast
Cancer. Cell Reports, 31(9), 107701. https://doi.org/10.1016/j.celrep.2020.107701
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Summary
Reports of CAFs’ roles in the tumor microenvironment are often inconsistent in the
literature. This may be due to the paucity of well-established molecular markers that can reliably
and consistently delineate CAF subpopulations, as well as the lack of mouse models that allow
for definitive functional analysis of these cells. Following our identification of mesenchymal marker
expression patterns in mammary tumors in Chapter 3, we probed the functions of three distinct
CAF subtypes, namely aSMA+, FAP+ and PDGFRb+ CAFs, using genetically engineered mouse
models that enable the specific depletion of respective CAF populations in mammary carcinoma.
aSMA+ CAF depletion led to a decrease in mammary tumor growth accompanied by several
changes in the tumor microenvironment, such as reduced angiogenesis and increased hypoxia,
differential mesenchymal marker expression, changes in immune cell composition, as well as
downregulation of overall tumor metabolism. Depletion of FAP+ CAFs had no effect on mammary
tumor growth or metastasis, but tumor immune response was distinctly modulated in FAP+ CAFdeprived tumors. While not included in the original TSA analysis in Chapter 3, PDGFRb is another
commonly used CAF marker that, similar to aSMA, labels tumor pericytes. Depletion of PDGFRb+
CAFs moderately decreased primary tumor growth and metastasis in one of the tumor models
tested. Changes in tumor immunity in PDGFRb+ CAFs depleted tumors were distinct from those
in tumors deprived of aSMA+ or FAP+ CAFs. In summary, our data suggests aSMA, FAP, and
PDGFRb are labeling and defining CAF subtypes that are functionally distinct.

Introduction
Numerous studies have described the interactions between CAFs and tumor cells, with
most studies featuring the tumor-promoting aspect of CAF functions. In the early 2000s,
research groups demonstrated breast cancer growth promoting functions of CAFs in co-culture
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experiments96–98. Later studies had identified signaling molecules involved in the promotion of
tumor growth such as fibroblast-secreted TGFb that induces EMT-mediated migration of cancer
cells58.
CAFs have traditionally been studied in the in vivo setting using so-called admix
experiments. These experiments showed co-injection of breast cancer cell lines with CAFs
in mice result in enhanced tumor formation and growth compared to co-injection of cancer
cells with normal fibroblasts or by themselves. Similar experiments, performed by several
research groups in varying experimental settings, had provided different conclusions regarding
the underlying mechanisms of the observed phenotypes. Orimo et al have shown CAFs
promote tumor growth through enhanced angiogenesis via SDF1 secretion11. Tyan et al. , on the
other hand, demonstrated CAFs to enhance breast cancer growth via HGF signaling upon
stimulation by cancer cells29. In these admix experiments, the injection of heterogeneous
fibroblast populations likely confounded the interpretation of the results.
Once the concept of heterogeneity was established, subsequent efforts were shifted
towards correlating distinct CAF functions with specific identifiers of CAFs. For example, a chemoresistant CD10+GPR77+ CAF subset was identified in breast cancers99 via microarray analysis.
These CAFs create a cancer stem-cell niche by secreting IL6 and IL8 in order to maintain
quiescent and chemo-resistant cancer cells, thereby promoting a pro-tumor effect. Costa et al.
identified four mammary carcinoma subsets, each with a distinct expression pattern of CD29,
FAP, aSMA, FSP1, CAV1, and PDGFRb measured by flow cytometry. Two of these identified
subsets have been shown to promote an immune-suppressive environment; one through
attracting and activating T regulatory cells, and the other one through suppression of T effector
cells91. While these studies have significantly advanced the field of CAF heterogeneity, they relied
on in vitro assays to test functions of the identified CAF subsets. As CAF phenotypes and
characteristics can change in 2D culture conditions, these analyses harbor inherent limitations100.
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One strategy to assess the functions of specific CAF subtypes in vivo is to target CAFs
with specific marker expression in animal models of cancer. To this end, a DNA vaccine against
FAP has been shown to reduce tumor growth and metastasis in combination with chemotherapy
in

the

4T1

mammary

carcinoma

model

through

the

remodeling

of

the

immune

microenvironment101. CAR-T cells targeting FAP have also been developed. Their effects on
mammary tumor growth, however, remain to be investigated as studies produced ambiguous
results102,103. An additional strategy is the utilization of transgenic mice that allow specific targeting
of cells based on marker expression. Our laboratory has established animal models in which the
viral thymidine kinase (vTK) transgene is engineered to be driven by specific promoters of
fibroblast markers. In these mice, continuous administration of ganciclovir (GCV) prevents the
accumulation of proliferating CAFs that express the respective marker, which would otherwise
happen during tumorigenesis, and thus results in specific depletion of the respective CAFs. With
this approach, we have previously tested the functions of FSP1+ CAFs in mammary carcinoma.
We demonstrated that FSP1+ CAFs had no substantial effect on primary tumor progression, but
facilitated metastatic growth in lungs through the secretion of VEGFA and Tenascin C57.
Only a handful of functionally and phenotypically distinct CAF subtypes have been
identified to date in breast cancer. Following our phenotypical identification of specific CAF
subsets in our animal models of mammary carcinoma in Chapter 3, we aimed to characterize their
specific roles in mammary tumorigenesis in this Chapter. We focused our efforts to those CAFs
characterized by their expression of aSMA, FAP and PDGFRb, respectively. Upregulation of

aSMA in fibroblasts is associated with their activation into myofibroblasts in wound healing and
fibrosis65. Due to close similarities between myofibroblasts in wound healing and CAFs, and the
abundance of aSMA expression in tumor stroma, aSMA has been the most commonly used CAF
marker in the literature encompassing all cancer types and is often used to identify CAFs in
mechanistic studies10,104–106. The population size and positive dynamics of ⍺SMA+ CAFs
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investigated in Chapter 3 suggested a functional role of these fibroblasts in tumor progression.

aSMA expression in patient tissues has been shown to correlate with both detrimental and
beneficial clinical outcome depending on the study design and breast cancer subtype90,107,
demonstrating the need to further clarify their specific functions in tumorigenesis.
FAP is a CAF marker also associated with the activation state of CAFs. In breast cancer
stroma, FAP expression has been correlated with favorable prognosis48,108. Functional studies of
FAP+ CAFs have suggested immunoregulatory functions for this CAF subset61,109; but targeting
of these cells in breast cancer animal models led to inconclusive results102,103. Even though we
had only observed a very small CAF population expressing FAP in our animal models, we
nevertheless sought to characterize the potential roles of this population in breast cancer
progression.
Lastly, we sought to study the roles of PDGFRb-expressing CAFs. While we did not use
this marker in our previous analysis described in Chapter 3, it is often used to identify CAFs10,65,91.
We have previously tested specific functions of pericytes during mammary tumorigenesis using
NG2 and PDGFRb as putative pericyte markers. Here, mammary carcinoma animal models were
utilized in which the vTK promoter drove NG2 and PDGFRb expression. Although a significant
reduction of pericytes was observed when PDGFRb expressing cells were targeted, the impact
of the inadvertent depletion of PDGFRb+ CAFs has not been addressed directly. Since aSMA is
a well-established marker for vascular smooth muscle cells and pericytes similar to PDGFRb, we
hypothesized that a direct comparison of cells expressing either aSMA, or PDGFRb could help
to decipher whether these markers are labeling functionally identical or distinct CAF as well as
pericyte populations. While some studies have shown a substantial overlap in expression patterns
between the two markers92, others have suggested the expression patterns of these two markers
varying within different CAF subsets91. This evoked the idea that targeting cells expressing aSMA
vs. PDGFRb+ cells in the context of mammary carcinoma might have different effects on tumor
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progression and differentially impacts the tumor microenvironment. Previous studies have
suggested an involvement of aSMA+ CAFs as well as FAP+ CAFs in regulating the immune cells.

aSMA and FAP showed distinct expression patterns in our animal models, suggesting that these
markers label distinct CAF subsets. Taken this knowledge into consideration, we hypothesized
that different subpopulation of CAFs, as defined by the expression of either aSMA, FAP or
PDGFRb, differ in their interactions with different immune cell populations in the tumor
microenvironment, as well as in their ability to restrict or promote breast cancer progression.

Functions of aSMA+ CAFs in mammary carcinoma
Growth kinetics and metastatic potential of orthotopically implanted 4T1 cells were evaluated in
⍺SMA-vTK transgenic mice64,77. Depletion of ⍺SMA+ CAFs via GCV administration was initiated
when tumors were firmly established and large (~500mm3), and pressure to limit CAFs
accumulation
via

GCV

administration
was continued
until

mice
reached

experimental
endpoint
Figure 10 ⍺ SMA+ CAFs promote primary mammary carcinoma growth
A. Tumor volume at Day 14 after cancer cell injection (GCV start). B. Tumor growth kinetics of
orthotopically implanted 4T1 cells in WT and ⍺SMA-vTK mice. GCV was started at day 14 post
cancer cell implantation. C. Tumor weight of tumors from A. at endpoint. D. ⍺SMA
immunolabeling of WT and ⍺SMA-vTK tumors with quantification. Negative control was incubated
with only secondary antibody. Immunolabeling was performed on tumors from an experiment
previously described in 194 (replicate of this experiment using the same WT and ⍺SMA-vTK mice
with the same observations on tumor growth.) Scale bar: 100µm. Patricia Philips performed the
staining. E. Body weight in WT and ⍺SMA-vTK mice at the indicated timepoints. At endpoint,
body weight was adjusted by subtracting the tumor weight.

requiring
euthanasia.
Depletion

of

⍺SMA+

CAFs

resulted

in

a
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significant reduction in the primary tumor growth (Figure 10A-C), indicating an important role of
⍺SMA+ CAFs in primary tumor growth. Reduction in ⍺SMA+ CAFs in tumors was confirmed by
immunohistochemistry (Figure 10D). Of note, this approach does not directly impact cancer cells,
which are deprived from expressing the transgene. Body weight was not measurably impacted
by the depletion of proliferating ⍺SMA+ CAFs (Figure 10E). ⍺SMA+ CAFs-depletion exacerbated
primary tumor hypoxia (Carbonic anhydrase 9, CAIX, Figure 11A) and diminished blood (CD31)
and lymphatic angiogenesis (Lyve1, Figure 11B-C). Pericyte coverage of blood vessels remained

Figure 11 ⍺ SMA+ CAFs deprived tumors show vascular remodeling
Immunolabeling of WT and ⍺SMA-vTK tumors with A. carbonic anhydrase 9 (CAIX), B. ⍺SMA, PDGFRb, and
CD31 and C. Lyve1. Representative images are shown together with quantification.
The immunolabeling experiments in this figure were performed on tumors from an experiment previously described
in 96. (This experiment is a replicate of the experiment in Figure 10 using the same WT and ⍺SMA-vTK mice with
the same observations on tumor growth). All scale bars including zoomed in images: 50µm

however unchanged (CD31 associated with PDGFRb, Figure 11B). Perivascular aSMA
expression increased (Figure 11B), indicating that the depletion strategy primarily impacts
proliferating CAFs rather than, possibly more quiescent, perivascular cells, and that the impact
on tumor angiogenesis is an indirect consequence of ⍺SMA+ CAFs depletion.
Despite significant decrease in primary tumor growth upon aSMA+ CAFs depletion, lung
metastases in the invasive breast cancer models studied were similar (Figure 12A). Metastatic
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disease was rarely seen at the time of GCV initiation in the 4T1 orthotopic model (at tumor burden
of 500mm3, WT GCV start Figure 12A). To test whether ⍺SMA+ CAFs play a role in lung
colonization as previously observed for FSP1+ CAFs57, 4T1 cells were intravenously (i.v.) injected
into aSMA-vTK and WT control mice. aSMA depletion caused by GCV administration did not
impact lung tumor growth (Figure 12B).
These results support that aSMA+ CAFs primarily play a role in suppressing primary tumor
growth.

Figure 12 ⍺ SMA+ CAFs depletion can enhance invasion and intravasation and has no effect on lung
metastatic outgrowth.
A. Quantification of metastatic area in WT mice at start of GCV, and in WT and ⍺SMA-vTK mice at experimental
endpoint. B. 4T1 cells were injected intravenously into WT and ⍺SMA-vTK mice. GCV was started 2 days prior to
cancer cell injection and continued until sacrifice. Representative pictures of lungs together with quantificatio of lung
surface nodules and metastatic area are shown. Scale bar: 2mm.

Next, these findings were recapitulated in the MMTV-PyMT (PyMT) mammary carcinoma
transgenic mouse model75,76. PyMT mice were crossed to aSMA-vTK mice (aSMA-vTK;PyMT)
and GCV treatment was initiated once the combined tumor burden reached 500mm3 to allow for
the accumulation of aSMA+ CAFs. Depletion of ⍺SMA+ cells in PyMT mice dramatically inhibited
primary tumor growth (Figure 13A) but had no significant effect on lung metastasis (Figure 13B),
similar to our observations in the 4T1 model. To analyze potential changes in the abundance of
different CAF subsets when ⍺SMA+ CAFs were depleted, we stained these tumors for ⍺SMA,
Vimentin, FAP, FSP1, Ki67, CK8, CD31 and DAPI simultaneously employing TSA-based
multiplex staining (Figure 13D). CAFs were defined as CK8–CD31– cells; and immune cells were
excluded based on shape and size (using Inform analysis program, see methods). Interestingly,
the percentage of fibroblasts (CK8–CD31–) out of all cells in the tumor was increased in ⍺SMA-

60

depleted tumors (Figure 13C). As expected, ⍺SMAs+ (including ⍺SMA+Ki67+) CAFs were
significantly reduced in ⍺SMA-vTK mice, confirming the depletion of proliferating ⍺SMA+ CAFs
(Figure 13E). FSP1- expressing CAFs were unaffected (Figure 13F), and FAP+ CAFs decreased
in aSMA+ CAFs depleted tumors. Moreover, Vimentin+ CAFs increased in tumors of ⍺SMA-vTK
mice (Figure 13D, compare total Vimentin numbers; and Figure 13H). We could not observe an
increase in proliferating (Ki67+) Vimentin+ CAFs (Figure 13I), suggesting that the Vimentin+
population did not increase via proliferation. The overall abundance of ⍺SMA-expressing CAFs
did not decrease (Figure 13D, compare aSMA total numbers) despite the dramatic reduction in
⍺SMAs+ and ⍺SMA+Ki67+ cells. We therefore hypothesized that ⍺SMA+ CAFs may have begun to
express additional markers in ⍺SMA-vTK mice. Indeed, there was a marked increase in
⍺SMA+Vim+ CAFs in these mice (Figure 13J). This, in turn could contribute to the overall increase
in Vimentin expression.
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WT

aSMA-vTK

Figure 13 aSMA+ CAFs depletion in PyMT tumors reduce tumor growth and change CAF marker
expression patterns. A. Tumor growth of WT;PyMT and aSMA-vTK;PyMT tumors from GCV start (~500mm3).
B. Metastatic burden in mice from A. C. CK8–CD31– cells (fibroblasts) in WT;PyMT and aSMA-vTK;PyMT
tumors. D. Venn diagrams of expression overlaps between aSMA, Vimentin, FAP and FSP1 in WT;PyMT and
aSMA-vTK;PyMT tumors (Numbers in diagram present amount of cells in any 10,000 CK8–CD31– cells). E-J.
Abundance of different CAF subsets in WT;PyMT and aSMA-vTK;PyMT tumors.

62

The ablation of ⍺SMA expressing cancer cells could potentially contribute to the lack of
tumor growth in aSMA-vTK; PyMT mice. To exclude this possibility, ⍺SMA-vTK mice were
implanted with fragments of tumors from parental PyMT mice (no vTK transgene, Figure 14A).
The histology of transplanted tumors was similar to the original PyMT tumors (Figure 14B).
Figure 14 PyMT transplantation model
A. Schematic of PyMT tranplantation model. Tumors
were harvested from PyMT mice, cut in small fragments
and implanted in recipient WT and vTK mice. See
methods for more information. B. Representative picture
of H&E stained original PyMT and transplanted PyMT
tumors. Scale bar: 50µm.

The transplanted tumors displayed similar growth stagnation in the ⍺SMA-vTK mice,
suggesting that the depletion of host ⍺SMA+ CAFs was the main factor in the delayed tumor
growth (Error! Reference source not found.A). ⍺SMA depletion was confirmed with IHC, as the
tumors were too necrotic for reliable analysis of multiplex staining (Error! Reference source not
found.C, IHC data not shown). Similar to the transgenic model, lung metastatic burden remained
unchanged (Error! Reference source not found.B). Given the significantly smaller volume of
aSMA-vTK+ tumors in both models, this suggests increased metastatic capability of the small

C
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⍺SMA-depleted tumors. Further investigations of the consequences of ⍺SMA+ CAF depletion
showed that ⍺SMA+ CAF-depleted tumors were extremely necrotic (Error! Reference source not
found.C), with reduced micro-vessel (CD31) and pericyte (PDGFRb) density (Error! Reference
source not found.E, F). In aSMA-vTK and WT tumors, 100% and 95% of vessels, respectively,
were covered by pericytes (Error! Reference source not found.G). Thus, aSMA-depleted tumors
displayed reduced angiogenesis and vascular normalization. Reduced angiogenesis may
contribute to the slower primary tumor growth and necrosis, but normalized vessels become better
conduits for metastasis. Assessment of hypoxia using CAIX (Error! Reference source not
found.D) and Hypoxyprobe (not shown) revealed large areas of hypoxia in WT as well as in
aSMA-depleted tumors. The proliferative activity of the tumor cells was unchanged by depletion
of aSMA+ CAFs (Error! Reference source not found.H). Cancer cells are still proliferating at the
same rates in the small aSMA-depleted tumors, likely because decreased angiogenesis causes
death and necrosis, rather than the lack of aSMA+ CAFs halting proliferation.

Figure 15 ⍺ SMA+ CAF depletion in transplanted PyMT tumors leads to growth stagnation and vascular
remodeling.
A. Tumor growth in WT and ⍺SMA-vTK mice implanted with PyMT tumors from GCV start. B. Metastatic burden in mice
from (A). Representative images of H&E staining (C) and CAIX immunolabeling (D) in tumors from (A). CD31 (E) and
PDGFRb (F) expression, as well as quantification of pericyte coverage of vessels (CD31+PDGFRb+, G) in tumors from
(A). H. Quantification of CK8+Ki67+ proliferating cancer cells in tumors from (A). Data presented as mean +/- s.e.m.,
individual dots in graphs indicate individual mice. Unpaired t test (with Welch correction when appropriate) or MannWhitney test were used, depending on normality distribution of data. *p < 0.05, **p < 0.01, ***p < 0.001. ns, not significant.
Scale bars: 50µm.
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CAFs have been reported to interact with different immune cell populations and thereby
shaping

the

immune

microenvironment

in

order

to

either

facilitate

or

suppress

tumorigenesis60,61,91. In order to measure the impact of aSMA+ CAFs depletion on immune cells,
tumors were dissociated after harvest and the single cell suspensions were probed with different
panels of immune cell markers (see methods). We observed downregulation of myeloid cells, and
increase of B-cells, with no changes in T-cells and NK cells (Figure 16A). When investigating
further subsets of those immune cells, the most interesting changes were observed within myeloid
cells. In aSMA+ CAFs-depleted tumors, relative abundance within the myeloid cell department of
Gr1– cells was increased, which present monocytes or macrophages110 (Figure 16B). PD-L1
expression on neutrophils (CD11b+Ly6G+) and on CD11b+Gr1– macrophages was significantly
upregulated. The increase in PDL1 expression on CD11b+Gr1– macrophages suggests M2
conversion111 (Figure 16D). Increased infiltrates of PD-L1+ tumor associated M2 macrophages
(or tumor-associated macrophages, TAMs) could explain persistent metastasis in ⍺SMA-vTK
mice despite the drastically reduced primary tumors112. PD-L1/PD1 signaling supports
macrophages’ proliferation and immunosuppressive functions. Both can be reversed by anti-PDL1/PD1

therapy112.

PD1

is

also

a

marker of

immunosuppressive,

tumor-promoting

macrophages112. In aSMA+ CAFs-depleted tumors, PD1 was increased in all myeloid cells,
including macrophages (Figure 16E). We therefore hypothesized that PDL1+ and PD1+ TAMs
promote metastasis upon aSMA+ CAFs depletion. To test this hypothesis, we treated aSMA-vTK
and WT mice transplanted with PyMT tumors with GCV + anti-PDL1 (or control IgG) antibody
(200ug / mouse, Figure 16F). Analysis of this experiment is still ongoing. As expected, we could
not observe any impact on primary tumor growth in WT or aSMA-vTK mice that received anti-
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PDL1 (Figure 16G). However, we are currently evaluating the metastatic burden in the lungs of
mice in different treatment groups.

Figure 16 aSMA+ CAFs depleted tumors show increased tumor associated macrophage infiltration.
A. % of CD3+, CD11b+, CD19+ and CD49b+ cells out of all CD45+ lymphocytes in WT (grey) and aSMA-vTK (blue)
tumors. B. relative expression of Ly6G and Ly6C in CD11b+ cells in WT and aSMA-vTK tumors. C. relative expression
of PDL1 in CD11b+Ly6G cells. D. relative expression of PDL1 in CD11b+Gr1– cells. E. relative expression of PD1 in
CD11b+ cells and CD11b+Gr1– cells. F. Experimental setup for PDL1 and GCV treatment in WT and aSMA-vTK mice
implanted with PyMT tumors. G. Tumor growth from GCV start in PDL1/GCV treated WT and aSMA-vTK mice
implanted with PyMT tumors. Data presented as mean +/- s.e.m., individual dots in graphs indicate individual mice.
Unpaired t test (with Welch correction when appropriate) or Mann-Whitney test were used, depending on normality
distribution of data. *p < 0.05, **p < 0.01, ***p < 0.001, ****p<0.0001.

In summary, we showed that aSMA+ CAFs are facilitating primary tumor growth, but do
not impact metastasis significantly using three independent animal models of mammary
carcinoma. Depletion of aSMA+ CAFs led to remodeling of the tumor microenvironment as
demonstrated by decreased angiogenesis, changes in different immune cells and new distribution
of CAF marker expression patterns. Moreover, aSMA+ CAFs seem to metabolically support tumor
growth, as overall tumor metabolism was downregulated upon depletion of this CAF subset.
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Functions of FAP+ CAFs in mammary carcinoma
Although FAP+ CAFs represented one of the least abundant CAF subsets in our model,
FAP+

CAFs

have previously
been implicated
in

breast

tumorigenesis91.
Moreover,

we
FAP+

saw

fibroblasts
Figure 17 Depletion of FAP+ CAFs does not impact primary tumor growth
A. Tumor growth from GCV treatment start in WT and FAP-vTK mice implanted with PyMT
tumors. B. Lung surface nodules in mice from (A). C. Venn diagrams of expression overlaps
between aSMA, Vimentin, FAP and FSP1 in implanted tumors of WT and FAP-vTK mice
(Numbers in diagram present amount of cells in any 10,000 CK8–CD31– cells). D-G Abundance
of different CAF subsets in implanted tumors of WT and FAP-vTK mice.

decrease

in
⍺SMA-

vTK;PyMT mice.
To

investigate

whether ⍺SMA+FAP+ CAFs were targeted in ⍺SMA-vTK mice, we postulated that FAP+ CAFs
depletion should result in decrease in ⍺SMA+ CAFs with possible similar phenotypes. We
therefore implanted tumor fragments from PyMT mice into the right mammary fat pad of recipient
FAP-vTK mice (generated in our laboratory). Tumor growth was comparable between FAP-vTK+
and WT mice upon GCV treatment (Figure 17A). Moreover, we did not observe any changes in
the number of lung surface nodules (Figure 17B). To confirm the depletion of FAP+ CAFs and to
investigate the expression of the remaining CAF markers, we performed TSA multiplex staining
as described before. Although overall FAP-expression did not decrease amongst all CAFs
(Figure 17C), the proliferating (Ki67+) FAP+ CAFs decreased significantly as expected in this
model (Figure 17D). We did not detect any changes in any of other CAF subset (Figure 17C, EG). ⍺SMA+ CAFs were thus not affected by depletion of FAP+ CAFs.
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Previous studies suggested FAP+ CAFs modulate tumor immune response91,113. We
therefore sought to analyze changes in immune cell populations in FAP+ CAFs-depleted tumors.
Depletion of FAP+ CAFs did not change abundance of T-cells, B-cells, myeloid cells or NK cells
in the tumors (Figure 18A). However, when we tested the abundance of subsets of these immune
cell types, we detected a decrease in Ly6C expression, accompanied by an increase in the Gr1–
myeloid cell population, similar to ⍺SMA-depleted tumors (Figure 18B-C).

Figure 18 FAP+ CAFs depleted tumors exhibit different immune cell composition.
A. % of CD3+, CD11b+, CD19+ and CD49b+ cells out of all CD45+ lymphocytes in WT (grey) and FAPvTK (purple) tumors. B-F. Relative abundance the indicated immune cell subsets in WT and FAP-vTK
tumors.

In addition to changes in the myeloid department, CD4+ T cells decreased in FAP-TK+ tumors
compared to wildtype tumors (Figure 18D). Within the CD4 T cells, regulatory T cells (Foxp3+)
were slightly downregulated. While we could not detect any significant change in CD8 T cells
when comparing CD8 expression in the CD3+ T-cell population, we did detect a significant
increase in CD3+CD8+ cells out of total lymphocytes in the tumor (CD45+). Therefore, while not
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effecting tumor growth and metastasis significantly, FAP+ CAF depletion caused changes in
immune cell populations.

Functions of PDGFRb+ CAFs in mammary carcinoma
The observed reduction in PDGFRb+ cells in ⍺SMA-TK tumors, prompted us to
investigate their functional role. Similar to ⍺SMA, PDGFRb is expressed by CAFs, as well as
intratumoral perictyes114. Interestingly, overall PDGFRb expression was reduced in stroma of
⍺SMA-vTK tumors, alongside CD31 reduction. However, CD31-associated PDGFRb expression
(pericyte PDGFRb expression) remained unchanged, which might suggest that PDGFRb+ CAFs
were reduced rather than PDGFRb+ pericytes in the ⍺SMA+ CAFs-depleted tumors. Studies from
our lab and others have shown the important prognostic and functional roles of PDGFRb+ cells
in the breast tumor microenvironment78,114–116. To directly compare PDGFRb+ cells to ⍺SMA+
cells in the breast tumor microenvironment, we tested their functions in the same experimental
setting and utilized PDGFRb-vTK (Pb-vTK) mice; either crossed to PyMT mice, or implanted
with PyMT tumors. Depletion of PDGFRb+ cells moderately reduced primary tumor growth and
metastasis in the transgenic tumor model (Figure 19A-C), but did not impact tumor growth of
implanted tumors (Figure 19D-E). Furthermore, no changes in microvessel coverage were
detected (Figure 19F-G). ⍺SMA, as well as PDGFRb expression in the stroma was moderately
reduced (Figure 19F, H-I). Necrotic tissue within these tumors potentially caused
autofluorescence. We therefore probed for PDGFRb expression using immunohistochemistry
and observed a strong reduction of PDGFRb expression in PDGFRb-vTK tumors (Figure 19J,
staining was not quantified). Tumors in the transplanted model showed changes in the immune
cell compartment, which were distinct from those described in ⍺SMA+ CAFs-depleted tumors.
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NK cells were significantly reduced compared to WT controls (Figure 19K). In addition, although
overall numbers of T cells were similar (data not shown), more T effector cells pertained in
tumors from PDGFRb-vTK mice, and T regulatory cells were decreased (Figure 19L-M).

Figure 19 Depletion of PDGFRb+ CAFs impacted tumor immunity
A. Tumor growth from GCV treatment start in WT,PyMT and PDGFRb-vTK, PyMT mice. B. Tumor weight of
tumors from (A). C. Lung surface nodules in mice from (A). D. Tumor growth from GCV treatment start in WT
and PDGFRb-vTK mice implanted with PyMT tumors. E. Metastatic burden in lungs of mice from (D). F-I.
Immunolabeling for CD31, aSMA and PDGFRb in tumors from (D). Representative image and quantification of
individual stains. J. Representative images of PDGFRb immunolabeling in tumors from (D). K-N. Changes in
immune cell subsets in tumors from (D).

Further analysis will determine the activation state of these cells and reveal what additional
stimuli are needed to coerce an immunosuppressive tumor microenvironment towards cancer
immune surveillance. Of note, we found activated (Ki67+) cytotoxic T cells (CD8+, Figure 19N)
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to be decreased in tumors from PDGFRb-vTK mice, which might cause the continued tumor
growth in these mice despite increase in T effector cells.

Interpretation of findings
While further analyses will be required to assess the mechanistic roles of aSMA+,
PDGFRb+, and FAP+ CAFs, it is evident that aSMA, FAP and PDGFRb each label functionally
distinct CAF subsets in the breast tumor microenvironement. CAFs identified by these markers
differentially modify primary tumor growth and the immune microenvironment.
We report a robust reduction in primary tumor growth when aSMA+ CAFs were selectively
depleted, yet metastasis was unchanged in three distinct mouse models of mammary carcinoma.
The similar metastatic burden in aSMA+ CAFs-depleted tumor bearing mice compared to the
control mice is significant because despite ~50% reduction in primary tumor, metastases were
still able to develop unabated, suggesting that cancer cells likely gained metastatic potential or
the remaining cancer cells were able to seed the lung at the same rate as the control tumors. We
also showed in a lung colonization assay (i.v. injection of cancer cells) that the depletion of aSMA+
CAFs did not affect metastatic outgrowth, suggesting a more dominant role for these cells in the
primary tumor. This was manifested principally by increased intratumoral hypoxia and suppressed
angiogenesis when aSMA+ CAFs were depleted.
We can conclude that aSMA+ CAFs promote the growth of the primary tumor, potentially
through increasing angiogenesis. While a decrease in microvessel coverage was observed upon
aSMA+ CAFs depletion in all tumor models (data for transgenic tumor model not shown),
intratumoral hypoxia was only impacted in the 4T1 mammary carcinoma model. These differences
are likely due to the inherent differences between the two tumor models, which represent different
breast cancer subtypes, and exhibit different baseline levels of necrosis and hypoxia (see Chapter
3). Interestingly, despite the observed vascular remodeling, aSMA+ pericytes were not targeted
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in our animal models, which stands in contrast to previous studies targeting PDGFRb+ pericytes
using the vTK system. This might indicate PDGFRb+ labels more proliferative pericytes and is
either expressed at higher levels in pericytes than aSMA, or labels a separate pericyte population.
Our lab previously reported significant overlap between aSMA and PDGFRb expression by CAFs
in 4T1 mammary carcinomas. This is in line with our findings of reduction in PDGFRb expression
upon aSMA+ CAFs depletion. Similarly, aSMA expression was reduced in PDGFRb-vTK mice in
our hands. Nevertheless, targeting aSMA+ CAFs and PDGFRb+ CAFs had distinct effects on
primary tumor growth, metastasis and the immune cell response in tumors, demonstrating that
despite expression overlaps, distinct subsets were targeted.
Out of all immune cell populations that were analyzed (see methods for list of markers
used in different flow cytometry panels), only a few changes in myeloid cell populations alongside
reduction in B cells were observed upon aSMA+ CAFs depletion. This was surprising considering
several studies had suggested that CAFs can impact immune system functions. As aSMA was
identifying such large fibroblast populations in breast tumors, we expected to see an effect on T
cell populations as previously reported91. However, most functional studies investigating CAFimmune cell interactions have been in vitro co-culture studies that do not capture the complexity
of interactions between all cells in the tumor microenvironment entirely. On the other hand, aSMA+
CAF depletion reshaped the tumor microenvironment by inducing vascular remodeling. Such
changes could potentially also impact the immune cells in the tumors, possibly counteracting or
masking effects of aSMA+ CAFs depletion on immune cell populations. Hypoxia can lead to the
accumulation of immunosuppressive cells in tumors117. Although we observed increased
intratumoral hypoxia in the 4T1 mammary cancer model when aSMA+ CAFs were depleted, this
was not the case in the transplantation model, in which we assessed immune cell composition.
Whether the significant increase in CD11b+Gr1–PDL1+ cells was caused by a decrease in
angiogenesis, or if a direct crosstalk exists between aSMA+ CAFs and these immune cells or
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other immune populations that influence CD11b+Gr1–PDL1+ cells, remains to be further
evaluated. Nevertheless, the increase in CD11b+Gr1–PDL1+ cells was intriguing. We interpreted
CD11b+Gr1–PDL1+ cells as M2-like macrophages112,118. At first glance, it seems counterintuitive
for immunosuppressive cells to accumulate in shrinking tumors. However, these cells could
potentially be the cause for metastasis to persist112 and therefore we hypothesized that targeting
aSMA+ CAFs together with inhibiting TAMs via anti-PDL1 treatment might lead to the reduction
of tumor growth and metastatic disease. Evaluation of the metastatic burden in mice from this
experiment is still ongoing and it is premature to draw any conclusions from this study at this point.
Of note, when investigating the immune cell composition in the 4T1 mammary carcinoma model
depleted of aSMA+ CAFs, TAMs were moderately, but not significantly increased (data not
shown). We did not include these data here, as only tumors from 4 mice in each group were tested
for changes in immune cells, a sample size too small to yield reliable results in our experience.
Of note, when we investigated CAF marker composition in the WT and aSMA+ CAFsdepleted tumors, mesenchymal marker expression was tested in the context of the control
markers CK8 and CD31. The WT tumors in the experiment serve as a control for our experiments
in Chapter 3, where the TSA panel for PyMT tumors lacked CD31 and CK8. When comparing
Figure 7A to Figure 13D, one can appreciate that expression overlaps between mesenchymal
markers were very similar, confirming that CAF marker expression patterns shown in Chapter 3
were representative of expression specifically by CAFs.
Depletion of FAP+ CAFs did not have any effect on tumor growth or metastasis. Metastasis
analysis was only based on the number of lung surface nodules, conclusions about the metastatic
phenotype might therefore have to be confirmed with a more thorough metastasis analysis as
described in other animal experiments (see methods). FAP+ CAFs depleted tumors contained
less CD4 T-cells and T regulatory cells (moderate decrease) when compared to WT control
tumors. While no change in CD8 T-cells was detected within all T-cells (CD3+), CD8 T-cells out

73

of total lymphocytes (CD45+) were increased in FAP+ CAF depleted tumors. Activation markers
Ki67 as well as Granzyme B were used in the immune panels as described in methods. An
increase in activated T-cells (based on Ki67 or Granzyme B) was not detected, which might
explain the unchanged primary tumor burden despite fewer T regulatory cells and more cytotoxic
(CD8+) T-cells within tumors. Immunoregulatory functions of FAP+ CAFs have also been
suggested when using a DNA vaccine against FAP. Here, in a 4T1 model, specific targeting of
FAP+ CAFs in combination with doxorubicin treatment significantly reduced tumor growth and
metastasis when compared to doxorubicin treatment alone. Disease reduction was attributed to
a Th2 to Th1 cytokine shift in the tumor microenvironment that is accompanied by a decrease of
immunosuppressive cells and an increase in cytotoxic T-cells101. Of note, tumor growth and
metastasis were not affected when mice were treated with only the FAP-targeting vaccine in the
absence of chemotherapy, in line with our findings from FAP+ CAF depletion experiment without
any further therapy. Studies using CAR-T cells targeting FAP reported opposing results in the 4T1
model102,103. Strategies such as vaccines or CAR T-cells affect all cells expressing the target
regardless of the proliferation status of the cells. As the viral thymidine kinase model relies on
proliferation to be effective, one can argue this approach is more specific to CAFs, which are by
definition activated and proliferating. Nevertheless, in all such approaches, targeting of non-CAFs
cannot be ruled out, as FAP has also been shown to be expressed in the immune cells119–122. This
raises the possibility that the effects on tumor immunity could stem from direct targeting of immune
cells. It remains to be determined whether in these studies, as well as in our model immune cells
were directly targeted.
Depletion of PDGFRb+ CAFs in our previous studies using the 4T1 mammary carcinoma
model has shown more dramatic effects on tumor growth and metastasis as shown here in the
PyMT models. This might be due to the inherent differences between these two animal models.
One should note that when we depleted aSMA+ CAFs in these two different models as shown in

74

this Chapter, the impact on tumor growth, metastasis and microenvironment was greater in the
4T1 model. We observed a moderate, but not significant reduction in primary tumor growth and
metastasis, a trend similar to the results reported when PDGFRb+ cells were depleted in small,
non-hypoxic 4T1 tumors. GCV treatment was started in the PyMT tumors when the combined
tumor burden reached 500mm3, at which stage all tumors are relatively small with generally lower
hypoxia (hypoxia levels in PyMT tumors of different sizes is demonstrated in the following
Chapter). In the transplantation model, no changes in primary tumor growth was observed.
Possible explanations why we cannot observe an effect in this additional tumor model might be
the inherent differences in the composition of the microenvironment between the two models.
Implantation of the tumors is accompanied by an inflammatory response, which might remodel
the microenvironment, so that the effect of PDGFRb+ CAFs depletion was masked. PDGFRb
expression was downregulated, confirming successful depletion. The observed changes in
immune cell populations could be partly responsible for the lack of tumor growth reduction. Even
though more T effector cells were present in the tumor, activated (Ki67+) cytotoxic T-cells number
was

reduced.

Preliminary

investigation

showed

aSMA

expression

reduced,

while

microvasculature (CD31) was unchanged. Further investigations are necessary in order to test
for vessel leakage and investigate the contributions of PDGFRb+ CAFs vs. PDGFRb+ pericytes
depletion.
While further investigations are needed in order to draw more definitive conclusions, we
can conclude that aSMA, PDGFRb and FAP label functionally distinct CAF subsets in mammary
carcinoma. Table 2 summarizes the different changes that were observed upon depletion of each
subset. In our previous studies we have demonstrated FSP1+ CAF’s involvement in facilitating
metastatic outgrowth in the lungs. When comparing these results to our results in this thesis, we
can conclude that FSP1+ CAFs represent a forth, additional CAF subset.
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Lastly, the vTK model is depleting CAFs only based on expression of one particular
marker. Using TSA-based multiplex staining we determined the expression overlaps between the
mesenchymal markers tested were minimal and therefore the depletion approach was
appropriate. However, this does not take into consideration the potential expression of additional,
untested CAF markers that may further delineate CAF subsets. Here, we have characterized four
CAF subsets based on expression of aSMA, PDGFR, FAP and FSP1. Further studies will
investigate the expression of additional markers within these groups to further delineate the cell
subpopulations.

Table 2 Effects of CAF subtype depletion in mammary carcinoma
a SMA-vTK

PDGFRb -vTK

Animal model

4T1

PyMT

PyMT Transpl.

Tumor growth
Metastasis

↓
No change

↓
No change

↓
No change

T-cell changes

B-cell changes

4T1
(previous115)
↓
↓/↑

FAP-vTK

PyMT

PyMT Transpl.

PyMT Transpl.

↓
↓

No change
↓

No change
No change
CD4+ (of CD3+)
↓
FoxP3+ (of
CD3+)↓
CD8+ (of CD45+)
↑

FSP1-vTK
4T1 (previous
194, 57
)
No change
↓

n/a

n/a

No change

n/a

n/a

FoxP3+ (of CD4+)↓
FoxP3– (of CD4+)↑
CD8+Ki67+ (of
CD8+)↓

↑
CD11b+ ↓
CD11b+PDL1+↑
CD11b+PD1+↑

n/a

n/a

No change

No change

n/a

n/a

n/a

No change

No change

n/a

Vascular
remodeling,
EMT
induction,
hypoxia,
ANG2 ↑

n/a

NK cells↓

n/a

VEGF ↓
Tenascin A ↓
(in lung)

n/a

n/a

Myeloid cell
changes

Similar trends
than Transpl.

n/a

Other changes

Vascular
remodeling,
hypoxia, tumor
metabolism

Change in
mesenchymal
marker
expression
patterns

Vascular
remodeling

n/a

Potential pitfalls and alternate approaches
Our previous experience with these models has indicated no enhanced immune infiltration
due to cell death caused by targeting of fibroblasts (unpublished data), neither have we observed
a bystander effect in this model. We have previously shown that the tumor stage at the onset of
GCV-induced depletion can is very critical to the outcome115. In the setting of aSMA+ CAFs
depletion we tested many different approaches using three distinct animal models. In the 4T1
model we repeated the experiment four times; in each setting tumors had progressed to a different
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stage at start of GCV administration (here only data shown for one experiment; the other
experiments were performed by another graduate student in the la). Robust reduction in primary
tumor growth was observed in all scenarios, but in one of the tested settings, metastasis increased
upon aSMA+ CAFs depletion (data not shown in this thesis). Therefore, our studies do not fully
elucidate aSMA+ CAFs’ contribution to metastasis and this aspect remains to be further assessed.
Here, 4T1 tumors of different volumes (different stages) in aSMA-vTK and WT mice could be
treated with GCV to probe whether GCV onset is critical in contributing to metastasis. Moreover,
when 4T1 cells were intravenously injected in the context of aSMA+ CAFs depletion, we did not
assay the lung tissue for reduction in aSMA. This critical immunolabeling in the lungs remains to
be performed in order to draw definitive conclusions from this i.v. experiment.
Since CAFs are by definition activated, proliferating fibroblasts, we expect the vTK system
to differentially target those cells. However, these models may miss any CAF population
potentially having important functions but remained quiescent. Depending on which subset one
wishes to target, alternative strategies, such as antibodies, vaccines, or other animal models
(such as diphtheria toxin-mediated depletion) could be used. On the other hand, non-CAF cells
expressing the respective markers might have been targeted inadvertently with our approach.
Here, a thorough analysis of expression of aSMA, FAP and PDGFRb by other cell types in the
context of the vTK models should to be undertaken.
We observed changes in the immune cell composition in the considerably smaller, and
less vascularized aSMA+ CAFs depleted tumors. Interpretation of these results are limited and it
is unclear whether observed changes were caused by the lack of aSMA+ CAFs in the stroma or
rather due to smaller and/or less vascularized tumors displaying different immune landscapes.
Tumors from WT mice of comparable size could be used for comparison, and vasculature
remodeling drugs such as anti-VEGF (Avastin) could be used as controls. The same holds true
for the metabolomic analysis of the tumors.
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Future Directions
Studies focus on the functions of aSMA+ CAFs and PDGFRb+ CAFs, especially with
respect to immune modulation are ongoing. Most importantly, due to the known roles of PD-L1+
TAMs in metastasis112, we are now testing whether aSMA+ CAFs depletion together with PD-L1
inhibition can reduce metastasis. Single-cell RNAseq will identify growth factors and cytokines
potentially involved in the interactions between aSMA+ and PDGFRb+ CAFs and different immune
cells.
A new TSA panel will also include PDGFRb, to determine the expression overlaps
between all CAF markers that were functionally characterized. Importantly, this panel will also
enable us to distinguish aSMA and PDGFRb expression by CAFs or pericytes in WT and tumors
in which aSMA+ cells or PDGFRb+ cells were depleted. This will therefore enable the deciphering
of the pericytes and CAFs’ respective contribution to tumorigenesis.
The expression dynamics of mesenchymal markers also demands more investigation. We
observed a gain of Vimentin expression in aSMA+ CAFs in vTK models. It would be interesting to
see if these cells acquire Vimentin expression and thereby become more quiescent to evade
targeting pressure. To test these dynamic expression patterns, transgenic animals that allow
lineage tracing of specific markers can be utilized.
We have established four functionally distinct CAF subsets via independent expression of
four mesenchymal markers. Future efforts should be directed towards probing expression of
additional mesenchymal markers within these subsets to further delineate functional CAF
subpopulations.
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CHAPTER 5

CANCER-ASSOCIATED FIBROBLASTS ARE REPROGRAMMED BY HYPOXIA TOWARD
INCREASED GLYCOLYSIS AND FACILITATE MAMMARY CARCINOMA PROGRESSION

The work in this chapter has been accomplished with the help and in collaboration with Drs. Joyce
Tse O’Connell, Annie Vo, Margo Cain, Valerie LeBleu, Desiree Tampe, Lauren Bizarro, Hikaru
Sugimoto, Anna McGow, Sughra Raza, John Asara, Kathleen McAndrews, Rafal Zielinski, Philip
Lorenzi, and Michael Zeisberg. Some of the data shown in this chapter was generated by Joyce
Tse O’Connell, Margo Cain and Hikaru Sugimoto (indicated in figure legends) and is shown with
their permission.

This chapter is based on findings in previous studies (In some instances, previously described
experiments were repeated or reproduced with permission, as indicated in figure legends):
Vo, A. P. Glucose Metabolism in Cancer-Associated Fibroblasts. Harvard Univ. (2013).
doi:10.1029/91JD03139
Tse, J. C. Functional Heterogeneity of Fibroblasts in Cancer Progression and Metastasis.
Harvard Univ. (2011). doi:10.16194/j.cnki.31-1059/g4.2011.07.016

Parts of the work in this chapter has been published previously and is taken verbatim from the
publication:
Becker, L. M.*, O’Connell, J. T.*, Vo, A. P., Cain, M. P., Tampe, D., Bizarro, L., Sugimoto, H.,
McGow, A. K., Asara, J. M., Lovisa, S., McAndrews, K. M., Zielinski, R., Lorenzi, P. L., Zeisberg,
M., Raza, S., LeBleu, V. S., and Kalluri, R. Epigenetic Reprogramming of Cancer Associated
Fibroblasts Deregulates Glucose Metabolism and Facilitates Progression of Breast
Cancer. Cell Reports, 31(9), 107701. https://doi.org/10.1016/j.celrep.2020.107701
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Summary
A specific mechanism, of how CAFs may contribute to tumor growth and progression is providing
metabolic support for cancer cells. CAFs exhibit an altered metabolism toward increased
glycolysis, which may help fuel cancer cells’ growth through increasing lactate availability in the
tumor microenvironment. While studies suggest such a lactate shuttle, how the metabolic
reprogramming in CAFs emerges and is sustained remains unknown. Studying fibroblasts
isolated from a large cohort of patients with benign breast tissues and breast cancer, in
conjunction with animal models, we demonstrate that CAFs exhibit a metabolic shift towards
lactate and pyruvate production and fuel biosynthetic pathways of cancer cells. In vitro studies
using patient derived benign and cancer associated fibroblasts demonstrated that the CAFs’
glycolytic phenotype can be induced in normal fibroblasts by altered oxygen availability. Hypoxia
leads benign fibroblasts to adopt a pro-glycolytic, CAF-like transcriptome. Our findings suggest
that glucose metabolism in CAFs evolves during tumor progression and their functional phenotype
is mediated, at least in part, by oxygen-dependent metabolic changes that favor a breast cancer
promoting function.

Introduction
CAFs are a heterogenous cell populations with several functionally distinct subtypes. We have
tested the functions of three different CAF subsets in chapter 4 and observed different impacts of
these cells on tumor growth and metastasis and on different components of the tumor
microenvironment. In this chapter, we sought to further probe one particular aspect of aSMA+
CAFs: their metabolic crosstalk with cancer cells. Previous studies from our lab show that
depletion of aSMA+ CAFs results in decrease in whole tumor metabolites, which suggested that
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these CAFs contribute to tumor metabolism and are possibly fueling cancer cell growth135 (data
not shown in this thesis).
CAFs have been proposed to undergo metabolic reprogramming toward aerobic
glycolysis, a phenomenon known as the reverse Warburg effect. It has first been observed in the
context of cancer by studying activated myofibroblasts. The absence of Caveolin1 (CAV1) has
been associated with fibroblast activation and a myofibroblast-like phenotype123,124. CAV1–/–
fibroblasts have been shown to upregulate expression of several enzymes involved in glycolysis.
Subsequent studies showed that in vitro co-culturing of breast cancer cells and fibroblasts caused
upregulation of the lactate exporter monocarboxylate transporter 4 (MCT4) in fibroblasts along
with expression of the lactate importer monocarboxylate transporter 1 (MCT1) in cancer cells.
Immunostaining of patient breast cancer tissue confirmed compartmentalized expression of the
two monocarboxylate transporters, suggesting that fibroblasts secrete and cancer cells take up
lactate125. Other in vitro studies showed co-culture of fibroblasts and breast cancer cells results in
increased mitochondrial mass in breast and decreased mitochondrial mass in fibroblasts. The
increase in mitochondrial mass in the cancer cells when in co-culture with fibroblasts could be
mimicked by feeding them lactate126. Further in vitro studies showed metabolic cooperation
between CAFs and cancer cells suggesting additional CAF-derived metabolites to fuel cancer
cells’ growth127–129. In vivo evidence for the metabolic liaison between cancer cells and CAFs is
limited. The most relevant study demonstrating a lactate shuttle has used a prostate cancer
model, in which knockdown of MCT1 in prostate cancer cells limited their growth potential in
vivo70.
In the center of all studies investigating the mechanism of metabolic reprogramming of
CAFs is the master regulator of glycolysis, HIF-1a130, but CAFs may also be metabolically
reprogrammed by paracrine signaling from cancer cells. Co-culture with cancer cells has shown
to induce loss of CAV1, increase in oxidative stress and reactive oxygen species production,
associated with HIF-1a upregulation66,125. The glycolytic phenotype of CAFs can be triggered by
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TGFb and PDGF treatment, which cause downregulation of IDH3a and HIF-1a stabilization131.
While these few studies offer possible explanations how CAFs may acquire a glycolytic
phenotype, the exact molecular underpinnings of such regulation remain to be discovered.
Interestingly, studies investigating the metabolic phenotypes detect distinct changes in CAFs
when compared to normal tissue fibroblasts, although normal fibroblasts have been shown to gain
a CAF-like phenotype in 2D cultures100. This intriguing observation points to irreversible epigenetic
changes in CAFs responsible for the glycolytic phenotype. In fact, CAFs present altered DNA
methylation patterns, but such have not been linked yet with specific functions and characteristics
of those cells132,133. Lastly, hypoxia has been reported to induce loss of global methylation in
human dermal fibroblasts134. In this chapter, we aimed to characterize the metabolic relationship
between cancer cells and CAFs and investigated CAFs’ metabolic regulation. We hypothesize
that CAFs’ altered metabolism is caused by specific changes in DNA methylation, which might be
induced by the hypoxic tumor microenvironment.
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CAFs display a glycolytic phenotype
Our lab has previous shown that depletion of aSMA+ CAFs in 4T1 tumors led to reduction
in overall tumor metabolites135. To identify whether aSMA+ CAFs depletion impacted glycolysis in
cancer cells, WT and aSMA-vTK 4T1 tumor tissues were probed for CK8 (to label cancer cells)
together with pyruvate kinase M2 (PKM2), hexokinase 2 (HK2) and glucose transporter 1
(GLUT1). While PKM2 expression in cancer cells was decreased, CK8-specific GLUT1 and HK2
expression remained unchanged (Figure 20A-C).
Figure 20 Glycolytic changes in cancer cells in
aSMA+ CAFs depleted tumors
A. Immunolabeling of CK8 and Glut1 in WT and
aSMA-vTK tumors. Representative images with
quantification. B. Immunolabeling of CK8 and PKM2
in WT and aSMA-vTK tumors. Representative
images with quantification C. Immunolabeling of CK8
and HK2 in WT and aSMA-vTK tumors.
Representative images with quantification. Data
presented as mean +/- s.e.m., individual dots in
graphs indicate individual mice. Unpaired t test (with
Welch correction when appropriate) or MannWhitney test were used, depending on normality
distribution of data. p values are indicate above
graphs. Scale bars in all images including inserts:
50µm
The immunolabeling experiments in this figure were
performed on tumors from an experiment previously
described in 194 (replicate of experiment in Figure 10
using the same WT and ⍺SMA-vTK mice with the
same observations on tumor growth).

In order to directly determine the metabolic shifts in CAFs, we purified and cultured CAFs (murine
CAFs or mCAFs) from PyMT tumors and fibroblasts derived from healthy murine mammary tissue
(hereafter referred to as murine normal fibroblasts or mNFs). Gene expression analyses revealed
elevated transcript levels for metabolic enzymes in mCAFs compared to mNFs. The elevated
enzymes included monocarboxylate transporter 4 (MCT4, encoded by Slc16a3), hexokinase 2
(Hk2), and pyruvate kinase M1/2 (Pkm). (Figure 21A).
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Figure 21 mCAFs are highly glycolytic compared to mNFs
A. Gene expression of key glycolytic enzymes and transporters in mCAFs compared to mNFs.
mCAFs were derived from mammary carcinomas in MMTV-PyMT mice. B. Glycolysis stress test
comparing mCAFs to mNFs. mCAFs were isolated from PyMT tumors. p values are indicated above
graphs.

Next, extracellular acidification was measured in mCAFs and mBFs via Seahorse Glycolysis
Stress Test. mCAFs demonstrated enhanced glycolysis compared to mNFs (Figure 21B,
increase in extracellular acidification rate (ECAR, p= 0.15 – 0.3) upon addition of glucose, as well
as oligomycin, which maximizes glycolysis by inhibition of mitochondrial respiration).
A lactate shuttle has been proposed in the literature between CAFs and cancer cells in
the tumor microenvironment70,126,136. We have previously investigated the impact of a potential
lactate shuttle between CAFs and cancer cells. In these experiments, 4T1 cells were
orthotopically injected and tumor growth was measured. 4T1 cells were either modulated for
reduced monocarboxylate transporter-1 (MCT1) expression, or implanted together with
fibroblasts with impaired lactate secretion achieved by Pdk4 knockdown. When cancer cells were
unable to take up lactate, tumor growth was impaired. Moreover, we found that lack of lactate
expression in fibroblasts (via Pdk4 knockdown) when injected together with 4T1 cancer cells,
resulted in tumor growth retardation135. Here, we tested whether any changes in tumor
vasculature or fibroblasts proliferation might have caused the reduction in tumor growth in these
experiments; as we saw with ⍺SMA+ CAFs depletion.
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Figure 22 Abrogation of lactate intake by cancer cells results causes no changes in tumor vasculature
A. Schematic presentation of proposed lactate shuttle. B. Slc16a1 (MCT1) expression in control 4T1 cells (shScrbl)
and 4T1 cells with MCT1 knockdown (shMCT1 #1/2). C. Tumor growth of control 4T1 cells and shMCT1 4T1 cells. D.
Tumor weight in tumors from (C). E. Lung metastatic area in mice from (C). F. aSMA expression in tumors from (C)
with quantification. G. Hypoxia levels measured by CAIX in tumors from (C). Representative pictures with
quantification. H. Immunolabeling for aSMA, PDGFRb and CD31 in tumors from (C). Representative pictures with
quantification. Data presented as mean +/- s.e.m., individual dots in graphs indicate individual mice. Unpaired t test
(with Welch correction when appropriate) or Mann-Whitney test were used, depending on normality distribution of
data. p values are shown above the graphs.
The immunolabeling experiments in this figure were performed on tumors from experiments previously described in 124.
Scale bars: A-B: 50 µm, C: 12.5 µm, D: 20 µm, E: 50 µm
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Loss of Slc16a1 (MCT1) in 4T1 cancer cells did not significantly change tumor vasculature
(Error! Reference source not found.B-C). These results support that limiting lactate uptake in
cancer cells inhibits tumor growth without affecting CAF recruitment. In tumors with fibroblasts
with Pdk4 knockdown, aSMA+ CAF numbers and their proliferative index, hypoxia, angiogenesis,
and pericyte coverage remained unchanged (Error! Reference source not found.D-F)
supporting that the enhanced glycolytic activity of mammary CAFs promote tumor growth via
lactate transfer to cancer cells.

Breast cancer-derived human CAFs display enhanced glycolytic activity
We evaluated the metabolic rewiring of human breast cancer-associated fibroblasts (hCAFs). We
used the established catalog of human breast fibroblasts, from both benign, as well as cancerous
breast biopsies as shown in Chapter 3. Fibroblasts were isolated from these samples and in ~39%
of all culture was successful; and ease of establishing cultures and their propagation did not
indicate any bias with respect to pathology or mammographic density parameters. All subsequent
analyses were performed on low passage fibroblasts cultures (< 20 passages, see methods), and
a selected number of lines were used for in-depth analyses. The biopsy-derived fibroblasts were
thereafter referred to as CAFs if derived from breast neoplasms (human CAFs, hCAFs) and enign
fibroblasts if derived from non-cancerous breast tissue (human benign fibroblasts, hBFs),
respectively (Figure 23A).
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Extracellular acidification rate (ECAR) measured by Seahorse Glycolysis Stress Test was
significantly increased in hCAFs compared to hBFs (Figure 23B). hCAFs exhibited increased
glycolysis, glycolytic capacity and glycolytic reserve when compared to hBFs (Figure 23C),
supporting a pronounced pro-glycolytic phenotype of hCAFs. The results support that cultured
human and murine CAFs demonstrate a pro-glycolytic phenotype compared to BFs, and such
acquired features are maintained even after in vitro passages of the cells.

Figure 23 hCAFs are highly glycolytic compared to hBFs
A. Representative pictures of isolated hBFs and hCAFs. Scale bar: 200µm B. Glycolysis stress test in hCAFs and
hBFs. Extracellular acidification rate was measured and arrows indication injection of glucose, oligomycin and 2deoxy glucose (2DG). C. Glycolysis, Glycolytic capacity and glycolytic reserve was measured in hCAFs and hBFs.
Data presented as mean +/- s.e.m., individual dots in graphs indicate individual mice. Unpaired t test (with Welch
correction when appropriate) or Mann-Whitney test were used, depending on normality distribution of data. p values
are shown in graphs.
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Cancer cells uptake and utilize CAF-secreted metabolites to fuel their metabolism
To define the metabolic exchange between CAFs and cancer cells, we evaluated the fate of
labeled metabolites in cancer cells fed with CAFs metabolic products. Uniformly labeled 13C
glucose ([U-13C] glucose) was fed to hCAFs (48 hours), and utilization of glucose by hCAFs was
evidenced by labeled metabolites implicated in glycolysis, TCA cycle, PPP, nucleotide
synthesis, AA biosynthesis, and urea cycle (Figure 24A).
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Figure 24 Cancer cells incorporate CAFs-derived metabolites in their metabolism
A. 13
C-glucose was fed to CAFs and labeled metabolites were measured in CAFs. B. CAFs were fed 13C-labeled glucose.
Subsequently CAFs were cultured in medium with no label to allow for labeled metabolites to be secreted in medium (conditioned
medium, CM). This CM was fed to a culture of MDA-MB-231 cells and metabolites were probed for 13C label in cancer cells. C. 13Clabeled metabolites in CAF CM. D. 13C-labeled metabolites in MDA-MB-231 cells fed with CAF CM.
This experiment was performed by Margo Cain and I analyzed the data.
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Next, the secreted,

13

C-labeled hCAFs metabolites were captured: hCAFs were fed [U-

13

C] glucose for 48 hours to label all glucose-derived hCAF metabolites; the cells were then

washed and cultured for 48 hours in unlabeled glucose media (Figure 24B). The hCAF-secreted
labeled metabolome revealed metabolites involved in PPP, TCA cycle and nucleotide synthesis
(Figure 24C). The CM containing hCAF-labeled metabolites was also used to feed triple negative
human breast cancer cells, MDA-MB-231, for 24 hours (Figure 24B). MDA-MB-231 cells were
harvested and

13

C labeled metabolites derived from these cells were measured (Figure 24D).

The analysis indicated that hCAFs-derived metabolites were used by cancer cells to fuel PPP and
nucleotide biosynthesis (Figure 24D). Controls for the metabolite transfer experiment included
unlabeled hCAFs, as well as unlabeled MDA-MB-231. These experiments indicate that human
cancer cells utilize hCAF-derived metabolites to fuel their metabolic needs, which includes nucleic
acid metabolism.

Oscillating oxygen tension results in reprograming of hBFs to attain CAF-like metabolic profiles
The pro-glycolytic metabolism of hCAFs was maintained despite repeated in vitro
passages in atmospheric oxygen conditions (21% O2). Metabolomic analyses revealed consistent
upregulation of glycolytic enzymes and accumulation of representative metabolites along with
elevated ECAR (Figure 23, Figure 24B). We have previously shown differential methylation
patterns of rate limiting glycolytic genes, namely fructose-1,6-bisphosphatase (FBP1), PKM,
LDHA, and HIF1A in hBFs and hCAFs from the same patient cohort135. Such epigenetic
reprogramming can at least in part contribute to the hCAFs glycolytic phenotype. To test this
hypothesis, we treated hBFs with the demethylating agent 5-Azacytidine (5-Aza). Upon exposure
to 5-Aza, hBFs showed an increase in LDHA, HIF1a, and PKM2 transcript levels, suggesting an
epigenetic regulation of pro-glycolytic genes in fibroblasts (Figure 25A). Previously, we found
HIF-1 protein and transcript levels elevated in hCAFs when compared to hBFs135. Chronic hypoxia
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is a feature of growing tumors, leading to the stabilization of HIF-1a protein. We hypothesized
that chronic hypoxia may initiate HIF-1a-mediated metabolic reprograming of CAFs due to
promoter hypomethylation, resulting in sustained elevation of HIF-1a levels in hCAFs compared

Figure 25 Chronic hypoxia induces stable expression of HIF-1a and glycolytic enzymes in hBFs.
A. Expression of indicated genes in hBFs when treated with 5Aza and untreated (CTR) assessed by qPCR. This
experiment was performed by Joyce Tse O’Connell and reproduced with permission. A similar experiment using
fibroblasts from different patients has previously been described in doctoral dissertation of Annie Vo124. B. HIF1-a
protein levels in hBFs from two distinct patients in the indicated conditions of normoxia, hypoxia and hypoxia followed
by reoxygenation. C. Transcript levels of HIF1-a in experiment from (B). D. Gene expression for indicated genes in
hBFs from three patients at normoxia, 3 days of hypoxia, or 3 days of hypoxia followed by 24hr reoxygenation.
The experiments in panels B-D are repetitions of experiments previously performed by Annie Vo124.

to hBFs135. To test this hypothesis, hBFs from two distinct patients were subjected to increasing
intervals of hypoxia (1% O2) for 1, 3, 5 and 7 days, followed by 48 hours of reoxygenation (21%
O2) for each timepoint. When hBFs were subjected to a prolonged exposure of hypoxia (5 and 7
days), HIF-1a protein expression was elevated despite re-oxygenation (Figure 25B).
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HIF-1a transcripts were elevated in one out of the two tested hBFs lines upon hypoxia
exposure and remained increased upon re-oxygenation (Figure 25B). Further, alternating
exposures of hBFs to hypoxia/re-oxygenation cycles elevated the normoxic baseline transcript
levels of HIF-1a and glycolytic enzymes SLC2A1, HK2, PFKL, PKM, and LDHA (Figure 25D). Of
note, we have previously performed similar experiments as shown in Figure 25 with similar
observations135. To determine if changes in intratumoral hypoxia in growing tumors contribute to
the accumulation of glycolytic CAFs in vivo, we evaluated the glycolytic profiles of CAFs in hypoxic
and normoxic tumor regions. Glycolytic CAFs, defined by co-expression of aSMA and PKM2 or
HK2 (aSMA/PKM2 and aSMA/HK2 CAFs) were more abundant in hypoxic (CAIX high) rather
than normoxic (CAIX low) areas of MMTV-PyMT tumors (Figure 26A). The inverse relationship
was observed for aSMA+ CAFs expressing FBP1 (presumed less glycolytic), with aSMA/FBP1
CAFs more abundant in normoxic rather than hypoxic areas (Figure 26A). In both MMTV-PyMT
and 4T1 tumors, larger tumor volumes were partly associated with increased intratumoral
hypoxia, and significant accumulation of glycolytic fibroblasts (aSMA/PKM2) (Figure 26B-C). In
4T1 tumors, aSMA/HK2 fibroblasts also significantly expanded with tumor growth. While nonglycolytic fibroblasts (aSMA/FBP1) remained unchanged in 4T1 tumors, in MMTV-PyMT tumors
this population significantly decreased as tumor volumes increased. Lastly, patient tissues were
probed for fibroblasts presenting with hypoxia. In tumors (IDC), there was a significant increase
in hypoxia-associated fibroblasts (aSMA+CAIX+ out of total aSMA), when compared to benign
tissues (Figure 26D).
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Figure 26 Glycolytic CAFs accumulate in hypoxic areas of tumors
A. Expression of HK2 (top panel), PKM2 (middle panel) and FBP1 (bottom panel) in hypoxic (CAIX
high) and normoxic (CAIX low) areas in PyMT tumors. Representative image from each immunolabeling
with quantification. B. Immunolabeling for Carbonic anhydrase 9 (CAIX, panel 1), aSMA/FBP1 (panel
2), aSMA/HK2 (panel 3), aSMA/PKM2 (panel 4) in MMTV-PyMT tumors of different volumes. Pearson
correlations between tumor volume and expression of respective markers are shown together with
representative pictures of each immunofluorescence labeling. C. Immunolabeling for Pimonidazole
(panel 1), aSMA/FBP1 (panel 2), aSMA/HK2 (panel 3), aSMA/PKM2 (panel 4) in 4T1 tumors of different
volumes. Pearson correlations between tumor volume and expression of respective markers are shown
as well as representative pictures of each immunofluorescence/ immunohistochemistry labeling. Scale
bars: 50 µm. D. Immunolabeling of aSMA and CAIX in patients with benign breast biopsies or breast
cancer. This experiment was performed by Hikaru Sugimoto and is shown with his permission.
One-tailed unpaired t test or Mann-Whitney test, Pearson Correlation, P and R2 values are indicated in
all graphs
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Together, our data suggests a model in which normal benign fibroblasts that are not tumor
promoting and not very glycolytic can convert into CAFs through tumor progression in which
oxygen tension changes and increased levels of hypoxia are observed. This causes the
epigenetic changes in HIF-1a and glycolytic enzymes we showed, which makes the CAFs highly
glycolytic and tumor promoting (Figure 27).

Figure 27 Proposed model of fibroblast reprogramming

Interpretation of findings
We have shown that murine as well as human CAFs present with a highly glycolytic
phenotype, compared to their benign or healthy counterparts, as it had been previously
suggested72,137,138. mCAFs derived from PyMT transgenic mice show a less pronounced glycolytic
phenotype than what we have observed previously in mCAFs derived from 4T1 orthotopic
tumors135, demonstrating the heterogeneity between different animal models. The differences are
likely due to higher hypoxia levels in 4T1 tumors when compared to PyMT tumors of similar
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volume (as shown in chapter 3), in agreement with our observations of hypoxia-induced metabolic
reprograming of CAFs.
In the previous chapter, we demonstrated that aSMA+ CAFs’ tumor promoting role in
mammary carcinomas is associated with remodeling of the tumor microenvironment, with CAFs
depletion impeding tumor angiogenesis and enhancing intratumoral hypoxia. In this chapter we
used tissues from a previous study135 that shows disruption of the lactate shuttle between cancer
cells and CAFs results in reduced tumor growth, and probed these tissues for changes in tumor
vasculature. Here, we could not detect changes we observed with aSMA+ CAFs depletion,
demonstrating that CAFs’ metabolic support for cancer cells is an independent tumor-promoting
mechanism of these cells. In aSMA+ CAFs depleted tumors, expression of glycolytic enzymes by
cancer cells upon was moderately decreased. High intratumoral hypoxia in CAFs-depleted tumors
is expected to elevate cancer cell glycolysis, thereby possibly masking greater effects of CAFs
depletion on cancer cells’ metabolism70,130,131.
In addition to a CAFs-cancer cell lactate shuttle, our metabolite transfer experiment
employing human breast carcinoma-derived CAFs indicates that CAFs-secreted metabolites fuel
biosynthetic processes of cancer cells, specifically pentose phosphate pathway and nucleotide
synthesis. While it remains unknown whether the uptake of CAFs-derived metabolites by cancer
cells could be influenced when nutrients are scarce, our experiments inform on the basal
metabolic relationship between CAFs and cancer cells. Here we carried out metabolite exchange
experiments in conditions wherein cancer cells were not deprived from critical nutrients or oxygen,
and despite the relatively short exposure time of cancer cells to the CAFs-derived metabolites,
the uptake was principally noted in biosynthetic pathways. For instance, erythrose-4-phosphate
was found in the CAF secretome, which can be taken up by cancer cells and fuel pentose
phosphate pathway by conversion into sedoheptulose-7-phosphate and PRPP139, and both of
these metabolites were found in MDA-MB-231 cancer cells when fed the

13

C labeled CAF
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conditioned media. These results support the notion that cancer cells likely present with
scavenging properties that enable efficient uptake of metabolites secreted by other cells, including
CAFs, thus effectively hijacking metabolites in the tumor microenvironment to support their growth
and survival140.
In our experimental setting, lactate was not amongst the top metabolites secreted by
CAFs. Although lactate was noted in the CAF secretome, the high false positive detection rate of
labeled lactate in the control unlabeled CAFs (> 5%) rendered its detection as CAFs-secreted
metabolite inconclusive. Increased lactate secretion was however confirmed by a glycolytic stress
test. In the metabolite transfer experiment, pyruvate was the second most abundant CAFsecreted metabolite. Previous studies suggest growth stimulatory effects of pyruvate on cancer
cells by fueling their mitochondrial respiration141. Moreover, pyruvate uptake by cancer cells has
been shown to render them resistant to metformin treatment. Gui et al. demonstrated that the
pyruvate taken up by cancer cells is converted to lactate to increase the intracellular NAD+ level,
which is lowered by metformin treatment. NAD+ is then utilized for aspartate biosynthesis142.
Since lactate as well as pyruvate can be transferred via MCT1, these reports are also in
agreement with our previous findings associated with Slc16a1 (MCT1) knockdown, and both a
lactate and pyruvate shuttle between CAFs and cancer cells may fuel cancer cell metabolism135.
Our study identified a hypoxia-induced re-wiring of fibroblasts towards a pro-glycolytic
phenotype and results in a sustained elevation of HIF1-a, PKM2, and LDHA, and suppression of
FBP1 gene expression. The acquired baseline pro-glycolytic phenotype, persistent in murine and
human breast carcinoma-derived CAFs was likely facilitated by changes in the DNA methylation
status of specific metabolic gene promoters135. Fibroblasts, along with cancer cells in growing
tumors, are exposed to chronic hypoxia, creating an opportunity for metabolic coupling,
coordinated by epigenetic events that favor the accumulation of pro-glycolytic CAFs with protumorigenic properties. The accumulation of pro-glycolytic CAFs in regions of increased
intratumoral hypoxia in our analyses of multiple breast tumor models supports this notion.
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Oxygen availability can drive metabolic adaptation of tissues143. Although not studied here,
it is possible that the increase in intratumoral hypoxia associated with aSMA+ CAF depletion
influenced the dissemination of cancer cells by impacting their metabolism, as reviewed by Rankin
and Giaccia144. In contrast to the increase in intratumoral hypoxia from genetically controlled
depletion of CAFs, the increase in intratumoral hypoxia in growing tumors, imposed by inadequate
angiogenesis promotes the emergence of pro-glycolytic CAFs which may, at least in part, fuel
cancer cell biosynthetic needs. Here we show that the chronic exposure to hypoxia and
reoxygenation of normal fibroblasts was sufficient to induce a transcriptome characteristic of
CAFs (pro-glycolytic). These findings suggest CAFs are cells with the capacity for hyperresponsiveness to hypoxia.
In summary, we identify that patient-derived breast CAFs exhibit an activated metabolism
with enhanced glycolytic activity. This feature of CAFs’ metabolism fuels cancer cells and
promotes tumor growth. Therapeutic agents targeting glycolysis that are currently undergoing
clinical evaluation might also function by concomitantly affecting the metabolism of protumorigenic CAFs in breast cancer.

Potential pitfalls and alternate approaches
The study was initiated to further investigate a phenotype of aSMA+ CAFs. While we
started the study based on our aSMA+ CAF depletion model, fibroblast heterogeneity was not
taken into consideration in later studies. Future experiments need to address this point and
investigate whether our observations were specific to aSMA+ CAFs.
In the metabolite transfer experiment, only unfed CAFs or unfed cancer cells were used
as controls. We can confidently conclude, that CAF-derived metabolites feed into cancer cells’
metabolism. However, this does not exclude the possibility of benign fibroblasts also metabolically
fueling cancer cells. In order to test whether normal benign fibroblasts are also able to provide
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cancer cells with metabolites, and if so, how those differ from CAF-derived metabolites, the
experiment needs to be repeated using benign fibroblasts or normal fibroblasts derived from
healthy breast tissue.

Future directions
Future directions of this study involve the unraveling of the exact mechanisms of
epigenetic modifications. We propose that hypoxia induced not only the observed stable
hypomethylation of HIF-1a135, but also the differential DNA methylation of PKM2, LDHA and FBP1
promoter in fibroblasts, as previously described135. However, future experiments will confirm or
disprove this suggestion. Intriguingly, hypoxia induced a glycolytic, CAF-like phenotype in benign
fibroblasts. Our study indicates that such fibroblasts could have acquired the tumor growth
promoting functions by providing metabolic fuel for cancer cells. Future studies will address this
question and test additional characteristics of hypoxia-activated fibroblasts, in order to test to what
extend those are comparable to CAFs.
TET hydroxylases are known regulators of DNA methylation, which are interestingly
dependent on binding to TCA cycle intermediate oxoglutarate145,146. It would be of interest to
further investigate potential feed forward loops between metabolism and DNA methylation,
particular in CAFs. Such questions should be addressed in future studies.
Loss of CAV1 has been associated with the glycolytic phenotypes of CAFs. Future
analyses will be focused on measuring CAV1 expression in human CAFs compared to benign
fibroblasts. In line with this, whole transcriptome analysis on these human-derived fibroblasts
could be performed to further decipher distinct CAF metabolic phenotypes in patient-derived
fibroblasts.
Lastly, we found several different metabolic pathways upregulated in hCAFs compared to
hBFs in previous investigations135. Future studies should be aimed to investigate the contributions
of additional differentially regulated metabolic pathways in CAFs to cancer progression.
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CHAPTER 6

DEREGULATED SIGNALING IN FIBROBLASTS CAN INITIATE EPITHELIAL
TUMORIGENESIS

This work is based on the previously published study:
Eikesdal, H. P.*, Becker, L. M.*, Teng, Y.*, Kizu, A., Carstens, J. L., Kanasaki, K., Sugimoto, H,
LeBleu, V. S., Kalluri, R. (2018). BMP7 Signaling in TGFBR2-Deficient Stromal Cells
Provokes Epithelial Carcinogenesis. Molecular Cancer Research, 16(10), 1568-1578.
https://doi.org/10.1158/1541-7786.mcr-18-0120
* Co-first authors
Data presented was generated by all authors on this publication and is shown with their
permission. Parts of this chapter are taken verbatim from the publication.

99

Summary
Fibroblasts can elicit their heterogeneous effects on tumor development and progression
indirectly, via matrix remodeling, and directly by secreting metabolites, cytokines and growth
factors (such as TGFb, FGF, HGF) that enhance or inhibit cancer cell proliferation, survival
(resistance to apoptosis) and migration. We have shown how different CAF subsets have distinct
roles in mammary carcinoma progression. Moreover, we have demonstrated how fibroblasts can
be epigenetically reprogrammed towards increased glycolysis with a CAF-like phenotype. This
glycolytic rewiring presumably happens during tumor progression due to limited oxygen
availability in the tumor microenvironment. In the last part of this thesis, we focused our
investigations on an additional aspect of CAF biology: CAFs or fibroblasts’ role in tumor initiation.
Deregulated TGFb signaling in the stromal fibroblasts has been shown sufficient to induce
tumors of epithelial origin36. Specifically, knockdown of TGFB RECEPTOR 2 (TGFBR2) in FSP1+
fibroblasts (TGFBRcKO animals) led to development of forestomach carcinoma with 100%
penetrance. In order to better understand cancer initiation in this intriguing mouse model, we
aimed to decipher the roles of downstream elements of the TGFb signaling cascade. We chose
to deplete the common Smad protein, SMAD4, in order to target both canonical arms of the TGFb
superfamily signaling pathway. Surprisingly, mice lacking both TGFBR2 and SMAD4 in FSP1+
fibroblasts (TGFBR/SMAD4cKO mice) no longer developed forestomach cancer. We found that in
the TGFBRcKO animals, BMP7 signaling caused increased HGF secretion by fibroblasts, which in
turn induced proliferation of epithelial cells via Met phosphorylation. This was supported by
upregulation of BMP7 receptor ALK6 in these fibroblasts. Taken together, our data suggests a
model of a complex feed forward loop, in which the loss of TGFBR2 specifically in FSP1+
fibroblasts allows BMP-dependent signaling due to upregulation of ALK6 receptor on the TGFBR2
deficient fibroblasts. This then leads to increased HGF production, which, in turn, results in Met
phosphorylation in the epithelial cells causing them to proliferate at an increased rate. The
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hyperproliferative epithelial cells are producing BMP7, which then binds to ALK6 on the fibroblasts
to further induce Smad4-dependent HGF production. Of note, in order to address the specificity
of TGFRB loss in FSP+ fibroblasts, we showed that the knockout of the receptor in aSMA+
fibroblasts caused no phenotype in mice. This underlines the distinction between aSMA+ and
FSP1+ CAFs, both in tumor initiation and progression.

Introduction
During all stages of tumorigenesis, cancer cells are continuously engaged in crosstalk with
cells of the surrounding stroma. Fibroblasts, which are abundant in the tumor microenvironment
(TME), have emerged as critical for development and progression of many solid cancers.
However, their exact roles are not fully understood. Published studies indicate that fibroblasts can
either promote or suppress tumor progression, suggesting bimodal functions and heterogeneity
amongst this cell type65. Apart from their intensely-researched involvement in tumorigenesis,
several studies indicate that fibroblasts play a causative role in tumor development whereby
mutational events in the fibroblasts can result in hyperproliferation and subsequent malignancy in
epithelial cells147,148. Such observations are exceptionally rare and need further investigation, but
they add another layer of complexity to an already intricate crosstalk between fibroblasts and
cancer cells. Fibroblasts can elicit their heterogeneous effects on tumor development and
progression indirectly, via matrix remodeling, and directly by secreting factors (such as TGFb,
FGF, HGF) that enhance or inhibit cancer cell proliferation, survival (resistance to apoptosis) and
migration65.
Transforming growth factor beta (TGFb) signaling is heavily involved in multiple aspects
of cancer-stroma interactions. TGFb binds to the TGFb receptor 2 (TGFBR2), causing recruitment
of TGFb receptor 1 (TGFBR1) and subsequently results in downstream signaling through multiple
Smad family proteins. These Smad proteins can also be activated by other ligands, such as
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activins, nodal proteins and bone morphogenetic proteins (BMPs), and their receptors, which are
all part of the TGF superfamily149. Canonically, TGFb elicits downstream signaling through
Smad2/3, while BMP signals through Smad1/5/8. However, both canonical signaling pathways
complex with Smad4 to initialize transcription149. TGFb signaling has been implicated to play
significant roles in most cancers. TGFb secretion by tumor cells and immune cells leads to
recruitment and activation of fibroblasts in the tumor microenvironment65. CAFs can in turn secrete
TGFb, which triggers tumor-promoting events150 and programs in cancer cells, such as epithelialto-mesenchymal transition (EMT)151. Therefore, in advanced stages of cancer progression, TGFb
critically contributes towards tumor growth and metastasis. However, TGFb is also known to have
quite opposing effects, as studies demonstrate its function as tumor suppressor in earlier stages
of tumorigenesis149. In most solid tumors, deregulation of the balance between TGFb/BMP
signaling is a common feature. In line with these observations, many cancers present with
mutations in genes linked to TGFb signaling pathways, such as TGFBR2 and SMAD4152.
However, studies using genetically engineered mouse models have shown insufficiency of such
mutations in epithelial cells alone to elicit carcinogenesis. For instance, depletion of TGFBR2
specifically in the epithelium of head and neck tissues, such as oral cavity, esophagus and
forestomach only resulted in tumorigenesis when combined with an additional KRAS mutation in
the epithelium, but not by itself153. In contrast, deregulated TGFb signaling in the stroma was
sufficient to induce tumors of epithelial origin. Specifically, Bhowmick et al. showed that mice with
conditional TGFBR2 knockdown in FSP1+ fibroblasts develop squamous cell carcinoma (SSC) of
the forestomach and neoplastic changes in the prostate36. All of these pieces of data suggest a
complex regulatory network involving many signaling molecules across and within various cell
types for tumor initiation and progression.
In an attempt to better understand this complexity with regard to the crosstalk between
cancer cells and fibroblasts that could lead to tumor initiation, we focused on the FSP1+ fibroblast
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loss of TGFBR2 model of forestomach cancer originally published by Bhowmick et al. In order to
better understand forestomach cancer initiation in this intriguing mouse model, we aimed to
decipher the roles of downstream elements of the TGFb signaling cascade. We chose to deplete
the common Smad protein, SMAD4, in order to target both canonical arms of the TGFb
superfamily signaling pathway and show the obligate Smad4-mediated signaling in FSP1+
fibroblasts lacking TGFBR2 to give rise to epithelial carcinogenesis in the forestomach.

Loss of Smad4-mediated signaling in FSP1+ stromal cells lacking TGFBR2 abrogates
forestomach cancer development
We faithfully replicated the findings by Bhowmick et al., wherein conditional loss of TGFBR2 in
FSP1+ stromal cells (Tgfbr2floxE2; FSP1-Cre mice, entitled TGFBR2 conditional knockout,
TGFBR2cKO mice) resulted in squamous cell carcinomas of the forestomach, with 100%
penetrance at 1.5 months of age, and moribundity between 1 to 2 months of age36 (Figure 28AC) Strikingly however, when these mice were further crossed onto the Smad4floxE8-9 background
to generate mice with FSP1+ stromal cells lacking both TGFBR2 and SMAD4 (Tgfbr2floxE2;
Smad4floxE8-9; FSP1-Cre, hereafter referred to as TGFBR2/SMAD4cKO), they no longer presented
with cancer, and had a normal life span, similar to control (wt) mice (Figure 28A-C).
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In contrast to the TGFBR2cKO mice,
TGFBR2/SMAD4cKO mice showed no
evidence

of

carcinogenesis

and

forestomach
presented

with

normal forestomach histology (Figure
28C). SMAD4 conditional loss in FSP1+
stromal cells (Smad4floxE8&9; FSP1-Cre:
SMAD4cKO) did not result in forestomach
cancer (Figure 28A, C), and these mice
presented

with

mild

cartilage

developmental defects as previously
described154.

Cre-negative

controls

(Tgfbr2floxE2 and Smad4floxE8-9) were
Figure 28 Loss of SMAD4 together with TGFRB2 in FSP1+
fibroblasts does not result in forestomach cancer
development.
A. Forestomach squamous cell carcinoma incidence rate and B.
survival of mice with the indicated genotypes. Log-rank (MantelCox) test. **** p<0.001. wt, n=7; TGFBR2cKO, n=38;
TGFBR2/SMAD4cKO, n=14 mice. C. Hematoxylin-eosin (H&E)
staining and FSP1 immunolabeling of forestomach tissue of mice
with the indicated genotypes. Scale bar: 50 µm. D. Visualization of
FSP1-GFP and aSMA-RFP fluorescent gene product in sections of
the forestomach of FSP1-GFP;aSMA-RFP double transgenic mice.
L: lumen, E: epithelium, S: stroma, SM: smooth muscle, *: green
autofluorescence in the epithelial keratin layer. DAPI (blue): nuclei.
Scale bar: 50 µm. E. EYFP visualization (green) and
immunolabeling for Cytokeratin 5 (CK5) detected with TRITCconjugated secondary immunolabeling in sections of the
forestomach tissue from R26-EYFP; FSP1-Cre+ mice. DAPI (blue):
nuclei. E: epithelium, S: stroma.

phenotypically normal (Figure 28A).
Notably, FSP1+ stromal cells appeared
equally abundant in the forestomach of
wild-type (wt) and TGFBR2/SMAD4cKO
mice (Figure 28C). These results
indicated that the loss of Smad4 in
FSP1+ stromal cells lacking Tgfbr2 did
not result in loss of FSP1+ cells in the

forestomach, but rather changed their downstream signaling, leading to a phenotypic, fully
penetrant, reversal of the oncogenic potential of FSP1+ stromal cells acting on the epithelium.
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Mesenchymal FSP1+ stromal cells specifically induce forestomach cancer
In the forestomach tumors of TGFBR2cKO mice, the squamous cell carcinoma cells were
characterized by cytokeratin 5 and phosphorylated p63 positive staining (Figure 29A), whereas
the FSP1 immunolabeling was localized to the stroma (Figure 28C). Systematic analysis of the
healthy gastrointestinal tract of double transgenic aSMA-RFP; FSP1-GFP mice demonstrated
that FSP1+ stroma cells were abundantly found immediately below the epithelium, whereas
aSMA+ stromal cells were mostly located in the deeper smooth muscle layers (Figure 28C,
Figure 29B).
Lineage tracing
of

FSP1+

cells

in

normal forestomach of
adult mice, employing
FSP1-Cre; R26R-LSLEYFP mice, indicated
that FSP1 was largely
Figure 29 Tumor initiation by conditional loss of TGFBR2 is specific to FSP1
fibroblasts
A. Immunolabeling for p64, CK5, CK20 and Ki67 in forestomachs of wt, TGFBR2cKO, and
TGFBR2/SMAD4cKO mice. S: stroma. Arrowhead points to a Ki67+ stromal cell. Scale
bar: 20 µm. B. aSMA-RFP, FSP1-GFP mice were used to probe for mesenchymal
marker expression in different tissues. L: lumen, E: epithelium, S: stroma, M: smooth
muscle, dotted line: outlines the boundaries of the esophageal lumen. DAPI (blue):
nuclei. Scale bar: 100 µm. Arrows point to FSP1-GFP+ stroma C. Immunolabeling for
CD45 and FSP1 in forestomachs of wt and TGFBR2cKO mice. White arrow: colocalization of FSP1 and CD45. * depicts CD45+ cells within a vessel. S: stroma. E:
epithelium. Scale bar: 50 µm.

expressed

in

the

stroma and not the
epithelium
forestomach
28E).

of

the

(Figure
Combined

immunolabeling

for

FSP1 and the pan-leucocyte marker CD45 indicated that a subset of the FSP1+ stromal cells were
leukocytes (Figure 29C), in agreement with previous reports155,156. While inflammation could
affect forestomach cancer progression157 leucocyte infiltration in the forestomach of TGFBR2cKO
mice was not a dominant feature of the histopathological findings. These results support that
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deregulated TGFb signaling specifically in the mesenchymal FSP1+ stroma most proximal to the
forestomach epithelium leads to forestomach carcinoma.

Loss of TGFBR2 in FSP1+ stromal cells induces epithelial proliferation via HGF/Met signaling
Analysis of forestomachs from TGFBR2cKO mice prior to the emergence of carcinoma
(mice 2 and 4 weeks old) indicated a progressive, robust induction of FSP1+ stromal cell

Figure 30 HGF signaling is elevated in forestomachs of TGFRB2cKO mice
A-B. Immunolabeling (A) and quantification (B) for FSP1, HGF and Ki67 expression in the forestomachs of 2week-old wt and TGFBR2cKO mice. n=2-3 distinct mice per group, unpaired two-tailed t test. C-D.
Immunolabeling (C) and quantification (D) for FSP1, HGF and Ki67 expression in the forestomachs of 4-weekold wt and TGFBR2cKO mice. n=2-3 distinct mice per group, unpaired two-tailed t test. Red arrow points to
FSP1+ fibroblasts in the pre-cancerous forestomach stroma of TGFBR2cKO mice. In A and C, DAB (brown) was
used as the color substrate for the immunohistochemistry, and nuclear hematoxylin counterstaining was
omitted for the Ki67 immunolabeling. S: stroma. Scale bar: 100 µm. E. Western blots analyses for HGF and
BMP7 protein levels in 4-week-old wt and TGFBR2cKO forestomach whole tissue lysates, 30 µg of protein
loaded per lane, each lane represents a distinct mouse. F. Immunolabeling for FSP1 and Ki67 and
quantification of Ki67 positive epithelial and stromal cells in the forestomachs of 6-week-old wt, TGFBR2cKO
and TGFBR2/SMAD4cKO mice. (for TGFBR2cKO: squamous cell carcinoma). Scale bar: 60 µm. The
quantification of Ki67 positive cells was based on three distinct mice per group, and the groups were compared
by one-way ANOVA. G. Western blot analysis for HGF in the forestomach lysate of 6-week-old mice with the
listed genotypes, 30 µg of protein loaded per lane, each lane represents a distinct mouse. H. HGF expression
in forestomach lysates of 2 weeks old wt and TGFBR2cKO mice. *p<0.05, **p<0.01.
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proliferation beneath the forestomach epithelium (Figure 30A-D, F). Elevated HGF was noted in
TGFBR2cKO forestomach tumor lysates when carcinomas had developed and this was not seen
in TGFBR2/SMAD4cKO forestomachs or in forestomachs of 2-week-old TGFBR2cK mice (Figure
30E and G-H).
These data suggested that HGF production by TGFBR2-deficient fibroblasts participated
in neoplasia of the forestomach. RT-PCR was used to assess gene expression of known growth
factors secreted by fibroblasts to directly affect epithelial cells, such as EGF, IL6, CTGF, and
others (see references 158–168).
1

2

3

4

1
2
3
4

wt
cKO
TGFBR2
cKO
TGFBR2/SMAD4
Buffer

Out of all tested growth factors, HGF
was

found

specifically

upregulated

in

TGFBR2cKO forestomach fibroblasts (Figure
31A). Increased secreted HGF levels by
TGFBR2cKO forestomach-derived fibroblasts
expanded in vitro, compared to wt control
forestomach

fibroblasts,

was

validated

using a mouse angiogenesis cytokine array
(Figure 31B-C). Immunolabeling analysis
showed
Figure 31 HGF signaling is elevated in TGFBR2cKO mice
A. RT-PCR electrophoretic product for the listed genes in the
forestomach fibroblasts from approximately 6-week-old mice
with the listed genotypes. Buffer: no template control. B.
Cytokine array using forestomach lysates from wt and
TGFBR2cKO mice. Bar graph below is the quantification of the
array.

TGFBR2cKO

that

fibroblasts,

in

contrast

TGFBR2/SMAD4cKO
fibroblasts,

had

forestomach
to

wt

and

forestomach
upregulated

HGF

expression (Figure 32A). Notably, all

fibroblasts expressed FSP1, and a specific loss of Tgfbr2 expression in TGFBR2/SMAD4cKO and
TGFBR2cKO forestomach fibroblasts was confirmed (Figure 32A).
The impact of elevated HGF production by TGFBR2cKO forestomach fibroblasts was
evaluated in the E10 normal mouse lung epithelial cell line (Figure 32B-C). Conditioned media
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from TGFBR2cKO
forestomach
fibroblasts
induced E10 cell
Met
phosphorylation,
Figure 32 Elevated HGF signaling in TGFBR2cKO fibroblasts causes Met phosphorylation
in neighboring epithelial cells A. Immunolabeling for FSP1, HGF and Tgfbr2 in cultured
forestomach fibroblasts isolated from mice with the listed genotypes. DAPI (blue): nuclei;
omitted in HGF panel. Red insets: negative control (Secondary antibody alone). Blue insets:
display the merged image while the larger image omits the DAPI signal to clearly show the
nuclear localization. Scale bars: 50 µm. B. Immunolabeling for phosphorylated Met (p-Met) in
E10 lung epithelial cell incubated with conditioned media from cultured forestomach fibroblasts
isolated from mice with the listed genotypes. DAPI (blue): nuclei. Red inset: negative control
(Secondary antibody alone). Scale bars: 50 µm. C. E10 lung epithelial cell proliferation
(methylene blue absorbance) after exposure to conditioned media of the forestomach fibroblasts
isolated from mice with the listed genotypes, with and without the Met inhibitor, SU11274 (10
µM). Unpaired two-tailed t test. The data is presented as the mean ± SEM. *p<0.05, **p<0.01,
ns: not significant. See accompanying source data. D. Immunolabeling for HGF and p-Met. Color
substrate: 3, 3´-diaminobenzidine (DAB, brown). Scale bar: 20 µm. S: stroma.

whereas
conditioned
media

of

TGFBR2/SMAD4cKO forestomach fibroblasts failed to induce Met phosphorylation (Figure 32C).
Critically, TGFBR2cKO forestomach fibroblasts conditioned media induced E10 cell proliferation in
a Met signaling dependent manner, with SU11274 Met inhibitor abrogating these effects (Figure
32C). While our transcriptomic analysis and cytokine array analysis of conditioned media from
purified forestomach fibroblasts indicate that additional cytokines and growth factors could play a
role in the induction of forestomach epithelial cell proliferation and emergence of forestomach
carcinoma (Figure 31A-C), HGF emerged as a critical player in forestomach carcinogenesis since
rescuing the malignant phenotype by additional SMAD4 deletion normalized HGF production and
Met phosphorylation (Figure 30G ,Figure 32D).
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BMP7/HGF imbalance in forestomach and epithelium paracrine signaling aggravates
forestomach carcinogenic response
Given that stromal SMAD4 deletion led to a complete rescue of the TGFBR2cKO
forestomach

cancer

(Figure

28A-C),

Smad4-dependent

signaling,

implicating

(bone

morphogenic protein) BMP and Activin receptor mediated signaling, thus emerged as critical for
carcinogenesis
forestomach
Within

of

the

epithelium.

the

TGFb

superfamily,

bone

morphogenic

proteins

(BMPs) and activins signal
Figure 33 BMP7 signaling is disrupted in TGFBR2/SMAD4cKO mice. A.
Western blots analyses for Smad2 and Smad1/5 phosphorylation levels in
forestomach tissue lysate from approximately 6-week-old mice with the listed
genotypes, 30 µg of protein loaded per lane, each lane represents a distinct
mouse. B. RT-PCR electrophoretic product for the listed genes in the forestomach
of approximately 6-week-old mice with the listed genotypes. Buffer: no template
control. C-D. RT-PCR electrophoretic product for HGF in the forestomach
fibroblasts from approximately 6-week-old mice with the listed genotypes with or
without (0.1% FBS) stimulation with BMP7 (C) or Activin A(D).

via

BMP

and

activin

receptors, respectively, to
activate

regulatory

Smads, which use Smad4
to

translocate

to

the

nucleus152. Forestomach lysates from TGFBR2cKO mice showed increased levels of
phosphorylated Smad1/5 and Smad2 (normalized to actin), while this was not observed in
forestomach lysates from wt and TGFBR2/SMAD4cKO mice (Figure 33A). We also assessed the
expression levels of alternative ligands of the TGFb superfamily (BMP2, BMP4, BMP6, BMP7,
Activin A and Activin B) in the forestomach that could activate Smad4 signaling (Figure 33B).
Activin A and BMP7 were both upregulated in TGFBR2cKO forestomachs in contrast to
TGFBR2/SMAD4cKO forestomachs (Figure 33B). BMP7 exposure robustly induced HGF
expression in TGFBR2cKO fibroblasts in vitro (Figure 33C), whereas Activin A failed to induce HGF
expression in TGFBR2cKO forestomach fibroblasts (Figure 33D).
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Transcriptomic analysis as well as BMP7-dependent HGF induction thus implicated BMP7 as a
key signaling molecule able to
induce HGF in fibroblasts lacking
Tgfbr2 but with intact Smad4. BMP7
protein level was markedly elevated
in forestomachs of TGFBR2cKO mice,
concomitant with increased HGF
expression,

during

forestomach

cancer progression (Figure 34A). In
situ hybridization demonstrated that
HGF

expression

localized

to

forestomach stromal cells, while
Figure 34 BMP7 is expressed by epithelial cells and FSP1
fibroblasts express the receptor ALK6.
A. Western blot analysis for BMP7 in forestomach tissue lysate from
approximately 6-week-old mice with the listed genotypes, 30 µg of
protein loaded per lane, each lane represents a distinct mouse. The
actin blot is the same as depicted in Figure 32G B. In situ
hybridization for HGF and BMP7 mRNA (NBT/BCTP substrate,
purple) in sections of the forestomach of the listed mice. L: lumen, S:
stroma, E: epithelium/cancer cells, M: smooth muscle. Arrows point
to stromal HGF and cancer cell BMP7 expression, respectively. Scale
bars: upper panel (HGF): 50 µm, lower panel (BMP7): 20 µm. C.
Immunolabeling for BMP7, ALK6, ALK6 & FSP1. Color substrate: 3,
3´-diaminobenzidine (DAB, brown); for ALK6 & FSP1: 3-amino-9ethylcarbazole (AEC, red) and Vector Blue. Scale bar: 20 µm. S:
stroma. Arrowhead points to FSP1+ fibroblast with ALK6
immunoreactivity. D. Immunofluorescence for ALK6 in cultured
forestomach fibroblasts from approximately 6-week-old mice with the
listed genotypes. Scale bars: 50 µm. Red inset: negative control,
scale bar: 20 µm. E. Immunolabeling for ALK6, ALK2, and ALK3 in
forestomachs of TGFBR2cKO mice. Scale bar: 50 µm.

BMP7

was

epithelium

produced

(Figure

in

34B).

the
BMP

ligands are known to signal via
ALK2, ALK3 or ALK6 to activate
Smad1/5/8,

bind

Smad4

and

translocate to the nucleus152,169.
BMP7

preferentially

signals

via

ALK2 and ALK6 and is known to
stimulate
growth166,170.

mesenchymal
BMP

receptor

cell
IB

(ALK6) was expressed on stroma
cells, as well as on the tumor epithelium, and double-staining demonstrated that the ALK6
receptor was present on FSP1+ cells (Figure 34C). Moreover, the ALK6 receptor was strongly
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expressed on the in vitro fibroblasts (Figure 34D). The two alternative BMP-specific co-receptors,
ALK2 and ALK3, exhibited weaker immunolabeling (Figure 34E).
BMP7 can also signal via non-Smad dependent pathways, including FAK, ERK1/2, JNK
and p38 MAPK-mediated signaling, depending on BMP7 concentration171,172. Phosphorylated Akt
and Erk1/2 levels were elevated in TGFBR2/SMAD4cKO fibroblasts, possibly as a compensatory
mechanism for lack of Smad4 (Figure 35A).
Critically

however,

the

activity of high levels of BMP7 on
forestomach fibroblasts indicated
enhanced proliferation in wt and
TGFBR2cKO

fibroblasts,

in

contrast to TGFBR2/SMAD4cKO
fibroblasts

(Figure

35B),

supporting Smad4 signaling is
required for BMP7 to stimulate
Figure 35 Forestomach cancer can be initiated through a feed forward
loop HGF/BMP7 signaling between fibroblasts and cancer cells
A. Western blot analyses of forestomach lysates of mice in the indicates
phenotypes. B. Cell proliferation (methylene blue absorbance) of wt (gray),
TGFBR2cKO (red) or TGFBR2/SMAD4cKO (blue) forestomach fibroblasts
cultured in vitro with the indicated treatments. The data is normalized by
setting the 0.1% FBS control at 1. Unpaired one-tailed t test compared to
0.1% FBS control, statistical analyses carried out on untransformed data.
The data is presented as the mean ± SEM. *p<0.05, **p<0.01, ns: not
significant. See accompanying source data. C. Diagram of the proposed
crosstalk between the Tgfbr2-deficient FSP1+ fibroblasts (blue) and the
overlying epithelium (black). FSP1+ fibroblasts produce HGF to activate
Met receptors on overlying epithelial cells, causing epithelial cells to
produce BMP7, which stimulates ALK6 receptors on FSP1+ fibroblasts to
produce HGF.

fibroblast proliferation (Figure
35B)

and

HGF

production

(Figure 33C). Altogether our
studies support a model wherein
carcinogenesis

of

the

forestomach

epithelium

may

ensue

perpetual

HGF

from

production by FSP1+ fibroblasts lacking Tgfbr2. HGF stimulates epithelial Met signaling and
induces epithelial cell proliferation (Figure 35C). HGF production is in part promoted by epithelialderived BMP7/ALK6 signaling via Smad4 in fibroblasts (Figure 35C). The deregulated
BMP7/HGF signaling between fibroblasts and epithelial cells enables carcinogenesis of the
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forestomach epithelium, wherein loss of Tgfbr2 in FSP1+ stromal cells promotes HGF production
due to increased dependence on epithelial cell-derived BMP7 signaling via ALK6 and Smad4
(Figure 35).

HGF mediated induction of epithelial carcinogenesis is specific to FSP1 stromal cells
After we observed this intriguing signaling crosstalk between fibroblasts and cancer cells,
we wondered whether this is specific to FSP1+ fibroblasts. We had previously crossed aSMA-Cre
mice to Tgfbr2floxE2 mice in order to knockout TGFb in aSMA+ fibroblasts. These Tgfbr2floxE2;aSMACre mice did not develop any pathologies and presented with normal forestomach development
(Figure 36A,77). We probed whole
tissue lysates from forestomachs of
Tgfbr2floxE2;aSMA-Cre

mice

for

BMP7 and HGF expression. Both
Figure 36 Epithelial cancer cells- fibroblast crosstalk via
BMP7/HGF signaling is specific to FSP1+ fibroblasts.
A. Forestomach histology of TGFbR2floxE2; aSMA-Cre mice. Scale bar:
50 µm. S: stroma. E: epithelium. L: lumen in the forestomach.
B. Comparison of BMP7 and HGF protein levels in forestomach whole
tissue lysates of wt, TGFbR2floxE2; aSMA-Cre and TGFbR2floxE2; FSP1Cre (TGFBR2cKO) mice. Western blots, 30 µg of protein loaded per lane.
BMP7 and HGF are highly upregulated in the TGFBR2cKO forestomach
cancer tissue.

proteins were expressed at levels
comparable

to

those

in

forestomachs of WT mice, and less
than in Tgfbr2floxE2;FSP-Cre mice
(Figure 36B).

We can therefore conclude that observed BMP7/HGF crosstalk is specific to FSP1+
fibroblasts.

Interpretation of results
The crosstalk between epithelial cells and the stroma is extensive, and while loss of TGFBR2 in
epithelial cells is not sufficient to elicit carcinogenesis149,153, deletion of TGFBR2 in FSP1+ stromal
cells mediates epithelial carcinogenesis36 pointing at the regulatory role of stromal Tgfbr2
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signaling towards the epithelium. We investigated more deeply the reported fibroblasts driven
forestomach carcinogenesis and found that Smad4 is required to elicit cancer. Furthermore, our
data demonstrate that BMP7 signaling via Smad1/5/8 up-regulates HGF production from
forestomach stromal cells to promote epithelial cell proliferation via Met activation.
Here we propose that a crosstalk circuit exists in TGFBR2cKO forestomachs consisting of
BMP7 secreted by the cancer cells and HGF secreted by the stroma, which is a known signaling
circuit in prostate cancer173.
Crosstalk between the cancer epithelial cells and the stroma is important for tumor
progression, and apart from HGF and BMP7, numerous other growth factors are known to be
secreted by these two cell compartments65,164,174,175. Importantly, the predominant source of HGF
production in epithelial cancers is the tumor stroma174 which was confirmed by in situ hybridization
shown in this chapter. Our collective analyses indicated a dominant role for HGF deregulated
signaling in TGFBR2-deficient forestomach fibroblasts, leading to the activation of epithelial Met
receptors, thereby stimulating epithelial proliferation. Furthermore, we report that BMP7 is
produced by the epithelial cells to activate BMP receptor signaling in the fibroblasts, and requiring
Smad4 to promote HGF production. In contrast, Tgfbr2 binds the TGFb ligand and mediates
signaling via Smad2/3 & Smad4 to inhibit cell proliferation in normal tissues, by up-regulating p21
and down-regulating c-Myc transcription176,177. Accordingly, our data demonstrate that stromal
SMAD4 is indispensable for epithelial carcinogenesis when TGFBR2 is deleted in FSP1+
fibroblasts.

Potential pitfalls and alternative approaches
Although we clearly show the BMP7-dependent upregulation of HGF expression in
TGFBR2cKO fibroblasts, the rescue experiment was not performed, in which TGFb signaling
should be restored in fibroblasts and effects on epithelial cell-fibroblasts cross-talk would be
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tested. In vitro co-culture experiments using isolated TGFBR2cKO fibroblasts could be used in
order to address this point.
Westernblot analyses for phosphorylated Smad1/5 and phosphorylated Smad2 compare
levels of phosphorylated proteins to beta actin. Instead, total Smad1/5 and Smad2 should be
measured to get a more accurate readout for phosphorylated proteins.

Future directions
The most important question that was not answered by our study is the reason for the
organ specificity to develop cancer. Whether the acidic environment of the forestomach preconditions epithelial cells for cancer development remains to be tested. Here, injury could be
induced in other organs, similar to early wounding studies20, and test if TGFBR2 knockout in
FSP1+ fibroblasts could have similar effect in wounded organs than in the forestomach. Of
particular interest would be mammary carcinoma, as here deregulated BMP signaling in the
stroma has already been shown to promote tumor progression148,178.
Moreover, it is most intriguing that despite similar abundance of aSMA and FSP1 in the
forestomach, TGFBR2 knockout in aSMA fibroblasts did not cause any abnormalities in mice.
Therefore, future studies should be directed towards investigating differences between aSMA+
fibroblasts and FSP1+ fibroblasts in the forestomach.
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CHAPTER 7

DISCUSSION
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Discussion

CAF heterogeneity
Over the past decade, it has become increasingly clear that successful cancer therapy
calls for targeting cancer cells as well as the tumor microenvironment simultaneously. Recent
successes in immunotherapy are evidence for this proposition. Here, immune cells are modulated
to increase their anti-tumor activity or decrease their immune-suppressive functions. While
extremely successful in hematopoietic cancers and melanoma, immunotherapy is only modestly
effective against solid cancers, in particular breast cancer179–181, and alternative approaches are
needed. Owing to their critical involvement in cancer progression, CAFs represent an
attractive therapy target in the tumor microenvironment65. However, multiple clinical
studies182–185 proved targeting CAFs a challenging task. For instance, Pegvorhyaluronidase
alfa (PEGPH20) is a recombinant enzyme degrading the ECM component hyaluronan. This
has shown moderate effects in a phase II clinical trial for pancreatic cancer183. Talabostat,
an inhibitor against FAP has failed to show efficacy in non-small cell lung cancer, colorectal
cancer and melanoma 182,184,185. In addition to directly targeting tumor microenvironment
components, CAF-specific signaling, such as Hedgehog signaling has been targeted with
several different drugs in many different cancer types, with disappointing results186. These
clinical studies demonstrate the urgency to understand CAF biology at a deeper level, so that
future targeting approaches can be more successful. CAF targeting might be such a great
challenge due to their extreme heterogeneity with tumor-promoting or tumor-suppressive
CAF subtypes, that to date are not clearly distinguishable. Therefore, it appears critical to
catalogue CAFs into distinct subtypes with defined functions in tumorigenesis. Similar
classification performed for myeloid cells in the past decades led to identification of tumorreactive and tumor-suppressive cell subsets. Such subsets can now be modulated with
specific therapies with the goal to suppress tumor progression, with great success. It stands
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to reason that a comprehensive classification of CAFs could promote new strategies to target
the most detrimental CAF subtypes while sparing tumor-restrictive cell populations in solid
tumors, in particular those which are less amendable to immunotherapy.
In this work, we have attempted to unravel CAF heterogeneity and identify new
functions of CAFs. We chose to focus on breast cancer, because of the large stromal content
of those tumors. Moreover, immunotherapy has not been very successful for breast cancer
patients and therefore additional tumor microenvironment targeting strategies could be of
great use. We first identified phenotypically distinct CAF subsets based on expression of
aSMA, FAP, FSP1 and Vimentin in two distinct murine models of mammary carcinoma. Of
course, many additional mesenchymal markers are used to identify CAFs and our approach
presents only a first step in order to delineate CAF subtypes. Moreover, spatial relationships
between different cell types should be taken into consideration in future analyses of our data.
While RNA sequencing, flow cytometry or CyTOF allow detection of many more markers
simultaneously, the necessary tissue digestion causes loss of cells and can therefore add
bias to the analysis93. Future experiments should consider newly developed CyTOF imaging
methods, which allow utilization of a multitude of markers on a tissue section. More
importantly, phenotypical analyses should go hand in hand with functional characterization
of the identified cells.
We identified functionally distinct CAF subtypes in our mammary carcinoma animal
models based on expression of aSMA, FAP and PDGFRb. FAP has been reported in the
literature to be critically involved in tumorigenesis, mainly in pancreatic cancer, as well as in
lung cancer and melanoma187,188. We observed no significant effect of FAP+ CAFs depletion
in our model of mammary carcinoma, in line with previous observations in mammary
carcinoma models101,102. One explanation why we could not detect any significant impact on
tumor growth or metastasis when FAP + CAFs were targeted might merely be the relatively
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low abundance of these cells in the breast tumor microenvironment when compared to other
CAF subsets we detected. This might also explain the differences of the impact of FAP
targeting between different cancer types102,103,109. Interestingly, when FAP targeting therapy
was combined with chemotherapy, it improved the effectiveness of chemotherapy, despite
showing no effect on its own 101. This suggests to test the functions of FAP+ CAFs in the
context of cancer therapies. Here, it would be of particular interest to assess FAP+ CAFs
roles in immunotherapy-treated tumors, due to FAP+ CAFs immunomodulatory effects we
and others observed.
PDGFRb, as well as aSMA label pericytes as well as CAFs in the tumor
microenvironment. All proteins used to identify CAFs are expressed by other cell types in the
tumor microenvironment. We found it therefore important to directly compare such markers
that label the same CAF and non-CAF cells in the tumor microenvironment. In the past, we
have shown that targeting PDGFRb+ pericytes resulted in tumor growth regression.
Metastatic burden was decreased when ablation was started when tumors were small and
non-hypoxic. However, when PDGFRb+ cells were depleted from larger, hypoxic tumors,
increase in lung metastatic burden was observed. Our results of PDGFRb+ CAFs/pericyte
depletion in the PyMT model mimic the observations when these cells were depleted from
small, non-hypoxic tumors in the 4T1 model. Intriguingly, when we depleted aSMA+ CAFs,
metastatic burden was unchanged; however, in studies not shown in this thesis revealed that
impact of aSMA CAFs depletion depends on the specific experimental setting (unpublished
data from the lab). We indeed could see an increase in metastasis when aSMA depletion
was started at larger tumor volumes95, therefore mimicking the previously observed effects
of PDGFRb targeting 189. We showed in this thesis that our strategy to deplete aSMA+ CAFs
did not impact perivascular aSMA+ cells. In our previous publication overall PDGFRb
expression was measured in tumors from PDGFRb-vTK animals. One might speculate that
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when targeting PDGFRb+ cells in our previous publication, CAFs were targeted as well. A
thorough analysis of expression of these two markers in tumors from aSMA-vTK and
PDGFRb-vTK is required in order to decipher distinct distribution from different cell types. In
the greater picture of cancer therapy, such distinction only matters if those cells are
functionally different. PDGFRb-expressing cells can directly be targeted using antibodies190
or other PDGFRb targeting drugs191. In this case all cells expressing the protein would be
targeted regardless of other cell characteristics. aSMA as a cytoskeletal protein cannot be
directly targeted with an antibody, or CAR-T cell based on surface recognition. However, one
can aim to disrupt tumor promoting signaling pathways between aSMA+ CAFs and cancer
cells; for instance treatment with antibodies targeting CXCL12 reduced breast cancer growth
after CXCL12 was identified as CAF-derived promoter of angiogenesis11.
We have identified several different roles of aSMA+ CAFs in the breast tumor
microenvironment. aSMA+ CAFs seem to impact tumor immunity, angiogenesis and tumor
metabolism. CAFs have been shown to induce angiogenesis; however, this has not yet been
attributed to a specific CAF type identified by a particular marker11. It remains to be
determined how aSMA+ CAFs induces angiogenesis in our model. We found an increase in
aSMA+Vimentin + CAFs accompanied depletion of aSMAs+ CAFs. One could speculate
whether Vimentin expression in CAFs renders those more quiescent. Therefore, acquisition
of Vimentin expression might present a mechanism to escape GCV treatment. Such
speculations can only be tested in sophisticated lineage tracing animal models. Most
intriguingly, aSMA+ CAFs have been shown to recruit tumor-associated macrophages in
pancreatic and colorectal cancer192,193. These studies stand in contrast to our findings.
Whether interactions between CAFs and immune cells are dependent on cancer type, or
whether different experimental settings (in vivo vs. in vitro experiments) are reason for these
opposing observations, remains to be addressed in future studies. When compared to
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depletion of PDGFRb+ or FAP+ CAFs, targeting aSMA+ CAFs in the tumor microenvironment
of mammary tumors had a variety of different effects. While such effects could be
consequential of tumor environment remodeling, this could also suggest multifaceted roles
of aSMA+ CAFs. We therefore propose that aSMA labels a large subset of CAFs, that can be
further delineated using additional markers. One can then hypothesize that one subset might
be responsible to induce angiogenesis, while another subset is involved in direct signaling
crosstalk with immune cells, and a third subset supplies cancer cells with necessary
metabolites to fuel their growth.

CAFs’ altered metabolism
We observed downregulation of whole tumor metabolites when we depleted aSMA+
CAFs in mammary tumors in previous studies135, which prompted us to further investigate
the metabolic liaison between cancer cells and CAFs. We showed transfer of CAF-derived
metabolites to cancer cells and direct incorporation of these metabolites in cancer cells’
metabolism. Moreover, we uncovered how normal fibroblasts can be reprogrammed by
hypoxia towards a CAF-like phenotype with increased glycolysis as we previously already
indicated 135.
While we initially observed downregulation of tumor metabolites in aSMA+ CAFs
depleted tumors and went on to further investigate CAFs metabolic function in mammary
carcinoma, we did not probe these functions particularly in aSMA+ CAFs, but used
heterogeneous CAF populations isolated from patient tissues for the majority of our
experiments. The main reason was the nature of the experiments, which encompassed
majorly experiments in 2D cultures of fibroblasts grown out of patient tissues. In our
experience, once fibroblasts are cultured on plastic, expression of markers are not
comparable to expression patterns in vivo (data not shown). Therefore, we did not carefully
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characterize the CAFs and benign fibroblasts in culture. However, in light of the current
findings, one could now further test population-specific metabolic phenotypes by utilizing
conditional knockout mouse models, such as LDHAfl/fl or PKM2fl/fl194,195 and cross to mice that
harbor Cre driven by a mesenchymal promoter, such as aSMA-Cre 77, or FSP1-Cre 196.
In our previous studies we have also shown that limiting the metabolic support of
CAFs can result in tumor growth reduction 135 independent of tumor microenvironment
remodeling . The effectiveness of the MCT1 inhibitor AZD3965 has been shown in preclinical
models, and is currently tested in early phase clinical trials197–199. Our results indicate that
MCT1 inhibition would also be effective in breast cancer. Indeed, recently a study
demonstrated its effectiveness in inhibiting 4T1 mammary carcinoma cell growth 200.
Moreover, an inhibitor of MCT4 has shown promising results in pre-clinical studies201,202. We
therefore hypothesize that combination therapy using MCT1 as well as MCT4 inhibition in
breast cancer might have beneficial effects. Moreover, Dichloroacetate is an FDA approved
drug used for inherited mitochondrial disorders. Preclinical studies indicate its effect in breast
cancer treatment203–205, in agreement with our findings. However, while these studies focus
of the effects of the drug directly on cancer cells, our work also suggests that Dichloroacetate
could potentially also inhibit CAF-derived lactate secretion and thereby provide an additional
beneficial effect in cancer treatment.

Fibroblasts’ roles in tumor initiation
We have discovered how chronic hypoxia can induce epigenetic reprogramming in normal
fibroblasts and render those more CAF-like. This is thought to occur throughout tumorigenesis
when oxygen availability within the tumor microenvironment is limited. To assess how changes in
fibroblasts can not only contribute to tumor progression, but also cause cancer initiation, we
focused our attention to a known model, in which deregulated TGFb signaling in FSP1+ fibroblasts
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has been shown to initiate carcinomas of the forestomach. We have discovered that Smad4 is
obligatory to elicit the hyperactivated HGF/BMP7 signaling crosstalk between fibroblasts and
epithelial cells leading to epithelial carcinogenesis. Murine forestomach cancer presents
squamous cell carcinoma of the esophagus in humans206. C-Met inhibitors are on the market for
treatment of non-small cell lung cancer and kidney cancer

207–209

. As fibroblast-derived HGF

signaling is not only involved in cancer initiation, but also in progression of esophageal cancer210,
this cancer type could be a potential additional application for such inhibitors. Bhowmick et al.
suggested elevated HGF signaling in fibroblasts to be responsible for epithelial carcinogenesis.
We identified Smad4 dependency of this signaling circuit in order to initiate epithelial
carcinogenesis.
The occurrence of carcinomas exclusively in the forestomach is most intriguing and further
studies are needed to explain the tissue specificity. One possibility is the importance of stroma
for tissue maintenance, specifically for the hyperproliferative squamous epithelium in the upper
part of the stomach. In this part of the stomach, high acidity level and continuous mechanical
erosion may cause damage to epithelial cells more and pre-condition them for cancer
development. Stromal BMP signaling is an important contributor to cancer progression in other
cancers. It was previously reported that conditional deletion of BMP receptor 2 (BMPR2) in FSP+
fibroblasts or disruption of BMPR2 in breast epithelial cells promotes breast cancer metastasis in
mice expressing the PyMT oncogene148,211. In contrast, when BMPR2 was deleted in nestinpositive stromal cells intestinal polyps developed147 and inhibition of BMP signaling in all cell
compartments with the BMP antagonist DMH1 suppressed breast cancer metastasis178. BMP
signaling in cancer is thus highly context dependent. The importance of BMP signaling in breast
cancer evokes the question whether breast carcinogenesis could also be initiated by deregulated
stromal TGFb/HGF signaling under highly proliferative circumstances such as pregnancy.
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Interestingly, we found that the HGF/BMP7 signaling axis does not exist between aSMA+
fibroblasts and epithelial cells, highlighting the heterogeneity in fibroblasts even in normal tissue
homeostasis. This opens up questions of the evolvement of heterogenous cancer-associated
fibroblasts from heterogenous fibroblasts in healthy host tissues. We have shown one mechanism
of who fibroblasts can be activated and reprogrammed. Future studies will test whether this
reprogramming is specific to a particular fibroblast population and gives rise to one particular CAF
subtype, or whether this is a universal mechanism for all fibroblast types in hypoxic tumor areas.
Lastly, it remains to be seen how relevant these findings are with respect to human
disease. Genetic mutations as well as epigenetic alterations have been detected in CAFs. In fact,
in breast cancer associated fibroblasts such alterations indicated changes in HGF and Tgfb
signaling212. Although, it is impossible to conclude whether mutations in fibroblasts preceded
cancer, or whether those arose throughout tumor progression. One could imagine designing long
term patient studies that probe for stromal mutations, e.g. in routine breast biopsies, and then
correlate them to later-on cancer development. However, the feasibility of such studies might not
be very high considering that in a cancer therapy setting it is irrelevant how the tumor arose.

Future directions
The biggest challenge in the field of CAF biology is currently the unraveling of
heterogenous CAF subtypes. Future and ongoing studies are focused on identifying new
CAF subsets and their functions in tumorigenesis. With this work with have identified
functionally distinct CAF subsets in breast tumorigenesis and simultaneously introduced new
questions. We have shown the multitude of potential functions exhibited by aSMA+ CAFs and
postulate that further subtyping of this population is necessary to delineate further subtypes
of this large CAF population. Similar to the cells in the hematopoietic system, CAFs need
careful cataloguing into distinct cell populations. With respect to CAF marker expression
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future lineage tracing studies will unravel how different CAFs evolve throughout
tumorigenesis. Here, not only CAFs in the tumor microenvironment, but also fibroblasts in
healthy tissues should be investigated. We saw distinct differences between aSMA+
fibroblasts and FSP1 + fibroblasts with respect to induction of forestomach carcinogenesis. In
breast cancer, we have discovered distinct expression of aSMA and FSP1 by CAFs, as well
as demonstrated that such aSMA+ and FSP+ CAFs have distinct functions in breast
tumorigenesis. Future studies might address whether these CAFs stem from the distinct
aSMA+ and FSP1 + fibroblasts in normal tissue, or whether they might stem from one
progenitor cell.
Finally, we have discovered a mechanism of how fibroblasts can be activated and
become highly glycolytic like CAFs. Future studies are aimed to investigate these
reprogrammed fibroblasts carefully and investigate their CAF-like characteristics, such as
primary tumor growth promotion via metabolic fueling of cancer cells.

Conclusion
Collectively, our studies have offered an insight into the multifaceted functions of CAFs in
the context of a highly complex tumor microenvironment. Depletion of CAFs resulted in a
multitude of changes within this signaling network of cells, which all are interdependent. It is
therefore important – as far as it is possible – to conduct research to decipher CAF functions in
model systems that take these intricate interactions into consideration. We are just at the
beginning of unraveling CAF biology and the future will bring many more exiting insights into the
diverse functions of this important cell type in cancer biology. In the hematopoietic system,
research over the past 25 years has resulted in a hierarchal layout of distinct immune cell types,
which have later been attributed specific functions in tumor biology. The successful cataloguing
of the cells of the hematopoietic system has allowed to develop therapies that specifically target
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and modulate tumor immune cell responses, with great success. It therefore stands to reason that
similarly delineating fibroblasts will open the doors for successful targeting of this most abundant
and highly critical component of the tumor microenvironment in the future.
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